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Abstract 
 
The main aim of the study was to develop real-time detection method for the notification of 
acute kidney injury in patients where creatinine was requested. A software application was 
developed that evaluated creatinine results for acute kidney injury against a variety of 
algorithms. In the initial stage the only algorithm reported was that developed by the Acute 
Kidney Injury Network but, in 2013 following an NHS England Patient Safety Notice, this was 
changed to the mandated algorithm and all historical results were also re-evaluated.  
Between 2010 and 2014 a total of 346,780 patients aged 18 and over covering 1,800,545 
individual requests were recorded in the database. Using the NHS England algorithm 25,551 
(7.4%) of patients had AKI at some stage in the study period. Analysis suggested that the 
introduction of AKI alerts coincided with a significant reduction in the relative risk for thirty-day 
mortality following an AKI episode; stage 1 mortality falling from 19.5% to 14.6%, stage 2 
mortality falling from 30.1% to 22.1% and stage 3 mortality falling from 35.3% to 25.9%. 
However, there was also a fall in mortality for stage 2 and 3 AKI at an associated Medical Unit 
that did not receive alerts suggesting a significant role for the educational elements and sharing 
of Consultant care across sites. The data also suggest that, following an episode of acute kidney 
injury full recovery of renal function may take in excess of 180 days.  
The data support the hypothesis that the introduction electronic alerts along with education 
can have significant impacts on subsequent mortality. However, other improvements in 
healthcare such as an increased focus on sepsis, an important factor in the development of 
acute kidney injury, may also have contributed to the reduction in mortality. 
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Chapter 1 An introduction to acute kidney injury 
 
 
This chapter will introduce acute kidney injury (AKI) and the concepts related to the current 
research. It will provide an overview of the epidemiology, financial and clinical impacts, and the 
various staging systems in current use. This will provide the background reasoning as to why 
the topic is an important area for research and clinical improvement. 
1.1 Overview 
 
Acute kidney injury (previously termed acute renal failure and acute renal insufficiency) is a 
common condition affecting up to 20% of emergency admissions to hospital (National Institute 
for Health and Care Excellence, 2013). There is increasing mortality as the condition worsens 
(Hoste et al., 2006; Uchino, Bellomo, Goldsmith, Bates, & Ronco, 2006) although there is also 
evidence that even small short-term decreases in renal function are associated with increased 
mortality (Lassnigg et al., 2004). In those who survive the episode there may be subsequent 
sequalae with failure to return renal function to pre-injury levels or even long term dialysis. The 
financial impact of acute kidney is considerable with estimates of each case increasing the 
hospital cost by up to £4,800 by increasing the unscheduled bed stay up to 11 days together 
with costs associated with Intensive Care treatment. Despite this being a common condition 
with significant impacts on mortality, morbidity and finances, evidence has demonstrated poor 
recognition of the condition (Stevens et al., 2001) and subsequent management when it is 
detected (National Confidential Enquiry into Patient Outcomes and Death, 2009). 
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Research into the condition has been hampered by lack of a consensus definition with many 
papers citing different criteria that may not always be transferable across these studies. These 
criteria may involve changes in the serum creatinine over a variable number of days (the 
baseline) with or without measuring the urine volume output.  
During the period of this study, NHS England introduced a consensus algorithm for the staging 
of acute kidney injury and mandated its introduction to all laboratories providing results to NHS 
patients. 
1.2 Anatomy and physiology of the kidneys 
 
The kidneys are a pair of organs located in the retroperitoneal space in the abdominal cavity. 
Blood is supplied via the renal arteries and drained by the renal veins. The urine they produce 
drains via the ureters into the bladder (the mechanism of normal urine production is discussed 
later in this chapter). The right kidney is usually smaller and sits slightly lower in the abdominal 
cavity due to the presence of the liver. The male kidney generally weighs more than the female 
kidney (125-170g vs 115-155g). 
The basic structural and functional unit of the kidney is the nephron and each kidney contains 
between 800,00 and 1,500,000 nephrons (figure 1-2).  
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Figure 1-2 - Basic structure of the nephron  
(by OpenStax College [CC BY 3.0 http://creativecommons.org/licenses/by/3.0)], via Wikimedia Commons) 
 
 
Figure 1-1 - Basic structure of the kidney 
1.Renal pyramid 
2.Interlobular artery 
3.Renal artery 
4.Renal vein 
5.Renal hilum 
6.Renal pelvis 
7.Ureter 
8.Minor calyx 
9.Renal capsule 
10.Inferior renal capsule 
11.Superior renal capsule 
12.Interlobar vein 
13.Nephron 
14.Minor calyx 
15.Major calyx 
16.Renal papilla 
17.Renal column 
By Piotr Michał Jaworski; PioM EN DE PL (Own work) [GFDL 
http://www.gnu.org/copyleft/fdl.html) or CC-BY-SA-3.0 
http://creativecommons.org/licenses/by-sa/3.0/)], via Wikimedia Commons 
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The kidneys act as the target of several hormones notably aldosterone and anti-diuretic 
hormone (ADH). It also produces hormones that act on remote targets such as renin and 
erythropoietin (Epo) as well as playing a role in Vitamin D metabolism. 
The renin-angiotensin-aldosterone hormone system regulates plasma sodium concentration 
and arterial blood pressure. When the plasma sodium concentration or the arterial pressure are 
low, renin is secreted from the juxta-glomerulus apparatus in the kidney which converts 
circulating angiotensinogen into angiotensin I. This is then converted into angiotensin II by 
angiotensin converting enzyme (ACE) found in the lungs. Angiotensin II causes arterial 
constriction resulting in an increase in arterial pressure and secretion of aldosterone from the 
adrenal cortex. The aldosterone acts on the renal tubular cells to cause reabsorption of sodium 
(and water) with resultant excretion of potassium into the urine. This system therefore acts to 
maintain arterial pressure via arterial constriction and reabsorption of sodium and water. The 
pre-operative use of inhibitors of the renin-angiotensin-aldosterone system has been shown to 
increase the incidence and mortality of AKI in patients undergoing cardiac surgery (Yacoub et 
al., 2013). ACE inhibitors are commonly used for the treatment of hypertension and congestive 
cardiac failure and whilst they may pre-dispose to AKI, their cessation should be carefully 
considered during an AKI episode and restarted at an appropriate dosage after the episode has 
resolved (Harty, 2014). However, the management of AKI and ACE inhibition remains an area 
under active review. 
Erythropoietin is a glycoprotein produced by the capillary cells surrounding the renal tubules 
and acts on the bone marrow to stimulate the production of erythrocytes (red blood cells). 
Whilst anaemia has a well-recognised association with chronic kidney disease, there are 
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relatively few studies in patients with acute kidney injury. One study (Song et al., 2009) used 
pre-operative Epo prior to coronary bypass graft surgery (CABG) and reported a decreased 
incidence of post-operative AKI (8% vs 29% for no Epo). However, these findings have not been 
repeated in other studies (Endre et al., 2010). A recent study concluded that anaemia is not a 
risk factor for progression of AKI (Powell-Tuck et al., 2016). 
Vitamin D is a hormone involved in the regulation of calcium. It is mainly derived from 
metabolism in the skin under the actions of ultra-violet light but a small amount may be derived 
from the diet. It is then converted to 25- hydroxycholecalciferol in the liver and then to 1,25- 
dihydroxycholecalciferol in the proximal tubules of the kidney. Studies have shown that vitamin 
D deficiency is associated with a more severe decrease in GFR and greater morphological 
damage in rats (de Braganca et al., 2015) and an increased risk of mortality and AKI in critically 
ill patients (Braun & Christopher, 2013).  
  
 Page 19 
 
1.3 Normal formation of urine 
 
The kidneys rely on a pressure gradient of approximately 17 mmHg across the glomerular 
capillary bed to filter the blood. This gives rise to the ultra-filtrate and contains few molecules 
exceeding 15 kDa in weight. Each nephron will produce approximately 100 µL of filtrate per day 
with an overall amount of 200L per day. As the ultra-filtrate passes through the tubule there is 
reabsorption of water and other solutes. Different regions of the tubule have different 
functions; the proximal tubule is the most metabolically active region where 60-80% of the 
filtrate volume is resorbed along with 70% of the sodium and chloride, most potassium and 
bicarbonate and secretion of 90% of the excreted hydrogen ion. Glucose is passively resorbed in 
this region but this mechanism is saturated at blood glucose concentrations around 10 mmol/L. 
In the loop of Henlé there is further reabsorption of sodium and chloride but water remains in 
the filtrate resulting in a dilute urine at this stage. In the distal tubule there is active secretion of 
hydrogen and potassium ions and water is reabsorbed here (and the collecting ducts) under the 
influence of anti-diuretic hormone (ADH) leading to concentration of the filtrate.  
Approximately 25% of cardiac output is directed through the kidney, around 1.1L per minute, 
with the majority (>90%) flowing through the renal cortex. In the normal kidney the cortex is 
well oxygenated with a pO2 around 9kPa but the in the outer medulla the pO2 is around 3 kPa 
making it relatively hypoxic. This hypoxic area is due to the high oxygen demands by the 
energy-dependent transport processes in the loop of Henle. This makes this area particularly 
vulnerable to processes that reduce oxygen delivery. 
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1.4 Acute Kidney Injury 
 
Acute kidney injury has been defined as the abrupt decline in renal function with a reversible 
increase in the concentrations of nitrogenous waste products which can be measured as either 
urea or creatinine (Nissenson, 1998).  
It may be divided into pre-renal, intrinsic and post-renal or obstructive acute kidney injury 
(table 1-1). Intrinsic AKI may be further subdivided based on the cause e.g. glomerular, vascular 
and tubulo-interstitial. In their study on community-acquired acute kidney injury Kaufman, 
Dhakal, Patel, and Hamburger (1991) found that 70% of cases were due to pre-renal causes, 
11% to intrinsic disease, 17% were obstructive and 2% that could not be classified. The major 
causes of acute kidney injury in patients admitted to ITU were septic shock (47%), post major 
surgery (34%), cardiogenic shock (27%) and hypovolaemia (26%) (Uchino et al., 2005). 
Most tubulo-interstitial acute kidney injury is a consequence of ischaemic injury and, as will be 
discussed later, there can be an overlap between pre-renal and ischaemic AKI due to different 
regions of the kidneys having varying susceptibility to injury at different oxygen concentrations. 
Following the initial insult there is a phase of renal injury initiation with a reduction in the 
glomerular filtration rate. This may be followed by a period where the renal injury extends and 
function declines further and finally a period where the injury is maintained and renal function 
remains compromised. The time period may be variable for each phase but the initiation phase 
is sudden and may only last hours. At any time during the injury process, there may be a 
recovery phase where the renal function improves but it may not necessarily return to pre-
injury levels (Molitoris et al., 2007). The loss of renal function, duration of the maintenance 
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phase and degree of functional recovery are all highly variable and cannot be predicted in 
individual patients. 
Table 1-1 Possible causes of acute kidney injury 
  Example cause 
Pre-renal AKI Hypotension 
Dehydration 
Gastrointestinal fluid loss 
Haemorrhage 
Sepsis 
Acute cardiac failure 
Intrinsic AKI Glomerular Rapidly progressive glomerulonephritis 
Goodpasture’s syndrome 
ANCA associated nephritis 
Systemic lupus erythrematosis 
Cryoglobulinaemia 
Vascular Scleroderma renal crisis 
Pre-eclamptic toxaemia 
Tubulo-interstitial Pre-renal AKI leading to ischaemic injury 
Nephrotoxic drugs e.g. NSAID, 
aminoglycosides 
Sarcoidosis 
Pyelonephritis 
Myeloma cast nephropathy 
Miscellaneous Contrast nephropathy 
Rhabdomyolysis 
Post renal (obstructive) AKI Tumours e.g. bladder, prostate 
Renal calculi 
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1.6 Renal blood flow and acute kidney injury 
 
The renal circulation is capable of a degree of autoregulation where the flow is maintained by 
interaction of vasoactive compounds (e.g. prostaglandins and nitric oxide) and autonomic 
activity over a wide range of arterial pressures (from 80 to 180 mmHg). When the pressure falls 
e.g. as a consequence of volume depletion, the normal response is vasodilatation of the 
afferent arteriole and constriction of the efferent arteriole; this maintains the pressure across 
the glomerular membrane. However, this auto regulation can only buffer pressure changes so 
far and when the pressure falls, there is vasoconstriction of the renal vessels leading to 
ischaemic injury (Hall et al., 1977). Thus a drop in blood pressure can initially result in less 
filtrate being formed as this is a pressure dependent process. However, there is also an overlap 
between the loss of pressure across the glomerular membrane and the depletion in oxygen to 
the energy dependent transport processes that leads to the clinical manifestation of acute 
kidney injury. 
Drugs that interfere with the balance of vasoconstriction and vasodilatation can cause a 
reduction in the glomerular filtration rate e.g. NSAID, angiotensin converting enzyme inhibitors 
and angiotensin 2 receptor blockers. Whilst these drugs are rarely the sole cause of AKI, they 
may exacerbate pre-existing risks enough to initiate the condition. Once acute kidney injury is 
established the kidneys lose their ability to auto regulate pressure changes which can then 
escalate the injury. 
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1.7 Ischaemic renal injury 
 
Ischaemic injury results in damage to the renal medulla which outweighs that seen within the 
cortex. The fall in oxygen concentration causes a fall in the intracellular ATP concentration and 
a corresponding rise in intracellular ADP/AMP due to inhibition of mitochondrial respiration. 
This in turn then leads to: 
 A rise in the intracellular calcium concentration, a consequence of which is activation of 
phospholipases, cytoskeletal degradation and protease activation. 
 Activation of the caspase pathway ultimately causing apoptosis or even necrosis. 
Clinically the failure of the active transport processes manifests as retention of hydrogen and 
potassium ions leading to acidosis and hyperkalaemia. 
The ischaemic injury within the kidney also leads to swelling of the endothelial cells and 
disruption of the cell membrane. This results in leak of fluid into the surrounding tissues and 
interstitial oedema. At the same time there may be activation of the clotting cascade and 
formation of micro-thrombi within the renal vasculature. In addition, this cell injury then 
initiates an inflammatory response with release of pro-inflammatory compounds such as cell 
adhesion molecules and cytokines which exacerbate the vasoconstriction and further impairs 
the ability of the renal circulation to supply oxygen to the damaged areas. 
The changes are histologically more pronounced in the proximal tubule than the distal tubule 
and may be due to the ability of the latter area to switch to anaerobic metabolism more easily 
(Bagnasco, Good, Balaban, & Burg, 1985). Overall, the functional decline may not be reflected 
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in the histological appearance because damage may be restricted to the outer medulla or 
blockage to a single collecting tubule affecting multiple nephrons. 
As part of the inflammatory response, a large number of molecules are released locally that 
may play a role in the immune response seen in ischaemic injury (Jang & Rabb, 2009). The 
release of these factors promotes the migration of neutrophils and leucocytes to the areas of 
injury which, in turn, leads to the release of more cytokines and reactive oxygen species causing 
an upturn in the inflammation. This is followed by migration of macrophages to the affected 
area whose role is to digest cellular debris. 
In the recovery phase there is the production of a variety of factors involved in the inhibition of 
the inflammatory response including Tamm-Horsfall protein and haem-oxygenase 1. There is 
also upregulation of genes for kidney injury molecule -1 (KIM-1) which plays a role in clearing 
necrotic cells and neutrophil gelatinase associated lipocalin (NGAL) which appears to promote 
cellular proliferation. Both these proteins have been proposed as markers for the early 
detection of acute kidney injury (Coca, Yalavarthy, Concato, & Parikh, 2008).  
Whilst there may be apparent full recovery of renal function after an episode of acute kidney 
injury, there is increasing evidence that it may not be without consequences which may later 
manifest as more chronic renal disease. The initial injury may cause loss in some areas of renal 
vasculature leading to a chronic hypoxia, fibrosis and chronic kidney disease. There may also be 
failure of dampening of the initial inflammatory response can lead to release of pro-fibrotic 
cytokines with chronic kidney disease as the clinical end point. 
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Several therapies have been proposed to mitigate the damage caused by an ischaemic insult 
including targeting caspase activation and anti-inflammatory therapies. The fact that many of 
these targeted therapies fail to work in human subjects highlights the complexity and multi-
factorial mechanisms underlying acute kidney injury. 
Whilst this section has discussed changes within the kidney as a result of ischaemic injury, it is 
worth noting that evidence now supports the notion of ‘organ cross-talk’ (White & Hassoun, 
2012). Increases in tumour necrosis factor-α (TNF-α) as a consequence of experimentally 
induced renal ischæmic injury have been shown to have remote cardiac effects with changes in 
the contractile ability of myocytes (Goldhaber et al., 1996). These changes were not seen in 
nephrectomised control animals suggesting that it is a consequence of the renal inflammatory 
response rather than accumulated toxins. Similar work has also shown an increase in lung 
water although this was attributed to accumulated toxins rather than pro-inflammatory 
molecules (Rabb et al., 2003). 
1.8 Acute Kidney Injury and sepsis 
 
Sepsis is a whole body inflammatory state in the presence of (or suspected) infection. Initially 
there is an appropriate innate immune response but this becomes amplified and dysregulated 
leading to a pro-inflammatory state followed by a subsequent anti-inflammatory state. Acute 
kidney injury is commonly seen as a complication of sepsis unless the underlying infection is 
treated in a timely manner (Uchino et al., 2005). 
In a similar manner to ischaemic acute kidney injury, the pro-inflammatory state is associated 
with increases in oxygen radicals, cytokines, complement/coagulation pathway activation, 
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protease activation (White & Hassoun, 2012). This is very similar to the changes seen in pure 
ischaemic acute kidney injury and may explain why the condition may be seen as a complication 
of sepsis. 
1.9 Acute Kidney Injury and multi-organ damage 
 
Acute kidney injury can occur in the presence of other organ failure. Again the mechanisms 
appear to be very similar to those seen in pure ischemic acute kidney injury with release of 
cytokines and oxidation products from both the kidneys and other organs e.g. lungs, liver, 
brain, gut (White & Hassoun, 2012). The fact that other organs can release these products in 
response to renal damage can set up a cycle of damage in the secondary organ causing further 
damage to the primary organ. Acute kidney injury in the presence of multi-organ failure has a 
much higher mortality than uncomplicated acute kidney injury (Wohlauer et al., 2012). 
1.10 Assessment of renal function 
 
 
Many methods, markers and procedures have been described other the years as surrogate 
measures of renal function. Perhaps the simplest is an assessment of urine output; this can be 
combined with a fluid intake chart to provide a measure of overall hydration status. 
Unfortunately, these fluid balance charts are often poorly completed leading to inaccurate and 
misleading assessments of renal and hydration status. Even if these are completed, studies 
indicate that timely review may not be undertaken or that the knowledge base for correct 
interpretation may be missing (Lobo et al., 2001) (Lobo, Dube, Neal, Allison, & Rowlands, 2002). 
Therefore, renal function is usually assessed using markers found in the blood which can be 
relatively easy and quick to measure are an invasive procedure. 
 Page 27 
 
1.11 Biological markers of acute kidney injury 
 
A biological marker (biomarker) may have a number of different definitions: 
‘A characteristic that is objectively measured and evaluated as an indicator of normal 
biological processes, pathogenic processes, or pharmacologic responses to 
therapeutic intervention’ (National Institute for Health) 
Any measurable diagnostic indicator that is used to assess the risk or presence of 
disease. (Federal Drug Administration) 
 
However, when related to acute kidney injury, the marker needs to indicate the presence of AKI 
and correlate with the degree of damage that has been done. Currently, all definitions for acute 
kidney injury rely on the measurement of serum creatinine, which, as we shall explore, is far 
from an ideal marker for the condition.  
Unlike other conditions e.g. myocardial infarction where the author has seen a change over the 
years in the biomarkers used, acute kidney injury (acute renal failure) has relied on serum 
creatinine for a number of decades (table 1-2). 
Table 1-2 Comparison of biomarkers for AKI and AMI 
Decade Myocardial infarction Acute kidney injury 
1970’s CK (CPK) Change in serum creatinine 
1980’s CK-MB Change in serum creatinine 
1990’s Troponin T Change in serum creatinine 
2000’s Troponin I Change in serum creatinine 
2010’s hs-Troponin I/T Change in serum creatinine 
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1.12 Creatinine as a ‘gold standard’ for AKI detection 
 
Creatinine (or its derivative, the estimated glomerular filtration rate) is currently the basis of all 
the common detection and staging proposals for acute kidney injury. However, creatinine is not 
without its own problems and, as such cannot be regarded as a gold standard for the condition 
(Waikar, Betensky, & Bonventre, 2009). Creatinine is a ‘passive marker’ of the glomerular 
filtration rate (GFR); it does not start to rise until after renal function has been compromised 
and, as such, measured increases lag behind the actual functional changes in the kidney. Thus a 
rise in creatinine occurs after the renal function has been compromised and, similarly, only 
starts to fall after renal function begins to recover. 
There are a number of physiological factors that affect the measurement of creatinine including 
diet, demographics (age, gender and ethnicity), volume of distribution and muscle catabolism. 
Finally, in order to use creatinine as a marker for the detection of acute kidney injury requires 
that there is a previous value to compare against the current value.  This may not always be 
available with emergency admissions and hence may cause a significant delay in the diagnosis. 
The current method within the Trust for the measurement of creatinine is based on the 
reaction between the analyte and picric acid, first described by Jaffe in 1886. Since then it has 
undergone some minor modifications (the reaction is now read as a kinetic response rather 
than end-point and dual wavelengths are used for blanking purposes). However, the basic 
principle remains after all these years as do the problems associated with non-specific 
reactions, notably interference from ketones, bilirubin and glucose although others have also 
been described. 
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𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 + 𝑝𝑝𝐶𝐶𝑝𝑝𝐶𝐶𝐶𝐶𝑝𝑝 𝐶𝐶𝑝𝑝𝐶𝐶𝑑𝑑 → 𝐶𝐶𝐶𝐶𝑑𝑑 𝑝𝑝ℎ𝐶𝐶𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝐶𝐶𝐶𝐶 
In the Best Practice guidance (Hill & Selby, 2014) as well as other studies (Lewington & 
Kanagasundaram, 2011), the enzymatic method is the recommended method for the 
measurement of creatinine  but this is expensive and, in the current economic climate, not used 
routinely in laboratories. The basic reaction used in this method is less prone to interference 
and has a superior performance at lower concentrations. 
𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 +  𝐻𝐻2𝑂𝑂  𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐�⎯⎯⎯⎯⎯⎯⎯⎯�  𝑝𝑝𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 
𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 + 𝐻𝐻2𝑂𝑂  𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐�⎯⎯⎯⎯⎯⎯�  𝑠𝑠𝐶𝐶𝐶𝐶𝑝𝑝𝑟𝑟𝑠𝑠𝐶𝐶𝐶𝐶𝐶𝐶 + 𝑢𝑢𝐶𝐶𝐶𝐶𝐶𝐶 
 
𝑆𝑆𝐶𝐶𝐶𝐶𝑝𝑝𝑟𝑟𝑠𝑠𝐶𝐶𝐶𝐶𝐶𝐶 + 𝐻𝐻2𝑂𝑂 + 𝑂𝑂2  𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑠𝑠𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 𝑠𝑠𝑜𝑜𝑐𝑐𝑜𝑜𝑐𝑐𝑐𝑐𝑐𝑐�⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯�  𝑟𝑟𝑔𝑔𝑔𝑔𝑝𝑝𝐶𝐶𝐶𝐶𝐶𝐶 + 𝐶𝐶𝑔𝑔𝑑𝑑𝐶𝐶ℎ𝑔𝑔𝑑𝑑𝐶𝐶 + 𝐻𝐻2𝑂𝑂2 
 
𝐻𝐻2𝑂𝑂2 + 𝑝𝑝ℎ𝐶𝐶𝐶𝐶𝑟𝑟𝑔𝑔 𝑑𝑑𝐶𝐶𝐶𝐶𝐶𝐶𝑑𝑑𝐶𝐶𝐶𝐶𝐶𝐶𝑑𝑑𝐶𝐶 + 4 𝐶𝐶𝑟𝑟𝐶𝐶𝐶𝐶𝑟𝑟𝑝𝑝ℎ𝐶𝐶𝐶𝐶𝐶𝐶𝑒𝑒𝑟𝑟𝐶𝐶𝐶𝐶       →  𝐶𝐶𝐶𝐶𝑑𝑑 𝑏𝑏𝐶𝐶𝐶𝐶𝑒𝑒𝑟𝑟𝑏𝑏𝑢𝑢𝐶𝐶𝐶𝐶𝑟𝑟𝐶𝐶𝐶𝐶𝐶𝐶𝑟𝑟𝐶𝐶𝐶𝐶𝐶𝐶 𝑑𝑑𝑔𝑔𝐶𝐶 
 
 
1.13 Neutrophil gelatinase-associated lipocalin 
 
Neutrophil associated gelatinase lipocalin (NGAL) is a 25kDa protein which can be found in 
three distinct molecular forms; a 25kDa monomer, a 45 kDa homodimer and a 135kDa 
heterodimer. The monomer is covalently bound to matrix metalloproteinase 9 (MMP-9).  NGAL 
is synthesised in the renal tubular cells (in the monomeric form) but also in neutrophils in the 
divalent form. However, current assays are unable to reliably distinguish between these two 
forms.  Thus, whilst NGAL has shown promise in the early detection of acute kidney injury 
further work is required before this can be used in the routine clinical setting (Devarajan, 2010). 
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1.14 Cystatin C 
 
Cystatin C is a 13 kDa cysteine proteinase inhibitor produced by nucleated cells. It is filtered 
freely at the glomerulus, reabsorbed in the tubules and then catabolized; it is not secreted 
within the tubules (Westhuyzen, 2006). Studies have demonstrated that it is superior to 
creatinine in the detection of acute kidney injury (Herget-Rosenthal et al., 2004). However, it is 
more expensive to measure than serum creatinine and has yet to receive wide acceptance as a 
routine test of renal function. 
1.15 Estimated glomerular filtration rate 
 
The estimated glomerular filtration rate (eGFR) is a derived parameter based on the age, 
gender and serum creatinine. Whilst a number of equations have been developed, the most 
commonly used one in the United Kingdom is from the Modification of Diet in Renal Disease 
(MDRD) study group (Levey et al., 1999) which is: 
𝐶𝐶𝑒𝑒𝑒𝑒𝑒𝑒 (𝑟𝑟𝑔𝑔𝑠𝑠/𝑟𝑟𝐶𝐶𝐶𝐶) = 186 𝑥𝑥  𝑝𝑝𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶88.4 −1.154  𝑥𝑥 𝐴𝐴𝑟𝑟𝐶𝐶−0.203 𝑥𝑥 (0.742 𝐶𝐶𝑖𝑖 𝑖𝑖𝐶𝐶𝑟𝑟𝐶𝐶𝑔𝑔𝐶𝐶) 𝑥𝑥 (1.210 𝐶𝐶𝑖𝑖 𝑏𝑏𝑔𝑔𝐶𝐶𝑝𝑝𝑏𝑏) 
But the factor of 186 has been changed to 175 to account for traceability of creatinine standard 
solutions to the international reference preparation. Use of the eGFR can help to assess 
changes in renal function in an individual over time as well as population cohort studies; 
creatinine varies with both age and gender but these are accounted for to some extent within 
the eGFR equation.  
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1.16 Creatinine assay, measurement uncertainty and reference change values 
 
The current method within the Trust for the measurement of creatinine is based on the 
reaction between the analyte and picric acid first described by Jaffe in 1886. The precision of 
the method was monitored by regular (3-4 times daily) assessment of quality control samples at 
two different concentrations on every analyser performing the assay. The performance typically 
recorded for the creatinine assay are shown in table 1-3. 
Table 1-3 Creatinine assay between batch performance 
Creatinine concentration 
(µmol/L) 
Standard Deviation Coefficient of variation (%) 
62 2.1 3.44 
415 8.9 2.14 
All UK based clinical laboratories are now assessed against ISO standard 15189. Section 5.6.2 of 
this standard requires all laboratories to  
“… determine the uncertainty of results, where relevant and possible.” 
with the rationale for this requirement being 
“The expression of the uncertainty of a result allows comparison of results from 
different laboratories, or within a laboratory or with reference values given in 
specifications or standards.” 
Whilst the calculation of the uncertainty measurement can be quite complex depending on the 
analyte, it can, in essence, be calculated according to the following formula: 
𝑟𝑟𝐶𝐶𝐶𝐶𝑠𝑠𝑢𝑢𝐶𝐶𝐶𝐶𝑟𝑟𝐶𝐶𝐶𝐶𝐶𝐶 𝑟𝑟𝑖𝑖 𝑢𝑢𝐶𝐶𝑝𝑝𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝑔𝑔 = 1.96 ± 𝑆𝑆𝑆𝑆𝐶𝐶𝐶𝐶 
 
This figure can then be used to describe the 95% confidence interval for the range where the 
true concentration of the analyte actually lies. Using this equation and the assay performance 
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measures shown in table 1-3 we can be 95% confident that the true concentration of creatinine 
in the quality control materials lies in the ranges shown in table 1-4. 
Table 1-4 Measurement of uncertainty values for the creatinine assay 
Quality control mean value Measurement of uncertainty range 
62 58 – 66 
415 397 - 432 
Once the measurement of uncertainty is known, this can then be used to assess the assay in 
terms of whether it is ‘fit for purpose’ by comparison with the biological variation of the analyte 
according to the following criteria (G. H. White & Farrance, 2004).  
Optimum: CVA = < 0.25 x CVI = 1.49 
Desirable: CVA = < 0.50 x CVI = 2.98 
Minimum: CVA = < 0.75 x CVI = 4.46 
The CVA is the variation ascribed to the analysis of the analyte and CVI is the biological variation 
of the analyte. The CVI for creatinine has been variously published as up to 5.95 (Gowans & 
Fraser, 1988; Nejat et al., 2010). Using these criteria, the assay meets the criteria for desirable 
performance at a concentration of 415 µmol/L and the minimum performance criteria at a 
creatinine concentration of 62 µmol/L. 
However, each individual also has their own biological variation which, in addition to the 
analytical variation, needs to be taken into account when determining whether a second 
measurement for an analyte differs significantly from the first measurement. This critical 
change is termed the reference change value and is given by the formula (Fraser, 2012):  
21/2 𝑥𝑥 𝑍𝑍 𝑥𝑥  (𝐶𝐶𝐶𝐶𝐼𝐼2 +  𝐶𝐶𝐶𝐶𝐴𝐴2)2  
 
Where CVI is the intra-individual biological variation; for creatinine this is 5.95 whilst CVA is the 
analytical variation. The Z-score is the desired level of statistical significance, usually taken as 
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95% so Z = 1.96. From the analytical and biological data the reference change value at a 
concentration of 62 µmol/L is 19.1 meaning that a change in the creatinine concentration is 
only significant if the subsequent measurement is outside the range 62±19.1 µmol/L. For the 
higher quality control value the RCV is 17.5 meaning the subsequent value must exceed 
415±17.5 µmol/L for the change to be significant. 
The implications for these figures are not obvious at the creatinine concentrations in the quality 
control samples. For example, the NHS England algorithm states that stage 1 AKI occurs when 
the absolute change exceeds 26 µmol/L within 48 hours. The data supports the notion that the 
assay performs at a level where, if this change it seen, it is not due to an analytical and 
biological variability as the measurement of uncertainty is less than the reference change value. 
In all assays, as the values tend towards the limit of detection there is an increase in the 
analytical coefficient of variation and creatinine is no exception. From the equations shown 
above it is possible to construct a table that details the reference change value that is 
significant based on various CVA and CVI values (table 1-5). Based on this table we can see that if 
the CVA increases to 10% then the RCV value will be 32.3 for the creatinine CVI of 5.95% 
(rounded up to 6%). 
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Table 1-5 Reference change values for differing CVA and CVI values 
CVI 
(%) 
CVA (%) 
4 5 6 7 8 9 10 12 15 20 
2 12.4 14.9 17.5 20.2 22.8 25.5 28.2 33.7 41.9 55.7 
3 13.9 16.2 18.6 21.1 23.7 26.3 28.9 34.3 42.4 56.0 
4 15.7 17.7 20.0 22.3 24.8 27.3 29.8 35.0 43.0 56.5 
5 17.7 19.6 21.6 23.8 26.1 28.5 31.0 36.0 43.8 57.1 
6 20.0 21.6 23.5 25.5 27.7 30.0 32.3 37.2 44.8 57.8 
8 24.8 26.1 27.7 29.4 31.3 33.4 35.5 39.9 47.1 59.7 
10 29.8 31.0 32.3 33.8 35.5 37.3 39.2 43.3 49.9 61.9 
12 35.0 36.0 37.2 38.5 39.9 41.6 43.3 47.0 53.2 64.6 
15 43.0 43.8 44.8 45.9 47.1 48.5 49.9 53.2 58.8 69.3 
20 56.5 57.1 57.8 58.7 59.7 60.8 61.9 64.6 69.3 78.3 
25 70.1 70.6 71.2 71.9 72.7 73.6 74.6 76.8 80.8 88.7 
30 83.8 84.2 84.7 85.3 86.0 86.8 87.6 89.5 92.9 99.9 
35 97.6 97.9 98.4 98.9 99.5 100.1 100.8 102.5 105.5 111.7 
From this table it is possible to derive the minimum creatinine value that can be used to 
evaluate acute kidney injury. For instance, the CVI for creatinine is 6% and the CVA (albeit at 62 
µmol/L) is 3.4% (≈ 4%). From the table we get a reference change value of 20.0 (highlighted) 
indicating that a change of at least this magnitude is clinically significant and any smaller 
changes may be due to analytical and biological variation. Without accurate data on the CVA at 
lower concentrations of creatinine it is not possible to positively state the impact on the ability 
to detect acute kidney injury at lower creatinine concentrations. However, based on the 
assumption that the CVA remains at 4%, then acute kidney injury should not be considered if 
the rise triggering the alert is less than the reference change value.   
In a recent study, Lin et al. (2015) found an overall false positive rate of 8% in the diagnosis of 
AKI which rose to 30.5% in patients where the creatinine exceeded 133 µmol/L. This was due to 
small changes in creatinine concentrations being attributable to analytical and/or biological 
variation rather than a true rise. 
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1.17 Epidemiology of acute kidney injury 
 
Over the years the multitude of different definitions for acute kidney injury has made it difficult 
to accurately assess the incidence of the condition. In addition, many studies have used a 
selected group of patients e.g. cardiac surgery, intensive care cohorts etc. Stevens et al. (2001) 
reported the incidence of acute kidney injury as being 486 per million of population per year. In 
June 2014 the population of the United Kingdom was estimated at 64.6 million and, taking the 
figures from the Stevens study, this would extrapolate to 31,396 cases per annum. This study 
defined acute kidney injury as a temporary rise in the creatinine to ≥300 µmol/L and/or a rise in 
serum urea to greater than 40 mmol/L. Importantly this study also highlighted that, of the 288 
cases of acute renal failure, 108 (37.5%) were iatrogenic and/or preventable.  
Hsu et al. (2007) described a rise in the community based incidence of acute renal failure not 
requiring dialysis from 322.7 per 100,000 person years to 522.4 between 1996/7 and 2002-3. 
There was also a rise in dialysis requiring acute renal failure from 19.5 per 100,000 person years 
in 1996-7 to 29.5 in 2002-3. This study also showed that both conditions were more common in 
males than females and associated with advancing age. Hou, Bushinsky, Wish, Cohen, and 
Harrington (1983) in a prospective study of 2,262 medical and surgical admissions calculated 
that renal insufficiency arose in 4.9% of the patients.  
The hospital admission rate in England is 1 in 10 per year (Robinson, 2010). The prevalence of 
the Kidney Disease Improving Global Outcomes (KDIGO) stages of risk, injury and failure (RIFLE) 
of AKI are estimated at 9.1%, 5.2% and 3.7% of hospital admissions respectively (Uchino et al, 
2006). From these figures we can extrapolate that the numbers of patients experiencing the 
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KDIGO risk, injury and failure are 9,100, 5,200 and 3,700 per million population which, given a 
UK population of 64.6 million (June 2014) equates to 587,860, 335,920 and 239,020 patients in 
each category per year. These figures are markedly different from those extrapolated from the 
data by Stephens and may highlight the issues that have arisen over the years with the different 
systems for the detection of the condition. 
A recent study in Greater Manchester of 420 emergency admissions showed that the median 
length of stay for patients who developed AKI was 17.8 days compared with 6.8 days for those 
without AKI ("Acute Kidney Injury - Prevent this Silent Killer," June 2011). In addition, 11.5% of 
those with acute kidney injury required intensive care unit treatment compared with 2.0% of 
those without acute kidney injury. Additionally, the mortality in the AKI group was 5.1% 
compared with 1.3% for the non-AKI group.  
1.18 Risk factors for AKI 
 
As the kidneys age they undergo a number of structural and functional changes including loss of 
nephrons, tubular mass and increasing numbers of sclerotic glomeruli. The glomerular filtration 
rate (GFR) declines from around the age of 40 and this decline accelerates in the mid-60’s 
(Davies & Shock, 1950). Therefore, it is not surprising that increasing age is a risk factor for 
acute kidney injury as these patients are already functionally compromised. As has been 
discussed in the section on the pathogenesis of ischaemic AKI, the presence of nephrotoxic 
medication, reduced renal blood flow, sepsis and compromised renal function can all play a role 
in the development of the condition. Despite this knowledge, the National Confidential Enquiry 
into Patient Outcomes and Death (2009) highlighted that the risk factors for AKI (table 1-6) 
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were poorly documented in 29% of cases; in only 3% of cases was there documentation related 
to all of these areas. The figure for inadequate documentation rose to 54% in those who 
developed acute kidney injury following admission. 
Table 1-6 Risk factors for acute kidney injury 
Number Risk factor Comments 
1 Age >75 years 
2 Co-morbidities Cardiac failure, Peripheral 
vascular disease, Hepatic disease, 
Diabetes mellitus, hypotension 
3 Medication Nephrotoxic medication 
4 Previous chronic kidney disease eGFR < 60 mL/min) 
5 Hypovolaemia  
6 Sepsis  
7 Biochemistry  
8 Urinalysis  
9 Weight  
10 Nutritional status  
 
These risk factors have been taken from the National Confidential Enquiry into Patient 
Outcomes (2009). 
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1.19 Problems with the detection of acute kidney injury 
 
Many years ago the definition of acute renal failure could be likened to the famous definition of 
pornography in the United States Supreme Court; 
‘You know what it is when you see it’. (Justice Potter Stewart) 
 
The criteria for the classification of acute kidney injury have been in a state of flux with 
numerous proposals being published. In 2013, NHS England published a Patient Safety Notice 
which required Trusts to implement the detection of acute kidney injury within the Laboratory 
Information Management System (LIMS). Reporting of electronic alerts in secondary care was 
to commence in March 2015 with primary care and other locations by March 2016. 
A typical biochemistry profile contains between 4 and 12 individual analytes but, in extreme 
instances, may be in excess of 20 individual analytes. The results are usually presented to the 
requesting clinician in the form of a spreadsheet (although they may be a single page containing 
just the results from the current request). Given that some of the acute kidney injury criteria do 
not compare the current result with the preceding request but are based on the lowest value 
over a previous number of days or the median value it is, perhaps, not surprising, that cases of 
AKI may be missed. Whilst laboratories will flag up those results outside the age and gender-
related reference ranges and will telephone grossly abnormal results as per the Royal College of 
Pathologists guidelines, it is quite possible for a result to rise significantly but remain within the 
reference range and therefore not be flagged or telephoned, but still meet the diagnostic 
criteria for AKI. Such changes can become easily lost in the plethora of other data relating to an 
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individual patient and may only become apparent at a much later date and more severe acute 
kidney injury stage. 
All commercial laboratory systems currently offer a facility for delta checking the current results 
against previous results for the same patient. A delta check is a comparison between the 
current value and the previous value held on file. The check can be limited to look back a 
specific number of days and flag those samples where the absolute or percentage change 
exceeds a given value. However, this check is based on the previous results and not the lowest 
result over a preset period of time as required by the criteria for KDIGO, AKIN and Waiker & 
Bonventre. Garner, Lewington, and Barth (2012) published a paper that used a simple delta 
check (comparing the previous result with the current result) and found generally good 
agreement for AKI using a cut off at 26 µmol/l for serum creatinine. Whilst, from a pragmatic 
viewpoint, this would be easy for most laboratories to implement, it does not have the 
evidence base for wider acceptance compared with other more established algorithms. A 
search of PubMed using the search terms ‘acute kidney injury’ and ‘delta check’ returned three 
articles whereas substituting ‘KDIGO’ for ‘delta check’ returned 148 articles. 
1.20 Why is early detection of acute kidney injury important? 
 
The section on the pathogenesis of AKI has highlighted the cyclical amplification that may occur 
where hypoxia may result in further hypoxia thus exacerbating the degree of injury. Therefore, 
it may seem intuitive that the earlier detection and intervention of AKI would lead to improved 
patient outcomes and reduced costs.  
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A recent meeting of at the Royal College of Physicians in Edinburgh (Feehally et al., 2013)  to 
discuss acute kidney injury highlighted the potential role for electronic alerts with the following 
statements. 
 If early identification of AKI, defined by changes in serum creatinine concentration, is to be 
achieved and early treatment facilitated, e-alerts should prove valuable tools in primary and 
secondary care. 
 E-alert systems should be introduced in the context of e-guidance on management of AKI, 
continuing education of clinical teams, and agreed care bundles. 
 At present systems are being developed ad hoc. A national group should be established to 
develop agreed standards for e-alert systems recognising the need for some system-dependent 
local flexibility. Components of the system should include an agreed definition of AKI based on 
the KDIGO classification and a standardised methodology for derivation of baseline serum 
creatinine. We recommend use of an enzymatic serum creatinine assay with an IDMS-traceable 
calibration to enable standardisation.  
 Healthcare providers employing e-alert systems must have robust arrangements to ensure 
appropriate and prompt responses with clear lines of accountability. 
 We [the Royal College of Physicians of Edinburgh] recommend audit and research to confirm that 
in addition to identification of AKI the use of e-alert systems improves outcomes 
An alert is defined in the Oxford English Dictionary as a ‘state of being watchful for possible 
danger’ (noun) and, more specifically with reference to this research as ‘a signal on an 
electronic device that prompts the user to do something or attracts their attention’,  
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The current study was conceived prior to this meeting, but it may provide evidence that 
electronic alerts have a valuable role to play in the improvement of patient outcomes. At the 
outset of this project there was very little published work on the use of alerts in acute kidney 
injury. However, there was an increasing yet still limited body of evidence of the use of these 
alerts at the time of final thesis submission. 
Colpaert et al. (2012) developed an ‘AKI sniffer’ for Intensive Care Unit patients based on the 
KDIGO(RIFLE) classification. This study had a 6-week pre-alert control phase followed by a 12-
week alert phase and, finally, a 6 week post alert period. The results showed that during the 
alert period a higher percentage of patients received treatment within 60 minutes (28.7%) 
compared with both the pre and post alert phases (7.9% and 10.4% respectively). This study 
also showed that a higher proportion of patients returned to baseline renal function within 8 
hours compared with the control group. In addition, during the alert phase more patients 
received fluid therapy, diuretics and vasopressors (table 1-7). 
Table 1-7 Effect of an AKI 'sniffer' on clinical intervention 
 6 week pre-alert 12 week alert 6 week post alert 
Fluids 4.9% 23.0% 9.2% 
Diuretics 2.6% 4.2% 0.8% 
Vasopressors 1.1% 3.9% 0.8% 
 
This limited study would appear to provide evidence that ongoing detection and alerting would 
be beneficial and the presence of the alerts has a positive impact on clinical practice.  
Other studies have shown the feasibility of automated detection and alerting (Flynn & Dawnay, 
2015) from within a Laboratory Information Management System (LIMS). Thomas, Sitch, and 
Dowswell (2011) implemented a system that provided a real time alert for any patient where 
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there was a ≥75% rise in serum creatinine. As part of this work they are currently implementing 
an outreach team to work with clinicians when patients with acute kidney injury are identified. 
They estimate a financial saving in the region of £21,000 per 100,000 population which is net of 
the outreach team investment. Unfortunately, there are no published data available on the 
effectiveness of this approach on patient outcomes. However, it is known that existing 
management is poor and often delayed. It would therefore seem intuitive that any initiative to 
highlight the presence of acute kidney injury to the clinical team should result in improved 
treatment, especially if the alert also contained prompts to aid the further investigation and 
therapy. In terms of the financial estimate of savings, if the figure postulated by Thomas et al is 
to be believed, it could lead to a saving of up to £13.5million based on the estimated 2014 UK 
population of 64.6 million. This figure seems to fall short of some estimated figures but it does 
include the cost of implementing an AKI outreach team and all the associated costs. 
One of the problems with any form of alerting system is that of ‘alert fatigue’. This is where the 
receivers of the alert become overwhelmed by the number of alerts or the false positive rate is 
so high that they become viewed as interfering with patient management (Lee, Mejia, Senior, & 
Jose, 2010). Most of the work in this field has been done with medication alerts but the same 
could hold true for AKI alerts (Kesselheim, Cresswell, Phansalkar, Bates, & Sheikh, 2011; Lee et 
al., 2010). 
In a review of the available evidence published by Hoste et al. (2016) the papers could be 
divided into 3 broad groups: 
1. Papers describing the implementation of electronic alerts without patient outcome 
data. 
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2. Electronic alert implementation/use which did not improve patient outcomes. 
3. Electronic alert implementation which improved patient outcomes. 
(Kolhe et al., 2015) showed that patient outcomes were improved when acute kidney injury 
care bundles were completed early and this can be facilitated by the use of electronic alerts. 
1.21 Detection and classification schemes for AKI 
 
Over the years a number of criteria have been proposed as indicative of acute renal failure/AKI. 
These include creatinine > 300 µmol/l, urea > 40 mmol/L (Stevens et al., 2001) plus urine output 
criteria. In recent years there has been a move away from absolute values towards the use of 
percentage and absolute changes in creatinine (Bellomo et al., 2004). The use of different 
measures for the detection and classification of AKI makes it difficult to transfer data from one 
study to another when different criteria have been used. In this study the focus has been on the 
NHS England algorithm mandated by the Patient Safety Alert. However, the opportunity arose 
within the study to evaluate patients by other algorithms outlined in table 1-8. 
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Table 1-8 Algorithms for the detection of acute kidney injury 
 Stage 1 Stage 2 Stage 3 
Acute Kidney 
Injury Network 
2007 
Increase serum 
creatinine >= 26 µmol/L 
within 48 hours  
OR increase of 1.5 – 1.9 
times reference serum 
creatinine  
OR urine output < 
0.5ml/kg/h for > 6 
consecutive hours 
Increase of 2 – 2.9 times 
reference serum 
creatinine  
OR 
urine output < 
0.5ml/kg/h for > 12 
consecutive hours 
Increase of >= 3 times 
reference serum creatinine  
OR serum creatinine >= 354 
µmol/L with a rise of >= 44 
µmol/L from the reference 
serum creatinine  
OR commenced renal 
replacement therapy  
OR urine output < 0.3ml/kg/h 
for > 24 consecutive hours  
OR complete anuria. 
KDIGO 2012 
(RIFLE) 
Increase in serum 
creatinine ≥26.5 µmol/L 
over baseline  
OR  
Increase in creatinine of 
1.5 - <2.0 over baseline  
OR a decrease in the 
GFR of >25% 
OR urine output <0.5 
ml/kg/h for 6–12 hours 
Increase in creatinine of 
2.0 -<3.0 over baseline  
OR a decrease in the 
GFR of >50% 
OR urine output <0.5 
ml/kg/h for >12 hours 
Increase in creatinine of ≥3.0 
over baseline  
OR an increase in serum 
creatinine by at least 44 
µmol/L from ≥354 µmol/L 
OR a decrease in the GFR of 
>75% 
OR in patients <18 years, 
decrease in eGFR to <35 
ml/min per 1.73 m2 
OR urine output <0.3 ml/kg/h 
for ≥24 hours OR 
anuria for ≥ 12 hours 
OR initiation of renal 
replacement therapy 
Waikar and 
Bonventre 
(2009) 
An increase in serum 
creatinine of ≥26 
µmol//L in 24 hours  
OR ≥ 44 µmol/L in 48 
hours 
An increase in serum 
creatinine of ≥44 µmol/L 
in 24 hours  
OR ≥ 88 µmol/L in 48 
hours 
An increase in serum 
creatinine of ≥88 µmol/L in 
24 hours  
OR ≥ 132 µmol/L in 48 hours 
Garner et al 
2012 
Increase in serum creatinine of ≥26 µmol /L from the previous value 
NHS England 
2013 
Increase in serum 
creatinine of 1.5 - <2.0 
times baseline 
OR rise in serum 
creatinine of >26 µmol/l 
within 48 hours 
 
Increase in serum 
creatinine of 2.0 - <3.0 
times baseline 
 
Serum creatinine > 354 µmol 
/L and increase > 1,5 times 
baseline 
OR increase in serum 
creatinine of ≥3.0 times 
baseline 
OR in patients < 18 years a 
serum creatinine > 3 upper 
reference limit for age 
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Notes: 
AKIN criteria - The reference serum creatinine is taken as the lowest value in the previous 48 hours 
although some authors suggest a longer baseline may be preferable (Batstone & Abdi). 
KDIGO - The reference serum creatinine is the lowest recorded serum creatinine in the previous 7 days. 
Waikar and Bonventre (2009) evaluated the clearance of creatinine in patients with chronic kidney 
disease using mathematical modelling and proposed that the criteria should be modified to avoid 
missing the development of acute change in patients with CKD. 
Garner et al proposed the use of a delta check whereby any increase in creatinine exceeding 26 µmol/L 
over the previous value would be taken as indicative of AKI. 
NHS England baseline is defined as the lowest creatinine in the previous 7 days OR the median of the 
values from days 8 to 365. The ratio of these results to the current serum creatinine is then calculated 
and the lowest ratio used for calculation the change ratio. 
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1.22 Screening for acute kidney injury 
 
The previous section on the classification of AKI highlighted the essential role of a baseline 
creatinine measurement. In the absence of such a sample, the diagnosis can only be assumed 
or made retrospectively. With the advent of the NHS England algorithm in 2013 the baseline 
period has now been extended to 365 days compared with 7 for some of the other algorithms, 
although this is not without its own problems as will be discussed later. 
It is recommended that patients seen as emergencies should have the renal function checked 
on admission and at appropriate intervals thereafter (National Confidential Enquiry into Patient 
Outcomes and Death, 2009). In addition, this publication recommends that:  
‘For those in-patients who develop AKI there should be both a robust assessment of 
contributory risk factors and an awareness of the possible complications that may 
arise’  
 
By mandating the NHS England algorithm within the Laboratory Information Management 
System, the task of evaluating many results looking for potential acute kidney injury has now 
been automated and takes place at the same time as the creatinine result is reported. 
However, this still necessitates the need to take samples at the appropriate times and take 
action when a detection alert is issued. 
1.23 Effects of Acute Kidney Injury 
 
Stevens et al. (2001) showed the overall survival from acute renal failure was 56% at discharge 
from hospital, 35% at 1-year follow-up, 31% at 2 years and 28% at 3 years. However, in 
discharged patients, recovery of renal function was complete in 69% of patients.  
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More recent studies have shown that outcomes vary depending of the stage of AKI and this is 
summarised in table 1-9. 
Table 1-9 Summary of acute kidney injury outcomes 
Study Number AKI stage Outcome 
Ali et al. (2007) 
 
562 AKI-F 
ACRF 
51% recover full renal function 
28% recover full renal function 
Ishani et al. (2011) 
 
233,803 AKI 
ACRF 
13 times more likely to develop ESRD 
41 times more likely to develop ESRD 
Hsu et al. (2009) 
 
1,061 ACRF-F 42-63% of hospital survivors progressed to 
ESRD 
Lo, Liu, and Hsu (2009) 
 
703 AKI-F Survivors are 28 times more likely to 
develop advanced CKD 
Amdur, Chawla, 
Amodeo, Kimmel, and 
Palant (2009) 
5,404 ATN 20% of patients with a diagnosis of ATN 
progress to CKD stage 4 within 20 months. 
Wald et al. (2009) 3,769 AKI-F Survivors 3 times more likely to develop 
ESRD 
AKI-F Acute kidney injury – RIFLE stage Failure, ACRF : Acute on chronic kidney disease;  
ESRD : End stage renal disease; ATN : Acute tubular necrosis 
The study by Lo et al. (2009) excluded patients who developed end stage renal disease within 
30 days of discharge hence this represents the development of renal disease following initial 
recovery of renal function. The risk factors associated with progression to chronic kidney 
disease include advanced age, diabetes mellitus and decreased baseline eGFR. Low serum 
albumin concentrations have been shown to correlate with poorer outcomes. This may be 
related to poor nutritional status and/or the presence of an inflammatory response. Chawla 
(2011) showed that progression to chronic kidney disease is associated with acute kidney injury 
severity as assessed by the KIDIGO (RIFLE) criteria and that patients who required renal 
replacement therapy were at higher risk of progression to CKD than those with less severe 
forms of AKI. 
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1.24 Acute kidney injury and subsequent mortality 
 
Many studies have shown an association between acute kidney injury and subsequent 
mortality. Stevens et al. (2001) showed the overall survival from acute renal failure was 56% at 
discharge from hospital, 35% at 1-year follow-up, 31% at 2 years and 28% at 3 years. Chertow 
et al (2005) showed the unadjusted odds ratio for mortality for mild increases in serum 
creatinine of >26 µmol/L was 6.9 (95% confidence interval 5.0 – 9.2). This rose with 
corresponding increases in serum creatinine where a rise of >44 µmol /L had an odds ratio of 
11.1 (8.7 – 14.2); >88 µmol /L had an odds ratio of 19.9 (15.1 – 26.1) and > 177 µmol /L had an 
odds ratio of 36.4 (24.3 – 54.6). Ostermann, Chang, and Riyadh (2008) demonstrated that those 
patients admitted to Intensive Care units with acute kidney injury had lower mortality than 
those treated outside these specialist units (table 1-10). 
Table 1-10 Mortality for ITU and non-ITU patients based on AKIN criteria 
 No AKI AKIN stage 1 AKIN stage 2 AKIN stage 3 
ITU mortality 10.7% 20.1% 25.9% 49.6% 
Hospital mortality 16.9% 29.9% 35.8% 57.9% 
Hoste et al. (2006) demonstrated a similar pattern of increasing mortality with acute kidney 
injury in intensive care patients using the KDIGO (RIFLE) criteria; no AKI mortality 5.5%; RIFLE 
risk 8.8%, RIFLE injury – 11.4%; RIFLE failure – 26.3%. 
It appears that patients die as a consequence of existing conditions rather than the acute 
kidney injury (Selby et al., 2012). In this study the major cause of death was sepsis (41.1%) with 
pneumonia being the major cause of this condition, cardiovascular disease (19.2%) and 
malignancy (12.9%). 
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1.25 Acute kidney injury and subsequent chronic kidney disease 
 
Studies have demonstrated an association between an initial episode of acute kidney injury and 
the subsequent development of chronic kidney disease. In a systematic review of 48 studies the 
incidence rate of chronic kidney disease following an episode of acute kidney injury was 7.8 
events per 100 patient years with end stage renal disease being 4.9 events per 100 patient 
years (Coca, Yusuf, Shlipak, Garg, & Parikh, 2009). The pooled adjusted hazard ratio for 
developing chronic kidney disease has been quoted as 8.8 (95% confidence interval 3.1 – 25.5) 
when compared with non-acute kidney injury patients (Coca, Singanamala, & Parikh, 2012). 
Bucaloiu et al (2012) demonstrated a similar association between reversible acute kidney injury 
and subsequent chronic kidney disease with a hazard ratio of 1.91. The magnitude of the acute 
kidney injury has been shown to be a predictor of subsequent chronic kidney disease (Chawla, 
Amdur, Amodeo, Kimmel, & Palant, 2011). Not only is the risk of chronic kidney disease 
increased but the risk of long term dialysis is also increased; hazard ratio 2.70; 95% confidence 
interval 2.42 – 3.00 (Wald et al., 2012). 
The mechanism behind the development of chronic kidney disease following acute kidney 
injury has not been fully elucidated nor have any predictive measures of which patients will 
fully recover and which will see declining renal function. 
With repeated episodes of acute kidney injury, there is migration of activated lymphocytes and 
macrophages to the renal tubular cells. Additionally, there is a local increase in TGF-β1 and 
connective tissue growth factor (CTGF) within the tubular cells and platelet derived growth 
factor (PDGF) in the proximal tubular cells. The pattern can lead to tubular atrophy and 
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interstitial fibrosis which in turn can cause glomerulosclerosis resulting in chronic kidney 
disease. 
1.26 Acute kidney injury and length of hospital stay 
 
Acute kidney injury is associated with an increase in the length of hospital stay (table 1-11). This 
increase in stay varies from 3.5 days (G. Chertow, E. Burdick, M. Honour, J. Bonventre, & D. 
Bates, 2005) to 18.5 days (Ali et al., 2007). 
Table 1-11 Length of hospital stay as a consequence of AKI 
Study Length of stay 
G. M. Chertow et al. (2005) 
 
3.5 days (creatinine rise > 24 µmol/L) 
5.4 days (creatinine rise > 88 µmol /L) 
7.9 days (creatinine rise > 177 µmol /L) 
Ali et al. (2007) 13.0 days – RIFLE stage R 
18.5 days – RIFLE stage I 
18.5 days – RIFLE stage F 
Wonnacott, Meran, Amphlett, Talabani, and 
Phillips (2014) 
 
7 days – community acquired 
15 days – hospital acquired 
Challiner, Ritchie, Fullwood, Loughnan, and 
Hutchison (2014) 
8.0 days – admitted with AKI 
11.0 days – developed AKI post admission 
4.0 days – no AKI 
 
The increase in length of stay was associated, not only with the presence of acute kidney injury, 
but also with the presence of chronic kidney disease, gastrointestinal disease and malignant 
disease. 
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1.27 Treatment of AKI 
 
 
In terms of the management of acute kidney injury, once it has been detected, the guidelines 
published by the National Institute for Health and Care Excellence (2013) are relatively clear 
and straightforward: 
 Obstructive uropathy should be referred to a urologist. 
 There should be early consultation if there is a possibility of the patient requiring renal 
replacement therapy. The indications for this form of management include any of the 
following if they are not responding to local treatment: 
o Hyperkalaemia  
o Metabolic acidosis 
o Fluid overload 
o Symptoms of uraemia 
o Pulmonary oedema 
 
 
 
  
 Page 52 
 
1.28 Financial impact of acute kidney injury 
 
Early studies from the United States have demonstrated that the costs associated with acute 
kidney injury rise as the creatinine concentration increases (G. M. Chertow et al., 2005). They 
estimated that the cost of a 50% increase in creatinine was $5,510, a 100% increase was $8,999 
and a 50% increase to a minimum creatinine concentration of 176 µmol/L was $11,719. By 
using data from the Organisation for Economic Cooperation and Development it is estimated 
that the United Kingdom equivalent costs in 2015 are £4,493, £7,339 and £9,557 respectively.  
In the United Kingdom, the early estimated costs of acute kidney injury to the NHS were 
between £434M and £620m per annum; which is 0.4 – 0.6% of the annual NHS budget in 2009-
10 ("Prevent this silent killer," 2011). There were 120,000 admissions in this period where acute 
kidney injury was one of the coded diagnoses. However, due to under-coding of the condition 
and the fact that this is much more likely to be coded only for the more severe cases, it was 
estimated that the true figure for acute kidney injury admissions may be as high as 360,000. 
Later, due to these factors, the group revised their figures on the annual cost of the condition 
upward to £1.02 billion per annum (Kerr, Bedford, Matthews, & O'Donoghue, 2014). These 
costs will represent the expense of the diagnosis and treatment of the condition, the extra bed 
stays that ensues as a consequence and costs associated with longer term sequalae of acute 
kidney injury e.g. chronic kidney disease or renal replacement therapy. There may also be costs 
associated with the use of beds for patients with acute kidney injury that could be used for 
other patients with their associated revenue streams for the hospital. 
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As has been shown, bed stay costs in AKI patients are increased compared with matched 
patients without the condition. Indeed, some authors claim this may be as high as 18.5 extra 
days (Ali et al., 2007). The average cost of a single excess bed stay in the NHS is estimated at 
£273 per day which rises to £1500 for a single day intensive care bed stay. Therefore, any 
initiative that can impact on the use of beds can have a significant benefit to the individual 
Trust and the NHS as a whole. 
1.29 Aim of the study 
 
The aim of this study was to implement an automated system for the real-time detection of 
acute kidney injury at the Royal Hampshire County Hospital (RHCH). This was subsequently to 
be expanded to the North Hampshire and Basingstoke Hospital when the two Trusts merged in 
2012. Subsequent data analysis was designed to demonstrate the extent of acute kidney injury 
in the patients served by the Trust and the effect that the introduction of alerting had on 
subsequent patient outcomes. 
As the literature has demonstrated, a significant percentage of acute kidney injury is 
preventable and it would therefore follow that systems designed for the early detection of this 
condition could result in the following improvements: 
 Improved patient outcomes with lower levels of mortality and morbidity. 
 Consistency in the application of acute kidney injury diagnostic criteria. 
 Less time spent by clinical staff on examining current and previous laboratory results to 
detect acute kidney injury. 
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 Improved diagnostic coding, recording and discharge summaries to reflect the presence 
of acute kidney injury. 
Should the hypothesis that earlier detection and warning leads to improved outcomes be 
proved correct this would demonstrate the added value as shown below. 
Objective Possible measure 
Improvement in mortality and 
morbidity 
Reduction in number of patients dying within defined time 
frames. 
Reduction in number of cases proceeding to develop end stage 
renal disease and chronic kidney disease. 
Reduction in cases transferred to ITU 
More appropriate treatment in a 
timely manner 
Reduction in bed stay 
Reduction in cases proceeding to more severe stages 
Reduction in cases transferred to ITU 
Increased operational efficiency Reduction in costs associated with acute kidney injury. 
Reduction in bed stay 
 
Improvement in patient 
management 
Reduction in unnecessary investigations 
1.30  Study setting 
 
The study was based at the Royal Hampshire County Hospital, Winchester. This is a district 
general hospital serving the population of Winchester and the surrounding areas. The hospital 
has around 500 acute beds although this number fluctuates as wards open and close as beds 
are needed. There is a small hospital at Andover providing non-emergency care and outpatient 
services to patients in that town. 
In 2012, the hospital merged with the Basingstoke and North Hampshire Hospital to form the 
Hampshire Hospitals NHS Foundation Trust (HHFT). 
Until 2013 all creatinine measurements at RHCH were performed on a DxC 800 analyser 
(Beckman) and, from that date, on a Dimension (Siemens). In both cases the measurement of 
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creatinine used the kinetic Jaffe reaction. The Laboratory Information Management System 
(LIMS) was WinPath version 5.32 (Clinisys). 
1.31 Objectives of the proposed research  
 
The aim of this study is to investigate whether an automated system for the evaluation of 
creatinine results and subsequent immediate notification to the clinical has any impact on 
subsequent patient outcomes when measured against comparable previous periods. 
Notification could take the form of personal contact via telephone, e-mails, SMS text messaging 
and web pages. The brief objectives are: 
 Perform a review of acute kidney injury (AKI) and the use of the automated systems to 
detect deteriorating renal function. 
 Develop a robust, automated and scalable system to analyse serum creatinine results 
and alert clinicians/biomedical scientists to potential acute kidney injury according to 
current accepted diagnostic criteria. 
 Perform a retrospective analysis to compare the incidence of acute kidney injury in all 
patients using current techniques against the proposed system. 
 Perform a prospective study on the impact of electronic alerting on detection, 
treatment and subsequent outcomes of patients found to have acute kidney injury. 
 Perform an analysis on the benefits of the introduction of the proposed system across 
the entire Trust (including primary care catchment areas). 
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 Once the study has concluded and, if successful, scale up the proposed solution across 
the entire Trust (which consists of two geographical sites). 
1.32 Research ethics governance 
 
This study did not require formal ethical approval as the samples were being analysed for the 
assessment of renal function (personal communication: Research Group, Royal Hampshire 
County Hospital). The manner in which clinical laboratories operate includes an assumed 
authority for the analysis by virtue of the request being made by, or under the direct 
supervision, of an appropriate healthcare professional. By virtue of the request for specific 
analyses the laboratory will assume that the patient has been consented for the tests being 
requested. 
1.33 Software as a medical device 
 
It is a moot point as to whether the developed software constitutes a medical device as defined 
by the Medicines and Healthcare products Regulatory Agency (MHRA). The definition, as 
outlined by the Medicines and Healthcare Products Regulatory Agency (Aug 2014) which states 
that software is considered a medical device if it: 
‘…it applies automated reasoning such as a simple calculation, an algorithm or a 
more complex series of calculations. For example, dose calculations, symptom 
tracking, clinicians guides to help when making decisions in healthcare. This is likely 
to fall within the scope of the medical devices directives. 
Some decision support software may not be considered to be a medical device if it 
exists only to provide information to enable a healthcare professional to make a 
clinical decision, as they ultimately rely on their own knowledge. However, if the 
software/ app performs a calculation or interprets or interpolates data and the 
healthcare professional does not review the raw data, then this software may be 
considered a medical device. Apps are increasingly being used by clinicians who will 
rely on the outputs from this software and may not review the source/raw data.’ 
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The developed software has aspects that fall into both camps in that it performs calculations 
but is not used as the sole judge of whether a patient has acute kidney injury as this is a clinical 
decision based on the creatinine value and the symptoms of the patient. In addition, the AKI 
comments are an addition to the raw data and not a replacement. 
However, by the time the author was made aware of the possible requirement to consider the 
software as a medical device, plans were in hand for the Trust to switch to a commercial 
solution. This was driven by the directive within the Patient Safety Notice that stated the 
algorithm was to reside within the Laboratory Information Management System. 
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Chapter 2 Development of the Acute Kidney Injury Detection Software 
 
All software described within this thesis for the implementation of AKI alerts was written solely 
by the author unless specified otherwise. This application code was written using programming 
languages and tools supplied by other parties as follows: 
 Access 2003 – Microsoft 
 Visual Studio (which incorporates Visual Basic and C#) – Microsoft 
 SQL Server (2008) – Microsoft 
 MySQL – Oracle Corporation. 
Data was extracted from the database using the Structured Query Language (SQL) which is part 
of the management studio of SQL Server. 
2.1 Initial proof of concept 
 
The initial proof of concept software was designed using a Microsoft Access 2003 database 
utilizing the embedded Visual Basic for Applications (VBA) to automate tasks. In order to run 
this software a query was created within the Laboratory Information Management System to 
extract all creatinine values with associated patient demographics into a text file. This 
extraction took place every twenty-four hours via an automated process. Every day the text file 
was manually imported into the Access database where the following processing was 
performed (figure 2-1). 
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 The file was loaded into memory and each patient in the file was processed as follows: 
• A search was made based on the current demographics for any previous results 
within the database. 
• If previous results were found, an evaluation took place based on the Acute Kidney 
Injury Network criteria. This looked for a rise of at least 26 µmol/L or an increase of 
over 50% from a baseline sample. 
• If acute kidney injury was detected based on these criteria, the stage was written 
back to the database. 
 A search was made for all acute kidney injury cases detected within the previous 24 
hours and a report printed. 
 All samples over 7 days old were removed from the database to preserve disc space, 
keep performance as fast as possible and minimize the risk of file corruption. 
All extract files were kept for 8 days to enable the database to be restored in the event of data 
corruption. 
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Figure 2-1 - Process flow chart of the initial AKI database 
Whilst this proof of concept worked it suffered a number of issues: 
 The import process was manual. 
 The database size grew very rapidly causing concerns about the robustness of the 
system. 
 The system did not operate in real-time therefore feedback to clinicians would be 
delayed. 
 The system did not allow for the results of the evaluation to be held within the main 
record of the Laboratory Information Management System. 
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2.2 Incorporating the AKI evaluation into the patient record 
 
In order to make the system operate as a real time solution it was necessary to ensure the 
result of any AKI evaluation was incorporated into the patient record within the Laboratory 
Information Management System and passed out to the result viewing system at the same time 
as the creatinine results. To achieve this functionality, a subsidiary program within the LIMS was 
utilized whose primary aim was to import results within text files originating from outside 
referral laboratories. This program processes a text file whose data items can be pre-defined in 
terms of order and position. The Access database was programmed to output the patient 
demographics and results of the acute kidney injury evaluation in the same order as that 
defined and expected by the referrals program. 
Initial testing using a manual import mode demonstrated the ability to incorporate data from 
the Access database into the patient laboratory record with subsequent transfer to the Trust 
results viewer (Figure 2-2). This process could be automated via a timed import running every 
minute but whilst this addressed the final issue further work was needed to handle the large 
amounts of data robustly and in a manner that allowed real-time detection and alerting. 
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Figure 2-2 Modified process flow to include AKI evaluations in the patient record 
The output file contained data items to ensure the record in the laboratory database was 
correctly matched to minimise the chance of an electronic transcription error e.g. laboratory 
number, surname, date of birth and then the test code that needed to be created and the 
result that would be stored in the test code. 
This phase demonstrated that it was possible to incorporate AKI evaluation results into the 
patient record in a timely manner such that they could be made available at the same time as 
the creatinine result. The definition of success or failure did not depend a strict metrics but 
rather a subjective assessment on whether the system would be capable of issuing the correct 
AKI evaluation at the same time as the creatinine results and hence ensure clinicians were 
made aware of the condition at the earliest possible opportunity. 
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2.3 Real-time detection of acute kidney injury 
 
As the initial proof of concept was deemed successful and issues hindering real-time detection 
of acute kidney injury were overcome, the following model was developed to resolve the issues 
encountered. 
From the basic flow of information from the hospital system, through the laboratory database 
to the analyser interfaces and back, it was possible to design a system that intercepted the 
messages to and from the analysers that would be capable of reading both demographic and 
result information in real-time without interfering with the processing within the laboratory 
(figure 2-3).  
Messages are passed between the laboratory database and the analysers via the hospital 
network in the format defined by the American Standards for Testing and Materials (ASTM). 
These messages were copied to a backup folder where an application read and processed them 
as shown in the following diagram. 
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Figure 2-3 Process flow for real-time AKI evaluation 
Note: Each background colour represents a different ‘area’ of the process; green is the hospital 
system, light blue the laboratory database/software, yellow the analyser, and dark blue the 
acute kidney injury database and software developed by the author. The data integrity check 
ensured that there was a complete match between the laboratory number, patient surname, 
gender and date of birth before any results from the authors’ software was accepted into the 
patient record. 
Following the initial ‘proof of concept’ success it was decided to write an application that could 
be used within the department that met the following criteria: 
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 Ran continuously and automatically in the background without the need for user 
intervention. 
 Read data in real-time and fed the results into the clinical record at the same time as the 
creatinine result. 
 Could be easily scaled if the workload increased. 
The software was written in a fashion such that it could utilise a number of different databases 
in which to store the data. The initial application utilised a MySQL (Oracle) database backend. 
The reason for this choice was that the database was supported by the Oracle Corporation, was 
widely utilised in many web based application and was free to end users. The front end user 
interface was written in Visual Studio Express 2010 using the C# programming language. The 
basic database schema is shown in figure 2-4. 
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Patients 
  PK Unique_ID Bigint 
 Surname varchar 
 Forename Varchar 
 Gender Varchar 
 DoB Date 
 NHSNo Tinyint 
 HospNo Varchar 
 CKD Char 
 DOD Date 
 
Samples 
PK LabNo Varchar 
 Patient_ID Bigint 
 Sampled Datetime 
 Source Varchar 
 PostCode Varchar 
 Processed Tinyint 
 CKD varchar 
 
Results 
PK LabNo Varchar 
 Code Varchar 
 Result Single 
  
Sources 
PK Code Varchar 
 Description Varchar 
 Class Varchar 
 AKI tinyint 
Comments 
PK LabNo Varchar 
 Code Varchar 
 Comment Varchar 
 Output Tinyint 
Figure 2-4 Basic database schema 
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Each patient was provided with a unique identifier within the database as neither the NHS 
number nor the hospital number could be relied upon to be unique. A patient was connected to 
this unique identifier based on linkage criteria (which were the same as those used by the 
laboratory software): 
 Try to link via the NHS number if the date of birth and surname are matched. 
 Try to link via the hospital number if the date of birth and surname are matched. 
 Try to link if the surname, forename and date of birth are matched. 
In the event that no match could be made, then a new entry was made in the patient database. 
Whilst these matching criteria are rightly open to criticism in that twins may share the same 
identifier, the decision was made by the author that the same linking criteria that was used in 
the Laboratory Information Management System would also apply to the AKI software for 
consistency. 
Once a patient was added to the database, no changes were made with the following 
exceptions: 
 NHS numbers could be added if they were not present and there was a match between 
the surname, forename and date of birth. 
 The chronic kidney disease flag for the patient could be changed based on the current 
eGFR. 
When a patient was added to the database, the laboratory number was read from the incoming 
data at the same time. This was used to create the sample record even if no further results 
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were received. The processed field was used to indicate if a record had been evaluated for 
acute kidney injury and was set once all evaluations on the record had been performed and 
written to the results database. This provided a mechanism to re-evaluate records e.g. when 
the NHS England criteria had been published. The sample chronic kidney disease flag was used 
to indicate the CKD status of the patient at the time of sampling whereas the same flag within 
the patient table indicated the chronic kidney disease status based on the last sample analysed. 
It was agreed with the clinical staff that chronic kidney disease would be recorded as present if 
there was a sample in the previous 30 to 365 days prior to the current sample where the 
estimated glomerular filtration rate (eGFR) did not exceed 60 mls/min. The 30-day rule was 
incorporated to exclude labelling patients as having chronic kidney disease when they may, in 
fact, have evolving acute kidney injury. Within the database the CKD flag was recorded at both 
the sample and patient level as a patient may go from one category to another based on the 
results of creatinine analysis. The idea behind the CKD flag was to afford the opportunity to 
inform the clinical staff via the AKI alert if the patient was known to have chronic kidney 
disease. 
The results record was created when result data were received from the analyser feed. Only 
numerical results were permitted; there was a check to ensure non-numeric data was omitted. 
As a consequence of this decision (which was to save database space and improve processing 
speed) it was necessary to recreate the eGFR calculation within the software application as 
results in excess of 90 mls/min were sent as textual data (‘>90’). As the database had been 
configured to accept numerical results only, a system was adopted to ensure that all results 
normally issued as being below or above a set limit, for example, C-reactive protein (CRP) that 
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would usually be reported as ‘< 3’ were recorded in the database as 1. The limits used and the 
numerical equivalent in the database are shown in table 2-1. 
Table 2-1 Limits of detection and over range results 
Assay Limit Stored database value 
Creatinine 10 (issued from LIMS as < 10) 9 
CRP 3 (issued from LIMS as < 3) 1 
Sodium 100 (issued from LIMS as < 100) 
200 (issued from LIMS as > 200) 
100 
200 
Urea 0.4 (issued from LIMS as < 0.3) 0.3 
Albumin 10 (issued from LIMS as < 10) 9 
The sources table was used to group individual sources together to enable data analysis at a 
higher level than the individual source e.g. treat all inpatient locations as a single entity. The 
data in this table were added whenever a new source was encountered and it was the 
responsibility of the author to manually update the classification. 
The first version of the AKI software was written on a home laptop and performed well; 
importing, evaluating and outputting at the rate of 1 record per second although performance 
fell away to 1 record every 2-3 seconds as the database grew in size. This showed that the 
system could cope with around 29,000 evaluations per day; this is well within the anticipated 
1,500 per day at the start of the project (which rose to 3,000 per day at the end of the study 
due to the Trust merger). However, once the application was transferred onto the hospital 
network for testing with live data rather than ‘dummy data’ the performance slowed to 1 
record every 10 minutes. Investigations into this issue took many days but it was eventually 
traced to the virus checker performing a full check of the database file every time a change was 
made to any table in the database. It was not possible to disable the virus checker so another 
mechanism was investigated. 
 Page 70 
 
The application was modified to utilise an SQL Server (Microsoft) database maintained within 
the Pathology Laboratory which was excluded from virus checking algorithms. This was written 
using Visual Basic and, wherever possible, as many queries and evaluations were written as 
stored procedures on the server. This made it easier to introduce new functionality in terms of 
searches and evaluations without the need to write new code and recompile and reinstall the 
application. However, in 2012 the decision was made to group all SQL servers spread 
throughout the Trust onto a single server maintained by the Information Technology 
Department. This resulted in the loss of the ability to access the stored procedures so the 
application needed to be rewritten to have the logic entirely placed within the code rather than 
spread between the client computer and the database server. Finally, in the autumn of 2012 
there was a system that was very stable and was capable of processing records at the rate of 
one per second (86,400 per day), outputting to the patient record in the laboratory database in 
real time.  
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Figure 2-5 AKI software main screen 
When processing the application changed colour to provide a visual indication of the current 
status; pale green (figure 2-5) indicates ready to process; dark green indicates the application is 
running in a timed mode; red indicates the application has encountered a major error and 
stopped processing. The database statistics area was mainly used to monitor the number of 
acute kidney injury events in the last 24 hours as this gave a good indication in the early days of 
processing of any undiscovered errors that prevented writing to the main database. The raw 
data display was present to provide reassurance that the files were being processed whilst the 
demographics area highlighted any issues where data could not be processed correctly e.g. 
missing data items such as date of birth (this sometimes occurred when these details were 
omitted from the request form). 
Processing 
status 
Raw data display 
Database 
statistics 
Demographics 
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Every routine within the code contained an error handling area which fed into a common 
subroutine writing to the error table within the database. This recorded details of the date and 
time of the error, the routine where it was first encountered, the internal error message and 
the values of the relevant variables within the detecting routine. In the initial stages this was 
complemented by step-through processing where each line of code is executed one line at a 
time and the contents of the individual variables used examined manually. Towards the end of 
the project errors were very rare and tended to be due to inability to correctly parse a data file 
e.g. incorrect dates or problems with accessing the SQL server. 
Not all samples are suitable for analysis and they may be rejected due to issues with sample 
integrity e.g. haemolysis. This may lead to incorrect results; in the case of haemolysis this can 
cause a falsely low creatinine value. This sample integrity data was transmitted from the 
analysers at the same time as the results of the creatinine analysis. Where the result integrity of 
the sample could not be guaranteed, a specific routine was run after each evaluation to ensure 
all results were removed from the database and were not used.  
The format of the output file was made configurable by using placeholders where data items 
would be inserted (figure 2-6). For example, the following structure was used as the skeleton 
for the output: 
"{0}",”{1}”"{2}","AKIC","{3}" 
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Each numbered item enclosed in ‘{ }’ was then replaced with the data items obtained from the 
following query. 
 
This extracted the laboratory number, surname, gender and acute kidney injury comment from 
the database where there is a comment that has not yet been output (C.Output = 0) and the 
date is later than a set date and the requesting source is equal to RHEMA. The data items are 
extracted in the order they appear in the query. For example, if the following data is returned 
fro
m 
the 
que
ry: 
 
 
The
se 
wo
uld be inserted to the output file as 
SELECT S.LabNo, P.Surname, P.Sex, C.Comment 
FROM Samples AS S 
INNER JOIN Patients AS P ON S.Patient_ID = P.Unique_ID 
INNER JOIN Comments AS C ON S.LabNo = C.LabNo 
WHERE C.Output = 0 
AND S.Sampled > '30-Jan-2015' 
AND S.Source IN ('RHEMA') 
 
S.LabNo = 13W123123 
P.Surname = SMITH 
P.Sex = M 
C.Comment = ‘AKI stage 1’ 
 
"13W123123","SMITH","M","AKIC","AKI Stage 1" 
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The import program then loads the laboratory record associated with the laboratory number 
13W123123 and checks the surname and gender on the import file match those within the 
laboratory record. It then creates a new test within the laboratory record, coded as ‘AKIC’, and 
inserts the text ‘AKI Stage 1’ in this test. This then becomes an integral part of the laboratory 
record and is treated as any other test i.e. authorised, reported, viewed. 
 
Figure 2-6 File output settings screen of the main application 
By making the export of data from the database (and import into the laboratory record) 
configurable it provided a mechanism that could be modified from outside the program without 
the need for in-depth knowledge of programming and recompiling of the software. The interval 
setting determined how often (in seconds) the software looked for new files to process. The file 
option is where the output file is placed once it is created; the import program was then 
programmed to look in this location at the interval in the interval settings variable (for routine 
processing this was set to 30 seconds). Using these settings, the maximum time between a 
creatinine result being written to a data file and the evaluation being imported into the 
laboratory record was approximately 2 minutes (the import program ran every 60 seconds) 
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and, in practice, it was often less. There were no reported instances where the acute kidney 
injury evaluation was available for authorisation after the creatinine result had been reported 
unless there had been an error in the software. 
The ability to output data based on criteria also made it possible to extend reporting in a similar 
manner by adding more criteria. For example, in the initial testing stages the AKI alerts were 
only issued on those requests originating from the lead AKI clinician (coded as SWALEP). The 
SQL statement for the output of the results was coded as: 
To extend to all patients from the Medical Admissions Unit the last line of the query was 
changed to: 
The output file handled multi-line comments by breaking them into a maximum of 40 
characters (as this is the display limit within the laboratory system) at an appropriate space. The 
output file signaled this was a multi-line comment by having further data items as follows: 
Example output from the program as displayed from the laboratory information system is 
shown in figure 2-7 and figure 2-8. 
SELECT S.LabNo, P.Surname, P.Sex, C.Comment 
FROM Samples AS S 
INNER JOIN Patients AS P ON S.Patient_ID = P.Unique_ID 
INNER JOIN Comments AS C ON S.LabNo = C.LabNo 
WHERE C.Output = 0 
AND S.Sampled > '30-Jan-2015' 
AND S.Clinician = ‘SWALEP’ 
 
AND S.Source IN ('RHEMA') 
 
"13W123123","SMITH","M","AKIC","AKI Stage 1",”.”,”Second line”,”.”,”Third 
line” 
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Figure 2-7 Example of a single line comment 
 
 
Figure 2-8 Example of a multi-line AKI comment 
Following discussion with the Trust lead AKI clinician (Dr. Philip Swales) the decision was made 
to report acute kidney injury detection alerts but only on patients where he was the listed 
consultant. To maximize detection, it was agreed that the algorithm used would be the Acute 
Kidney Injury Network using a baseline extending back 90 days. Following a short period of 
evaluation (6 weeks) it was then agreed by clinical and laboratory consultants to extend the 
reporting to all patients on the Emergency Medical Admissions Unit (EMAU) at RHCH in 
December 2012. 
In May 2013, a Patient Safety Notice was issued by NHS England which mandated the detection 
of acute kidney injury and provided the algorithm that was to be used. This was coded into the 
current software application and, following a period of testing, was used as the detection 
algorithm from July 2013 to the end of the study. The detection alerts were never extended 
beyond the EMAU as there was a Trust merger with the Basingstoke and North Hampshire 
Hospital resulting in the eventual loss of both Consultant Scientists at Winchester and 
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reluctance to extend a new service when the primary aim became consolidation of the existing 
services and a major transfer of work from Winchester to Basingstoke. 
A major weakness in the approach was the isolation of the acute kidney injury database from 
other systems that would enable a far better analysis of the data e.g. admissions and 
discharges. This was due to concerns about the workload on Information Technology staff, 
impact it would have on the size of the database when server space was already at a premium 
and concerns over allowing ‘amateur programmers’ access to live Trust data. However, it was 
possible to obtain the date of death via a text file which was then imported at regular intervals 
into the patient record using the NHS number as the primary identifier and the date of birth 
and surname as a secondary check. 
2.4 Examples of patient evaluation 
 
The following figures show the creatinine results of two different patients and how the 
algorithm evaluated these patients as having acute kidney injury. The ages of the patients and 
dates of the samples have been amended to ensure total anonymity but the timelines in terms 
of date differences are accurate. 
Patient A was a 65 year old female who developed stage 3 acute kidney injury and was 
transferred to the Intensive Care Unit. She was admitted as an emergency on the 28th July 
2013 with hypoxia and shock. The previous creatinine results are shown in figure 2-9 and table 
2-2table 2-2 
Figure 2-9 Patient A creatinine timeline 
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Table 2-2 Patient A creatinine results 
Working from the oldest result forward, on the 17-Feb-
2013 the creatinine had moved from a median of 76 
µmol/L to 104 µmol/L. This gives a ratio of median to 
current of 1.37 which is below the threshold to trigger 
an AKI alert although at this point the result is higher 
than previous results. Shortly after there is a fall in the 
creatinine to a nadir of 50 µmol/L the day after 
emergency admission due to hypoxia and shock. The 
first alert for acute kidney injury would be issued on 
the 31-Jul-2013 when the creatinine is 78 as there has 
been an increase of over 26 µmol/L in the previous 48 
hours; this would be classed as stage 1. The following 
day the creatinine had risen to 162 µmol/L (confirmed 
by a repeat sample) at which point the patient has acute kidney injury stage 3; the lowest 
creatinine in the previous 7 days is 50 whilst the median value is 77. This gives a ratio for the 
previous 7 days of 3.24 and for the median it is 2.10. Taking the highest ratio we get an AKI 
stage 3 (the NHS England criteria stage is defined as a ratio > 3). Even though the low value of 
50 has gone by the 6-Aug, the median value at this stage is now 78.5. Using this as the 
denominator in the calculation we get a ratio of 3.22 so the patient remains at stage 3. In fact, 
stage 3 alerts would have been issued every day from the 1 Aug-2013 to the final sample (when 
the median was 83 µmol/L). This case demonstrates the issuing of an acute kidney injury alert 
Date/time Creatinine 
15-Oct-12 61 
13-Nov-12 82 
5-Jan-13 76 
17-Feb-13 104 
23-Feb-13 81 
31-Mar-13 87 
16-Apr-13 74 
26-May-13 84 
28-Jul-13 52 
29-Jul-13 50 
30-Jul-13 60 
31-Jul-13 78 
1-Aug-13 08:03 162 
1-Aug-13 09:46 166 
2-Aug-13 192 
3-Aug-13 230 
4-Aug-13 238 
5-Aug-13 266 
6-Aug-13 253 
7-Aug-13 257 
8-Aug-13 317 
9-Aug-13 289 
10-Aug-13 267 
11-Aug-13 260 
12-Aug-13 259 
13-Aug-13 307 
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despite the fact that the creatinine value was just within the reference value (31-Jul-2013). The 
following day the rapid notification of the stage 3 AKI prompted a repeat sample for 
confirmation and rapid transfer to the Intensive Care Unit. However, this also demonstrates the 
possibility of ‘alert fatigue’ as the alerts continued on every sample submitted for analysis from 
the 31-Jul-2013 onwards. 
Patient B was a 31 year old female who attended her GP for ‘routine screening’. She had 
previously given birth in 2012. These and subsequent results are tabulated in table 2-3 and 
shown in graphical form in figure 2-10. 
 
Figure 2-10 Patient B creatinine timeline 
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Table 2-3 Patient B creatinine results 
 
Despite being well, this patient would 
have been flagged as having acute 
kidney injury stage 1 on the 27-Feb-
2013; there has been an increase in 
creatinine of 7 µmol/L in the previous 4 
days which is not sufficient to trigger a 
warning. However, the median value associated with this sample is 42.5 µmol/L (samples from 
the pregnancy period 26-Mar-2012 and 19-Jun-2012). This gives a ratio of 1.55 which equates 
to acute kidney injury stage 1. This case highlights one of the possible causes of a false positive 
warning where the normal dilutional effects that occur during pregnancy manifest 
biochemically as lower creatinine values and hence lower the median values during this period. 
This highlights the important role of education, not only in the correct treatment of acute 
kidney injury but also in the way in which the condition is detected and the possible causes of 
false positive results.  
The commonest cause of both false positive alerts and false negative alerts is due to the 
mislabeling of samples on the wards. These events cause the incorrect values to be stored in 
the database against that particular patient which, if not spotted and corrected, are then 
subsequently used as part of the evaluation algorithm. A simple example is where a patient 
with normal renal function is bled but labelled with the demographic details from someone 
with abnormal renal function. This could cause an alert to be issued with all the consequences 
Date Creatinine Stage 
01-Apr-10 66  
23-Apr-10 56  
22-Nov-10 59  
07-Nov-11 58  
26-Mar-12 41  
19-Jun-12 44  
23-Feb-13 59  
27-Feb-13 66 1 
05-Jun-13 67  
26-Nov-14 68  
27-May-15 40  
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that ensue. The key point here is education of clinical staff to question the validity of the alert if 
it does not accord with the clinical condition and to repeat the analysis if there is doubt. 
2.5 Summary 
 
This chapter has shown how it was possible to produce an automated, real-time system for the 
detection of acute kidney injury and how algorithm changes could be implemented due to 
nationally mandated changes in timescales that were not achievable with commercial software. 
It has also shown that there are issues with the algorithms and the creatinine assay on which 
these algorithms are based. The next chapter will present the results obtained from an analysis 
of the acute kidney injury database. 
  
 Page 82 
 
Chapter 3 Results Analysis 
 
The previous chapter has discussed the barriers to automated real-time acute kidney injury 
detection and how these were overcome to provide a system that operated, as far as the 
clinical staff were concerned, in real time. This chapter will present the findings of an analysis of 
the data from the database with respect to acute kidney injury and chronic kidney disease.  
The study period covered the years 2011 to 2014 inclusive and final data analysis was 
performed between May and August 2015. The reason for this delay between the last data 
entry (31 Dec 2014) and the analysis starting in May 2015 was twofold: 
1. Having a delay period allowed the collation and import of data on mortality to be 
undertaken such that 30-day mortality at the end of the study period (31st December 
2014) would be valid and hence not influence the analysis or interpretation.  
2. Initial data analysis in March revealed that the export programs were not extracting the 
correct data. This was traced to a missing variable initialization where a single field from 
the database was not being output to the data file.  Each extraction took in excess of 12 
hours and tied down the computer terminal for that entire period, this was not a 
process that could be undertaken in the background. 
Due to the vast amounts of data generated during the study period there have been large areas 
where it has not been possible to begin any form of analysis; this may form part of a separate 
study or be given to staff members who require a project as part of their formal qualifications. 
The major part of the work was directed toward generating acute kidney injury alerts for use in 
the clinical areas. However, this work generated data that are useful for investigating other 
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aspects of acute kidney injury other than the impact of alerts e.g. albumin concentration. This 
chapter is divided into distinct sections covering: 
• the basic data in terms of patients, results and number of alerts 
• how the various AKI algorithms perform in terms of ability to evaluate submitted 
samples and the numbers of AKI alerts that would have been issued. 
• the impact of alerts on subsequent renal recovery and 30-day mortality 
• the impact of alert on primary care 
• seasonal variation in acute kidney injury 
• urine protein analysis and acute kidney injury 
3.1  Data Extraction 
 
Data were extracted from the database either via the Structured Query Language (SQL) built 
into SQL Server Management Studio or, for more complex queries, by software specifically 
written in the C# programming language. The data files were then imported into Excel 
(Microsoft) or SPSS (version 22, IBM) for data analysis or graphical presentation. Initial 
discussions with the paediatric consultant team revealed they did not wish to be included 
within the study as the British Association for Paediatric Nephrology were working on their own 
guidelines and the team felt they wished to await the outcomes of these discussions. Whilst the 
NHS England algorithm had a specific limb dedicated to patients aged 17 or less, these patients 
have been excluded from any subsequent data analysis. 
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3.2  Study periods 
 
To assess the effect of electronic alerts on subsequent patient outcomes, the study periods 
were divided based on the date ranges of the alerts being issued: 
 Pre-alert phase – in this phase no alerts were generated and this period is used as a 
baseline for comparison with other periods. This phase lasted from 1 Jan 2011 to 31-Nov 
2012. 
 AKIN phase – in this phase alerts were issued based on the Acute Kidney Injury Network 
criteria but using a baseline ‘look back’ of 90 days to maximize the ability to capture 
patients for evaluation. This phase lasted from 1-Dec-2012 to 30-Jun-2013. 
 NHS England phase – in this phase the NHS England algorithm was used to generate 
alerts. This phase lasted from 1-Jul-2013 to 31-Dec-2014. 
The alerts were only issued to the Emergency Medical Assessment Unit at RHCH. 
 
Whilst there were three distinct phases to the project, the latter two phases (AKIN and NHS 
England) have been amalgamated into a single ‘post-alert’ phase for the purposes of data 
analysis to avoid small numbers in the groups, especially the shorter AKIN phase. 
Pre alert 
phase 
1-Jan-2011 to  
31-Nov-2012 
AKIN phase 
1-Dec-2012 to  
30-Jun-2013 
NHS England 
phase 
1-Jul-2013 to  
31-Dec-2014 
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3.3  Statistics 
 
Numerical data are shown as the mean value and the 95% confidence interval around the mean 
unless otherwise stated. When comparing rates between groups the risk ratio (also known as 
the relative risk and abbreviated to RR) has been used and is displayed as the ratio, the 95% 
confidence interval for that ratio and the p value. It can be calculated using the formula: 
𝑒𝑒𝑒𝑒 =  𝑝𝑝1
𝑝𝑝0 = 𝑑𝑑1 𝐶𝐶1�𝑑𝑑0
𝐶𝐶0�   
where: 
d1 = number in exposed group who experienced the event 
d0 = number in the unexposed group who experienced the event 
n1 = total number in exposed group  
n0 = total number in unexposed group 
 
The exposed group in terms of the relative risk calculation were those that received the AKI 
detection alert whilst the unexposed group were those who did not have an AKI alert. In the 
interpretation of p values, those equal to or less than 0.05 were considered to be statistically 
significant. 
3.4  Number needed to treat 
 
The number needed to treat (NNT) is a measure of the effectiveness of a treatment or 
intervention. It is the ‘number of patients that need to be treated in order to prevent one 
adverse event’ (Kirkwood & Sterne, 2006). It is calculated as: 
𝑁𝑁𝑁𝑁𝑁𝑁 =  1|𝐶𝐶𝐶𝐶𝑠𝑠𝑏𝑏 𝑑𝑑𝐶𝐶𝑖𝑖𝑖𝑖𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝑝𝑝𝐶𝐶| 
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The risk difference is taken as the absolute value. The risk difference if given by: 
𝑒𝑒𝐶𝐶𝑠𝑠𝑏𝑏 𝑑𝑑𝐶𝐶𝑖𝑖𝑖𝑖𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝑝𝑝𝐶𝐶=  𝑃𝑃𝐶𝐶𝑟𝑟𝑝𝑝𝑟𝑟𝐶𝐶𝐶𝐶𝐶𝐶𝑟𝑟𝐶𝐶 𝑏𝑏𝐶𝐶𝐶𝐶𝐶𝐶𝑖𝑖𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝑟𝑟 𝑖𝑖𝐶𝐶𝑟𝑟𝑟𝑟 𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝑑𝑑𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝑟𝑟𝐶𝐶
− 𝑃𝑃𝐶𝐶𝑟𝑟𝑝𝑝𝑟𝑟𝐶𝐶𝐶𝐶𝐶𝐶𝑟𝑟𝐶𝐶 𝑏𝑏𝐶𝐶𝐶𝐶𝐶𝐶𝑖𝑖𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝑟𝑟 𝑖𝑖𝐶𝐶𝑟𝑟𝑟𝑟 𝑝𝑝𝑟𝑟𝐶𝐶𝐶𝐶𝐶𝐶𝑟𝑟𝑔𝑔  
When the NNT is 1 then every patient having the intervention will benefit whereas if the NNT is 
-1 then every patient in the control group benefitted whilst those in the intervention group did 
not. 
3.5  Problems with data analysis 
 
The main problem with the data analysis was having in excess of 1.8 million sample records 
giving rise to a multitude of potential research questions. As a consequence of many hours 
spent chasing data down various paths to which there was no set problem to answer, it was 
decided to limit the analysis to the following topics: 
 How does the NHS England algorithm for AKI detection compare with the other 
algorithms, notably, how does the extended baseline help spread the number of 
patients and sample that can be evaluated for AKI. In addition, how does chronic kidney 
disease and the regular follow-up of these patients impact on the ability of the NHS 
England algorithm to evaluate the presence or absence of acute kidney injury 
 What is the incidence of acute kidney injury in patients and samples and how is this 
affected by age, gender and the presence of CKD? 
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 Is there any difference in measureable outcomes (mortality, AKI stage progression, 
subsequent CKD) in those patients who received AKI alerts compared with those who 
did not? 
 How do the different algorithms for the detection of AKI compare in the same group of 
patients. 
 How do patients with community acquired acute kidney injury fare with regards to 
mortality and subsequent renal function? 
 Is there a seasonal variation in AKI or in deaths associated with AKI that may influence 
data interpretation? 
 Can urine albumin/creatinine ratio be used to predict the development of AKI? 
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3.6  Basic data analysis 
 
Between the start of January 2011 and the end of December 2014, there were 346,780 unique 
patients recorded in the database (table 3-1). These were associated with 1,800,545 samples 
and 22,294,565 individual results. Of those samples 1,605,202 (89.2%) had a creatinine assay 
and 1,301,153 (72.3%) of these samples had an AKI evaluation by the NHS England algorithm.  
The number of patients with the highest AKI stages of 1, 2, and 3 by the NHS England algorithm 
was 17,233 (4.97%), 5,178 (1.49%) and 3,150 (0.91%) respectively over the 4 year period. 
Table 3-1 Basic database metrics from 2001 to 2014 (aged 18 years and over) 
Item Number (%) 
Individual patients 
Total 
Male 
Female 
 
346,780 
152,569 (44.0%) 
193,460 (55.8%) 
Individual samples 1,800,545 
Individual results 22,294,565 
CKD patients 
 Total 
 Male 
 Female 
 Not stated 
 
58,415 (16.9%) 
21,703 (37.2% of CKD patients) 
36,641 (62.7% of CKD patients) 
71 (0.1% of CKD patients) 
AKI evaluations (NHS England) 1,301,153 
AKI patients (highest AKI stage) 
 Stage 1 
 Stage 2 
 Stage 3 
 
17,223 (4.97%) 
5,178 (1.49%) 
3,150 (0.91%) 
Number of alerts issued 3,021 
Number of deaths 
Non CKD 
 Total 
 Male 
 Female  
CKD 
 Total 
 Male 
 Female  
5,855 (1.7%) 
 
2,279 (38.9%) 
1,292 (22.1%) 
982 (16.8%) 
 
3,576 (61.1%) 
1,602 (27.4%) 
1,971 (33.7%) 
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The number of acute kidney injury alerts issued on clinical reports to the Emergency Medical 
Admissions unit was 3,021. 
In all, 58,415 (16.9%) of patients had chronic kidney disease (eGFR not above 60 mls/min in the 
previous year). This sub-group contained a preponderance of females compared with males 
(62.7% vs 37.2%). In the period covered by the study 5,855 (1.7%) of patients died. Despite the 
fact that patients with known chronic kidney disease comprised 16.9% of the study population, 
they accounted for 3,576 (61.1%) of the recorded deaths.  
3.7  Age and gender distribution 
 
The age and gender distribution of patients is shown in table 3-2. Females represented 55.8% of 
study population at sampling. The reason for choosing the age banding (table 3-2) was to avoid 
small numbers of patients in the younger age groups when analyzing AKI related data which 
may make age related comparisons very difficult to analyse and interpret. The numbers in this 
table do not exactly match the numbers in the summary statistics table as the study period was 
over 4 years and some patients crossed over the age band boundary during this time. 
Table 3-2 Age distribution of patients 
Age band Male Female 
18 to 34 22,418 (6.5%) 43,003 (12.4%) 
35 to 44 22,184 (6.4%) 31,521 (9.1%) 
45 to 54 32,942 (9.5%) 37,904 (10.9%) 
55 to 64 34,362 (9.9%) 34,682 (10.0%) 
65 to 74 32,311 (9.3%) 32,648 (9.4%) 
75 to 84 19,536 (5.6%) 22,309 (6.4%) 
>=85 7,684 (2.2%) 13,498 (3.9%) 
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3.8  Ability of algorithms to detect acute kidney injury 
 
In the UK, the mandated algorithm for the detection of acute kidney injury is that published by 
NHS England (June 2014). However, until this was published, a variety of algorithms were 
utilised and will continue to be used especially in countries who are not covered by the NHS 
England directive. Therefore, for every sample evaluated by the software, an attempt was 
made to evaluate AKI using the KDIGO (RIFLE), AKIN (2, 7, 30 and 90 day baseline) and Waikar & 
Bonventre algorithms.  
All the AKI algorithms require the presence of a baseline sample in order to evaluate the 
current sample for AKI. The time period for this baseline sample is a set criterion within the 
algorithm and therefore has a major influence on the ability of that algorithm to detect AKI 
which, in turn, impacts on derived measures e.g. incidence, mortality rates etc. Shorter baseline 
time intervals may miss some cases of AKI picked up by other criteria whilst longer baseline 
periods may label progressive yet chronic changes as an acute episode. 
The NHS algorithm was able to evaluate 74.0% of all patients and 81.7% of samples submitted 
for creatinine analysis for acute kidney injury. This contrasts with 21.3% of patients and 27.6% 
of samples using the KDIGO (RIFLE) criteria, 48.5% of patients and 55.2% of samples using the 
AKIN (90-day baseline) criteria and 15.7% of patients and 18.1% of samples using Waikar and 
Bonventre criteria (table 3-3). 
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Table 3-3 Ability to evaluate AKI using various algorithms 
  Number (%) 
Patients Samples 
Total in database 346,780 1,800,545 
Total with a creatinine value 328,967 (94.9) 1,469,495 (81.6) 
AKI evaluation by NHS England criteria 256,585 (74.0) 1,200,429 (81.7) 
AKI evaluation by RIFLE criteria 73,825 (21.3) 405,433 (27.6) 
AKI evaluation by AKIN (2 day baseline) criteria 54,358 (15.7) 266,098 (18.1) 
AKI evaluation by AKIN (7 day baseline) criteria 73,818 (21.3) 405,435 (27.6) 
AKI evaluation by AKIN (30 day baseline) criteria 119,604 (34.5) 601,482 (40.9) 
AKI evaluation by AKIN (90 day baseline) criteria 168,250 (48.5) 810,548 (55.2) 
AKI evaluation by Waikar & Bonventre criteria 54,358 (15.7) 266,098 (18.1) 
The percentages against the AKI evaluation algorithm are based on the total number of patients 
or total samples with a creatinine measurement.  
This demonstrates that the longer the baseline period used in the algorithm the greater the 
number of patients in whom it is possible to evaluate the presence of acute kidney injury 
(figure 3-1). 
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Figure 3-1 Effect of baseline on patient and sample evaluation 
When grouped by requesting location the ability of the NHS algorithm to evaluate AKI in 
samples submitted for creatinine measurement was 82.6% of Emergency Department samples, 
93.8% of Medical Admission Unit samples, 70.3% of General Practitioner samples, 98.3% of in-
patient samples and 89.4% of out-patient samples. All the other algorithms showed inferior 
performance in respect of the ability to evaluate AKI due to the shorter baseline time they 
employ (table 3-4). 
Table 3-4 Ability of algorithms to detect AKI based on source classification (samples) 
  Emergency 
Department 
Medical 
Admissions 
Unit 
Primary Care In-patient Out-
patient 
Number with 
creatinine 
111,216 63,595 656,138 360,860 187,452 
NHS England 92,096  
(82.6) 
59,621  
(93.8) 
460,981  
(70.3) 
354,704  
(98.3) 
167,507 
(89.4) 
RIFLE 20,358  
(18.3) 
41,700  
(65.6) 
17,678  
(2.7) 
296,614  
(82.2) 
11,531  
(6.2) 
AKIN (2-day baseline) 10,779  
(9.7) 
32,515  
(51.1) 
4,125  
(0.6) 
207,702 
 (57.6) 
2,352  
(1.3) 
AKIN (7-day baseline) 20,360  
(18.3) 
41,700  
(65.6) 
17,678  
(2.7) 
296,614 
 (82.2) 
11,531  
(6.2) 
AKIN (30-day 
baseline) 
39,673  
(35.7) 
48,031  
(75.5) 
92,589  
(14.1) 
328,551  
(91.0) 
58,415 
(31.2) 
AKIN (90-day 
baseline) 
60,686  
(54.6) 
53,040  
(83.4) 
198,503  
(30.3) 
341,340  
(94.6) 
108,585 
(57.9) 
Waikar & Bonventre 10,779  
(9.7) 
32,515  
(51.1) 
4,125  
(0.6) 
207,702  
(57.6) 
2,352  
(1.3) 
In order to assess the impact on patients of the inability to evaluate a sample for acute kidney 
injury, those samples which were not evaluated were grouped according to the creatinine value 
(>150 µmol/L, >200 µmol/L and > 300 µmol/L). The number of samples in each group is shown 
in table 3-5.  
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Table 3-5 Patients without an AKI evaluation with raised creatinine values 
  Emergency 
Department 
Medical 
Admissions 
Unit 
Primary Care In-patient Out-patient 
 Total 5,031 
2,351 
915 
3,893 
2,112 
934 
6,481 
2,498 
831 
6,388 
3,345 
1,426 
2,559 
967 
349 
NHS England 447 (8.9) 
192 (8.2) 
67 (7.3) 
96 (2.5) 
33 (1.6) 
110 (11.8) 
593 (9.1) 
191 (7.6) 
61 (7.3) 
 23 (0.4) 
9 (0.3) 
5 (0.4) 
 92 (3.6) 
29 (3.0) 
9 (2.6) 
RIFLE 1,391 (72.4) 
1,660 (70.6) 
620 (67.8) 
820 (21.1) 
406 (19.2) 
134 (14.3) 
5,140 (79.3) 
1,840 (73.7) 
592 (71.2) 
 379 (5.9) 
123 (3.7) 
40 (2.8) 
 2,015 (78.7) 
717 (74.1) 
266 (76.2) 
AKIN (2 day 
baseline) 
729 (85.5) 
1,968 (83.7) 
735 (80.3) 
1,113 (28.6) 
561 (26.6) 
193 (20.7) 
6,099 (94.1) 
2,303 (92.2) 
756 (91.0) 
 976 (15.3) 
386 (11.5) 
125 (8.8) 
 2,381 (93.0) 
889 (91.9) 
315 (90.3) 
AKIN (7 day 
baseline) 
1391 (72.4) 
1660 (70.6) 
620 (67.8) 
820 (21.1) 
406 (19.2) 
134 (14.3) 
5140 (79.3) 
1840 (73.7) 
592 (71.2) 
 379 (5.9) 
123 (3.7) 
40 (2.8) 
 2015 (78.7) 
717 (74.1) 
266 (76.2) 
AKIN (30 day 
baseline) 
2495 (50.4) 
1134 (48.2) 
402 (43.9) 
552 (14.2) 
269 (12.7) 
77 (8.2) 
3289 (50.7) 
1081 (43.3) 
367 (44.2) 
 167 (2.6) 
50 (1.5) 
16 (1.1) 
 1153 (45.1) 
369 (38.2) 
141 (40.4) 
AKIN (90 day 
baseline) 
2506 (50.2) 
667 (28.4) 
224 (24.5) 
334 (8.6) 
159 (7.5) 
46 (4.9) 
2073 (32.0) 
639 (25.6) 
202 (24.3) 
 98 (1.5) 
24 (0.7) 
8 (0.6) 
 589 (23.0) 
186 (19.2) 
71 (20.3) 
Waikar & 
Bonventre 
729 (85.5) 
1968 (83.7) 
735 (80.3) 
1113 (28.6) 
561 (26.6) 
193 (20.7) 
6099 (94.1) 
2303 (92.2) 
756 (91.0) 
 976 (15.3) 
386 (11.5) 
125 (8.8) 
 2381 (93.0) 
889 (91.9) 
315 (90.3) 
The top line in each cell is the number of samples where the creatinine concentration was 
above 150 µmol/L, the second line in each cell is where the creatinine was greater than 200 
µmol/L and the third line in each cell is where the creatinine is greater than 300 µmol/L. 
This table shows that of the 5,031 samples from the Emergency Department where the 
creatinine was in excess of 150 µmol/L (top line of each cell), the NHS algorithm was unable to 
evaluate AKI in 447 (8.9%) of them. When the creatinine exceeded 300 µmol/L (bottom line of 
each cell) the NHS England algorithm could not evaluate AKI in 67/915 (7.3%) of the cases. The 
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NHS England was superior in being able to provide an AKI evaluation in cases where the 
creatinine was raised when compared with the other algorithms. 
3.9  Influence of the presence of CKD on the ability to detect AKI 
As the presence of chronic kidney disease may result in more frequent monitoring of renal 
function, it may be hypothesized that patients with this condition are more likely to have 
baseline samples within the AKI algorithm baseline time period than non-CKD patients. 
Therefore, this group may be more likely to be labelled as having AKI by the algorithms than 
non-CKD patients. 
Patients were labelled as having chronic kidney disease if there was no sample in the previous 
year where the eGFR did not exceed 60 mls/min. The algorithm for CKD excluded any samples 
in the previous 30 days in case this was evolving AKI rather than true CKD. The CKD result was 
stored against both the patient record and the individual sample. This was done as a patient 
may move between CKD states over the study and this method provided the ability of 
monitoring changes using a single flag system rather than individual eGFR values. 
Data were extracted between January 2011 and December 2014 for those patients aged 18 
years and over where the patient record indicated the presence or absence of acute kidney 
injury and counted: 
 The total number of records 
 The number of records where there was a sample with a creatinine measurement 
 The number of records where there was a sample with an AKI evaluation using each of 
the available algorithms. 
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This process was repeated but instead of using the patient record as the indicator of CKD, the 
individual sample record was used. 
Patients known to have chronic kidney disease by the described criteria had a creatinine 
measurement recorded during the study period in 99.7% of cases compared with 93.9% of non-
CKD. Regardless of acute kidney injury algorithm, the chronic kidney disease patient group 
consistently had a higher percentage of AKI evaluations (94.1% vs 69.9% for the NHS England 
algorithm) than the non-CKD group. This would appear to indicate that the CKD group had 
creatinine assays performed more often thus ensuring a measurement was available as a 
baseline value for the evaluating algorithm (table 3-6 and figure 3-2). 
Table 3-6 Patients and samples evaluated by various AKI algorithms 
 No CKD CKD 
Patients Samples Patients Samples 
Total 288,365 1,428,112 58,415 253,363 
Total with creatinine 270,729 
(93.9%) 
1,214,744 
(85.1%) 
58,238 
(99.7%) 
253,354 
(100%) 
NHS England 201,606 
(69.9%) 
959,003 
(67.2%) 
54,979 
(94.1%) 
252,831 
(99.8%) 
KDIGO 50,451 
(17.5%) 
315,683 
(22.1%) 
23,374 
(40.0%) 
91,941 
(36.3%) 
AKIN (2 day baseline) 35,593 
(12.3%) 
206,459 
(14.5%) 
18,765 
(32.1%) 
60,592 
(23.9%) 
AKIN (7 day baseline) 50,444 
(17.5%) 
315,685 
(22.1%) 
23,374 
(40.0%) 
91,941 
(36.3%) 
AKIN (30 day baseline) 86,354 
(29.9%) 
476,329 
(33.4%) 
33,250 
(56.9%) 
129,778 
(51.2%) 
AKIN (90 day baseline) 126,408 
(43.8%) 
646,683 
(45.3%) 
41,842 
(71.6%) 
171,295 
(67.6%) 
Waikar & Bonventre 35,593 
(12.3%) 
206,459 
(14.5%) 
18,765 
(32.1%) 
60,592 
(23.9%) 
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Figure 3-2 Ability of algorithms to evaluate AKI in patients and samples with and without CKD 
The data show that patients with CKD are more likely to have sufficient baseline creatinine data 
for evaluation of AKI irrespective of the algorithm used. 
When the data are then grouped by the source classification, a similar pattern is revealed 
where those patients with CKD are more likely to be evaluated for AKI than non-CKD patients 
(table 3-7 and figure 3-3). 
Table 3-7 Effect of source classification and CKD status on the ability to evaluate patients for AKI 
Source classification No CKD CKD 
Primary care 60.2% 88.3% 
Emergency Department 78.2% 89.0% 
Medical Admissions Unit 85.0% 93.9% 
In-patient 88.6% 97.7% 
Out-patient 75.2% 90.1% 
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Figure 3-3 Percentage of patients evaluated for AKI based on source classification and CKD 
status 
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3.10 Overall acute kidney injury incidence 
 
As each individual patient can have samples that span the range of AKI stages, a query was 
constructed that showed the highest AKI stage reached for the patients. This revealed that, at 
some time during the study period and based on the NHS England algorithm, 17,223 (4.97%) of 
patients had AKI stage 1 whilst 5,178 (1.49%) had AKI stage 2 and 3,150 (0.91%) reached AKI 
stage 3. Therefore, a total of 25,551 (7.37%) patients had at least one episode of AKI during the 
four years of the study period. A similar query was used to extract the highest stage for the 
other algorithms and the data is shown in table 3-8 for comparative purposes. 
Table 3-8 Percentages of patients by highest AKI stage 
 Highest AKI stage 
Algorithm Stage 1 Stage 2 Stage 3 
NHS England 4.97 1.49 0.91 
KDIGO 4.29 1.38 0.55 
AKIN (2 day baseline) 1.89 0.33 0.33 
AKIN (7 day baseline) 2.43 0.67 0.47 
AKIN (30 day baseline) 3.32 1.13 0.68 
AKIN (90 day baseline) 4.34 1.52 0.88 
Waikar & Bonventre 1.75 
The Waikar and Bonventre algorithm does not classify patients into stages but just whether 
they have AKI or not.  
The data above demonstrate the impact that the different baseline periods and algorithms have 
on the classification of acute kidney injury; longer baselines being able to capture and evaluate 
more samples. Due to the longer baseline of the NHS algorithm, it classified more patients with 
acute kidney injury than the other algorithms in this study. 
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The impact of gender and the presence or absence of chronic kidney disease on acute kidney 
injury is shown in table 3-9. 
Table 3-9 Effect of gender and CKD status on acute kidney injury 
Gender   AKI 
 Total Stage 1 Stage 2 Stage 3 
Male No CKD 130,866 6,097 (4.66%) 1,743 (1.33%) 721 (0.55%) 
 CKD 21,703 2,541 (11.7%) 911 (4.20%) 982 (4.52%) 
Female No CKD 156,819 4,265 (2.72%) 1,142 (0.73%) 548 (0.35%) 
 CKD 36,641 3,312 (9.04%) 1,136 (3.10%) 809 (2.21%) 
When comparing males and females, the former had a relative risk of acute kidney injury of 
1.72 (1.67 – 1.78; p < 0.001) in the non-CKD grouping and 1.42 (1.37 – 1.48; p < 0.001) in the 
CKD group. Males with CKD had a relative risk of 3.12 (3.02 – 3.23; p< 0.001) of acute kidney 
injury when compared with those not known to have CKD; for females the relative risk was 3.78 
(3.65 – 3.91; p< 0.001). The data demonstrate that males were more likely to develop acute 
kidney injury than females and that, regardless of gender, those with chronic kidney disease 
were more likely than those without CKD to develop AKI. 
In terms of the numbers of patients experiencing an episode of acute kidney injury grouped by 
age band and gender, the data are shown in table 3-10. 
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Table 3-10 Number of patients experiencing AKI by age band and gender 
Age band Gender No AKI Stage 1 Stage 2 Stage 3 
>= 85 Male 4,915 1,143 399 335 
Female 8,830 1,858 666 342 
75 - 84 Male 13,622 1,606 613 478 
Female 15,563 1,664 530 337 
65 - 74 Male 21,849 1,518 513 339 
Female 21,810 1,153 366 254 
55 - 64 Male 20,968 1,175 359 234 
Female 21,196 794 199 162 
45 - 54 Male 18,960 1,236 283 136 
Female 21,824 643 175 104 
35 - 44 Male 12,821 936 222 90 
Female 17,738 553 134 69 
18 - 34 Male 13,329 1,129 281 102 
Female 25,502 992 220 96 
 
From this information the relative risk for AKI was calculated based on age and gender using the 
lowest age band (18 – 34 years) in each stage as a baseline. The tabular results for males and 
females are presented in table 3-11 and represented graphically in figure 3-4. 
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Table 3-11 Relative risk for acute kidney injury by gender and age band 
Age 
band 
Gender Stage 1 Stage 2 Stage 3 
>= 85 
years 
Male 2.42 (2.24 – 2.61) 
p < 0.001 
3.60 (3.11 – 4.17) 
p < 0.001 
8.40 (6.75 – 10.5) 
p < 0.001 
Female 4.64 (4.31 – 5.00) 
p < 0.001 
8.20 (7.05 – 9.53) 
p < 0.001 
9.94 (7.94 – 12.5) 
p < 0.001 
75 - 84 Male 1.35 (1.26 – 1.45) 
p < 0.001 
2.09 (1.81 – 2.40) 
p < 0.001 
4.46 (3.61 – 5.52) 
p < 0.001 
Female 2.58 (2.39 – 1.78) 
p < 0.001 
3.85 (3.29 – 4.50) 
p < 0.001 
5.65 (4.50 – 7.08) 
p < 0.001 
65 – 74 Male 0.83 (0.77 – 0.90) 
p < 0.001 
1.11 (0.96 – 1.28) 
p = 0.151 
2.01 (1.61 – 2.51) 
p < 0.001 
Female 1.34 (1.23 – 1.46) 
p < 0.001 
1.93 (1.63 – 2.28) 
p < 0.001 
3.07 (2.43 – 3.88) 
p < 0.001 
55 – 64 Male 0.68 (0.63 – 0.74) 
p < 0.001 
0.82 (0.70 – 0.95) 
p = 0.010 
1.45 (1.15 – 1.83) 
p = 0.002 
Female 0.96 (0.88 – 1.06) 
p = 0.437 
1.09 (0.90 – 1.32) 
p = 0.389 
2.02 (1.57 – 2.60) 
p < 0.001 
45 – 54 Male 0.78 (0.73 – 0.85) 
p < 0.001 
0.71 (0.60 – 0.84) 
p < 0.001 
0.94 (0.73 – 1.21) 
p = 0.623 
Female 0.76 (0.69 – 0.84) 
p < 0.001 
0.93 (0.76 – 1.13) 
p = 0.472 
1.26 (0.96 – 1.67) 
p = 0.096 
35 – 44 Male 0.87 (0.80 – 0.95) 
p = 0.001 
0.82 (0.69 – 0.98) 
p = 0.030 
0.92 (0.69 – 1.22) 
p = 0.552 
Female 0.81 (0.73 – 0.89) 
p < 0.001 
0.88 (0.71 – 1.09) 
p = 0.228 
1.03 (0.76 – 1.41) 
p = 0.836 
 
This data shows a progressive increase in the relative risk for acute kidney injury as the 
patients’ age increases. Whilst the previous data demonstrate that males tended to have a 
greater incidence of AKI compared with females, this data show that as age increases the 
relative risk for AKI rises faster and higher in females than males. 
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Figure 3-4 Relative risk for AKI by age band and gender 
As acute kidney injury has received many ‘column inches’ in both learned journals and the 
mainstream press, there is also an issue of time and publicity to consider as this may alter 
requesting practices. The number of patients where an acute kidney injury of stage 1 or greater 
was detected in each of the study years using the NHS England algorithm is shown in table 3-12. 
Table 3-12 Patients with acute kidney injury by year with the NHS England algorithm 
 Year 
2011 2012 2013 2014 
Number of patients with a measured creatinine 159,335 162,497 164,742 175,191 
Number of patients with an AKI evaluation 111,859 
(70.2%) 
111,248 
(68.4%) 
109,871 
(66.7%) 
117,237 
(66.9%) 
Number of patients with an AKI Stage > 0 5,879 5,861 7,871 8,136 
% of patients with an AKI (of patients with a 
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The data appear to show an increase in the overall AKI incidence between 2011 and 2013 with 
a subsequent fall in 2014. When broken down by individual AKI stage (figure 3-5) the same 
pattern appears with a rise between 2011 and 2013 and a fall in 2014. This demonstrates that 
the changes seen in the incidence are not due to a change in a particular AKI stage. 
 
 
Figure 3-5 AKI Stage by year for all patients using the NHS England algorithm 
A similar pattern is seen for patients with chronic kidney disease (eGFR < 60 mls/min) although 
the percentage of patients with AKI is much higher in this patient group (figure 3-6). 
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Figure 3-6 AKI stage by year for patients with chronic kidney disease 
 
3.11 Chronic kidney disease and acute kidney injury 
 
Chronic kidney disease (CKD) was recorded in the database against both the patient and the 
individual sample. CKD was defined as a previous eGFR not exceeding 60 mls/min in the 30 to 
365 days prior to the current sample. The 30-day cut-off was chosen to exclude patients who 
were experiencing a current episode of AKI and hence could have been falsely labelled as 
having CKD due to the lowered eGFR that occurs in AKI. 
Of the 346,780 patients in the study group population, 58,415 (16.9%) were classified as having 
CKD; females comprised 36,641 of the CKD group with 21,702 males; in 71 cases the gender 
was not available. In the CKD group there were 3,576 deaths recorded which was 6.1% of the 
CKD group. 
Data were extracted based on the highest AKI stage and was based on the NHS England criteria 
(table 3-13). Not all patients had an AKI evaluation therefore the total figures do not match the 
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total number of patients in the database. Similarly, not all patients had a recorded gender so 
the numbers of males and females do not match the total numbers. 
Table 3-13 Highest AKI stage reached for CKD and non-CKD patients 
 All Female Male 
Number (%) Number (%) Number (%) 
No AKI No CKD 186,017 91.0 99,773 94.0 85,775 90.4 
CKD 44,926 81.7 28,777 84.1 16,110 77.8 
Stage 1 No CKD 11,124 5.4 4,604 4.3 6,492 6.9 
CKD 6,089 11.1 3,434 10.0 2,649 12.8 
Stage 2 No CKD 6,052 3.0 1,209 1.1 1,832 1.9 
CKD 2,123 3.9 1,178 3.4 941 4.6 
Stage 3 No CKD 1,315 0.6 573 0.5 739 0.8 
CKD 1,835 3.3 831 2.4 1,002 4.8 
TOTAL No CKD 204,508 106,159 94,838 
CKD 54,973 342,20 20,702 
 
The relative risk (with 95% confidence interval and p-value) of developing acute kidney injury 
when comparing the CKD with the non-CKD group was calculated as: 
Stage 1 AKI  2.12 (2.05 – 2.18)  p < 0.0001 
Stage 2 AKI 1.43 (1.36 – 1.50)  p < 0.0001 
Stage 3 AKI 5.59 (5.21 – 6.00)  p < 0.0001 
Overall, 18.3% of the CKD group experienced an episode of AKI as defined by the NHS England 
algorithm compared with 9.0% of the non-CKD group.  
 
 Page 106 
 
 
Figure 3-7 Comparison of maximal AKI stage reached for CKD and non-CKD patients 
 
3.12 Thirty-day mortality following acute kidney injury 
 
To assess the overall 30-day mortality following AKI, data were extracted based on the presence 
of acute kidney injury and the date of death. The overall relative risk of death within thirty days 
was 7.1 (95% confidence interval 6.9 – 7.5) when comparing those with acute kidney injury to 
those without. This data is a crude calculation and does not have any correction for any age, 
gender or AKI stage bias that may exist within the data. 
In order to calculate the effect that the highest acute kidney injury stage has on the relative risk 
of thirty-day mortality, the number of patients was extracted based on the highest AKI stage 
they experienced and any mortality in the subsequent thirty days following that AKI episode. 
This is presented in table 3-14 and is based on the NHS England algorithm.  
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Table 3-14 Thirty-day mortality following acute kidney injury 
 No AKI Stage 1 Stage 2 Stage 3 
Total 231,033 17,233 5,178 3,151 
Died 2,335 1,403 736 732 
Relative risk  
(95% confidence interval) 
 8.0 
(7.6 – 8.6) 
14.1 
(13.0 – 15.2) 
23.0 
(21.3 – 24.8) 
 
This demonstrated an increase in the relative risk of thirty-day mortality following acute kidney 
injury from 8.0 for stage 1 to 23.0 for stage 3 AKI (table 3-14). These figures are based on the 
NHS England algorithm but, to date, there are no published data assessing mortality rates using 
this algorithm. Therefore, to assist with the comparison of this data against other published 
work, the relative risk for 30-day mortality following AKI was also calculated for the other 
algorithms and is shown in table 3-15. 
Table 3-15 Comparison of thirty-day mortality relative risk by AKI stage and algorithm 
Algorithm Stage 1 Stage 2 Stage 3 
NHS England 8.0 (7.6 – 8.6) 14.1 (13.0 – 15.2) 23.0 (21.3 – 24.8) 
KDIGO 2.8 (2.6 – 3.0) 5.0 (4.6 – 5.4) 5.6 (5.1 – 6.2) 
AKIN (2 day baseline) 3.1 (2.9 – 3.3) 2.7 (2.4 – 3.1) 4.4 (4.0 – 4.9) 
AKIN (7 day baseline) 3.5 (3.3 – 3.7) 4.2 (3.8 – 4.6) 5.8 (5.3 – 6.4) 
AKIN (30 day baseline) 5.0 (4.6 – 5.3) 7.3 (6.7 – 7.9) 10.0 (9.2 – 10.9) 
AKIN (90 day baseline) 5.9 (5.5 – 6.3) 9.6 (8.9 – 10.4) 14.4 (13.3 – 15.6) 
Waikar & Bonventre 3.4 (3.2 – 3.6) 
 
This data show that the relative risk for 30-day mortality following acute kidney injury using the 
NHS England algorithm is similar to other algorithms in having a rise in the relative risk as the 
AKI stage increases. For all algorithms, the relative risk for thirty-day mortality following an 
episode of AKI was statistically significant compared with non-AKI patients (p < 0.001). 
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3.13 Chronic kidney disease, acute kidney injury and mortality 
 
In order to assess the impact of chronic kidney disease on mortality from acute kidney injury 
data were extracted based on gender, known CKD status and acute kidney injury status. This 
was combined with the date of death (if this occurred within thirty days of sampling in the case 
of non-AKI patients or the highest AKI stage) and the output is shown in table 3-16. 
Table 3-16 Effect of gender and CKD on thirty-day mortality from AKI 
   AKI Stage 
 No AKI Stage 1 Stage 2 Stage 3 
Male No CKD Alive 85,807 6,495 1,834 739 
Died 518 (0.60%) 236 (3.63%) 183 (9.98%) 135 (18.3%) 
CKD Alive 16,107 2,651 941 1,003 
Died 601 (3.73%) 480 (18.1%) 181 (19.2%) 248 (24.7%) 
Female No CKD Alive 99,828 4,609 1,209 573 
Died 379 (0.38%) 167 (3.62%) 124 (10.3%) 106 (18.5%) 
CKD Alive 28,782 3,434 1,179 831 
Died 836 (2.90%) 520 (15.1%) 248 (21.0%) 243 (29.2%) 
The impact of chronic kidney disease on thirty-day mortality is demonstrated by an overall 
relative risk of death in the absence of acute kidney injury of 5.99 (5.34 – 6.73, p < 0.001) in 
males. When acute kidney injury stage 1 was present the relative risk was 4.37 (3.76 – 5.08, p < 
0.001), at stage 2 it was 1.77 (1.47 – 2.15; p < 0.001) and at stage 3 it was 1.28 (1.06 – 1.55; p = 
0.010). In females the relative risks were 7.46 (6.61 – 8.42; p < 0.001) without acute kidney 
injury, for stage 1 AKI was 3.76 (3.18 – 4.45; p < 0.001), for stage 2 was 1.87 (1.53 – 2.29; p < 
0.001) and at stage 3 was 1.45 (1.18 – 1.78; p < 0.001). The data show that chronic kidney 
disease is associated with an increased risk of thirty-day mortality compared with non-CKD 
patients. However, the influence of CKD on mortality decreases at higher stages of acute kidney 
injury. 
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The effect of acute kidney injury alerts 
 
Acute kidney injury alerts were only issued to patients where the requesting location was the 
Emergency Medical Admissions Unit at RHCH. Patients under the age of 18 years were actively 
excluded from having alerts issued as these patients fell under the paediatric team who had 
previously indicated they wished to wait for guidance from the British Association of Paediatric 
Nephrology. The following sections highlight the impact the introduction of alerts had on 
subsequent renal function (as measured by eGFR) and thirty-day mortality. 
3.14 The effect of alerts on recovery of renal function following acute kidney injury 
 
To assess the recovery of renal function following an episode of acute kidney injury data was 
extracted from the database for patients eligible to receive an AKI alert that included: 
 The lowest creatinine value in the 30 - 180 days prior to the AKI episode 
 The highest AKI stage and associated creatinine 
 The lowest creatinine value in the 30 - 90 and 91 – 180 days post AKI episode. 
The SQL query used to extract this data was quite complex and relied on the use of several 
stored functions details of which are shown below.  
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The creatinine values are shown as the mean and 95% confidence interval. Only those patients 
where all samples (pre AKI and post AKI) were present were calculated (table 3-17); those 
patients where any value was missing i.e. no follow up at 91-180 days were excluded as this 
then allowed comparisons across each group without correcting for missing values. 
 
DECLARE @START DATETIME  
DECLARE @END DATETIME 
SET @START = '1-Dec-2012 00:00:00' 
SET @END = '30-Jun-2013 23:59:59' 
SELECT 
 t.ID,  
 t.Sampled, 
 t.AGE, 
 t.Sex, 
 t.CKD,  
 t.Death,  
 t.AKISTAGE, 
 t.AKICREAT, 
 dbo.GetLowValue (DATEADD(day, -365,t.Sampled), 'CRE2', 335, t.id) AS LOWCREAT, 
 dbo.GetLowValue (t.Sampled, 'CRE2', 90, t.id) as LOWCREAT90, 
 dbo.GetLowValue (DATEADD(day, 90, t.Sampled), 'CRE2', 90, t.id) as LOWCREAT180, 
 dbo.GetLowValue (DATEADD(day, -365,t.Sampled), 'egfr', 335, t.id) AS LOWgfr, 
 dbo.GetLowValue (t.Sampled, 'egfr', 90, t.id) as LOWgfr90, 
 dbo.GetLowValue (DATEADD(day, 90, t.Sampled), 'egfr', 90, t.id) as LOWgfr180 
FROM 
( 
SELECT 
 ROW_NUMBER() OVER(PARTITION BY S.Patient_ID ORDER By R.Result DESC) AS row, 
 P.CKD AS CKD, 
 p.DOD as Death, 
 P.Sex as Sex, 
 DATEDIFF(year, P.DoB, s.Sampled) AS AGE, 
 S.Patient_ID AS ID, 
 S.Sampled as Sampled, 
 R.Result as AKISTAGE, 
 Creat.Result as AKICREAT 
FROM Samples as S 
INNER JOIN Patients as P ON S.Patient_ID = P.Unique_ID 
INNER JOIN Results as R On S.LabNo = R.LabNo 
INNER JOIN Results as Creat on R.LabNo = Creat.LabNo 
WHERE S.Source IN ('RHEMA', 'RHMCG', 'RHTAU') 
AND S.Sampled BETWEEN @START AND @END 
AND R.Code = 'AKI' 
AND Creat.Code = 'CRE2' 
) t 
WHERE t.row = 1 
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Table 3-17 Renal function pre and post AKI 
Highest 
AKI stage 
n Pre AKI eGFR AKI creatinine 
(µmol/L) 
Post AKI eGFR (mls/min) 
90 days 180 days 
No AKI 1462 63.5 
(62.1 – 65.0) 
95.7 
(92.8 – 98.7) 
62.0 
(60.7 – 63.4) 
65.5 
(64.0 – 67.0) 
1997 66.8 
(65.4 – 68.2) 
p = 0.049 
96.4 
(94.5 – 98.4) 
p = 0.006 
68.8 
(67.3 – 70.3) 
p < 0.001 
86.5 
(68.3 – 104.5) 
p = 0.074 
Stage 1 197 55.5 
(50.7 – 60.2) 
154.1 
(144.1 – 164.1) 
45.3 
(41.7 – 48.8) 
53.9 
(49.7 – 58.2) 
358 61.1 
(57.2 – 65.0) 
p = 0.189 
145.2 
(138.7 – 151.7) 
p = 0.67 
52.9 
(49.0 – 56.8) 
p = 0.001 
72.8 
(60.8 – 84.8) 
p = 0.049 
Stage 2 52 63.5 
(55.6 – 71.5) 
196.5 
(180.2 – 212.8) 
44.8 
(33.8 – 55.9) 
58.6 
(50.5 – 66.8) 
106 61.0 
(55.6 – 66.3) 
p = 0.678 
178.2 
(164.1 – 192.3) 
p = 0.165 
45.9 
(38.6 – 53.3) 
p = 0.953 
63.5 
(57.3 – 69.7) 
p = 0.116 
Stage 3 62 49.6 
(41.6 – 57.5) 
467.6 
(418.7 – 516.5) 
15.5 
(11.9 – 19.1) 
43.2 
(34.3 – 52.2) 
103 53.6 
(42.1 – 65.2) 
p = 0.377 
386.5 
(346.0 – 426.9) 
p = 0.83 
22.3 
(18.4 – 26.3) 
p = 0.010 
48.9 
(39.8 – 58.1) 
p = 0.785 
 
Rows in white represent the data prior to alerts being issued; the grey rows represent the data 
once alerts had been implemented. The p value is based on the comparison of the mean for the 
combination of AKI stage and creatinine or eGFR in the pre-alert and post-alert period. 
This data suggests there was a small but significant difference between the pre and post alert 
non-AKI groups in terms of renal function. When the AKI groups are compared, those with stage 
1 had significantly higher eGFR at both 30 - 90 and 91 - 180 days post AKI episode compared 
with the pre-alert group. In addition, those with AKI stage 3 did not experience such a profound 
fall in renal function at day 30 - 90 compared with the pre-alert group.  
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Interestingly, the patients without AKI had a significant difference in the creatinine in the 
admission sample, and in the eGFR in the previous 30-365 days and the eGFR following the 
admission sample.  
In the pre-alert group, the mean eGFR in all AKI groups is lower in the 30 to 90-day group than 
the pre-AKI sample and whilst this recovers in the 90 to 180-day group, in no AKI stage does it 
exceed the pre-AKI values (figure 3-8). In contrast, following the introduction of AKI alerts, the 
mean eGFR at 90 to 180 days post AKI exceeds the pre-AKI baseline in all AKI groups. The data 
also suggest that renal monitoring following an episode of acute kidney injury should last at 
least 6 months. 
 
Figure 3-8 eGFR pre and post AKI before and after AKI alert implementation 
The ‘pre-stage’ is prior to the introduction of AKI alerts whilst the ‘post stage’ is following AKI 
alert implementation. 
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Patients were grouped into CKD stages as defined by the Renal Association (2009) for both pre 
AKI eGFR and 90 - 180 days post AKI as shown in table 3-18.  
Table 3-18 Renal Association classification of chronic kidney disease 
CKD Stage eGFR (mls/min) 
1 >= 90 
2 60 – 89 
3A 45 - 59 
3B 30 – 44 
4 15 – 29 
5 < 15 
In terms of renal recovery, the data were also analysed comparing whether the patients 
demonstrated an improvement or deterioration in renal function at 90-180 days based on the 
pre-AKI CKD stage. Patients were classified as improved or deteriorated if the post-AKI CKD 
stage had changed by one or more stages relative to the pre-AKI CKD stage. This was done for 
both the pre- and post-alert phases and the number of patients (and percentages) are shown in 
table 3-19. 
Table 3-19 Changes in renal function following acute kidney injury 
 Pre alerts Post alerts 
CKD Improved No change Deteriorated Improved No change Deteriorated 
Stage 1  777 99 (11.3)  1432 292 (16.9) 
Stage 2 130 (8.5) 1226 169 (11.1) 109 (5.3) 1624 308 (15.1) 
Stage 3A 86 (9.5) 708 114 (12.6) 118 (10.6) 828 167 (15.0) 
Stage 3B 109 (14.2) 589 65 (8.5) 112 (12.2) 724 79 (8.6) 
Stage 4 75 (19.4) 305 7 (1.8) 109 (20.2) 412 17 (3.2) 
Stage 5 27 (22.3) 94  32 (21.2) 119  
From this data it was possible to calculate a relative risk for deterioration (and improvement) 
using the pre-alert phase and CKD stage as the baseline. The results (table 3-20) demonstrate 
little improvement in renal function at 180 days following the introduction of AKI alerts whilst 
there is a statistically significant deterioration following AKI in patients with CKD stages 1 and 2 
in the post alert period. 
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Table 3-20 Relative risk of renal function deterioration and improvement 
CKD Improvement Deterioration 
Stage 1  1.50 (1.21 – 1.85) p = 0.0002 
Stage 2 1.03 (1.02 – 1.05) p = 0.0003 1.36 (1.14 – 1.62) p = 0.0006 
Stage 3A 0.99 (0.96 – 1.02) p = 0.40 1.20 (0.96 – 1.49) p = 0.11 
Stage 3B 1.02 (0.99 – 1.06) p = 0.22 1.01 (0.74 – 1.39) p = 0.93 
Stage 4 0.99 (0.93 – 1.06) p = 0.74 1.75 (0.73 – 4.17) p = 0.21 
Stage 5 1.01 (0.89 – 1.15) p = 0.82  
 
3.15 Effect of AKI alerts on thirty-day mortality 
 
Data were extracted from the database to compare the relative risk for 30-day mortality 
between the pre-alert phase and the post-alert phase. The pre-alert phase was used as the 
baseline comparator for the relative risk calculation. 
In the pre-alert period there were 265 deaths in the 30-day period following AKI out of a total 
of 1,076 AKI patients (24.6%). In the post-alert phase there were 316 deaths from a total of 
1,737 AKI patients (18.2%).  
Table 3-21 Effect of alerts on thirty-day mortality 
Highest AKI stage Pre-alert Post-alert 
Patients Died (%) Patients Died (%) 
No AKI 5,877 362 (6.2) 7,235 383 (5.3) 
1 660 129 (19.5) 1,057 154 (14.6) 
2 195 58 (30.1) 371 82 (22.1) 
3 221 78 (35.3) 309 80 (25.9) 
 
The data reveal that there is an increasing mortality in the group of patients within the 
Emergency Medical Admissions Unit, Winchester (EMAU) with the increasing highest AKI stage. 
Following the introduction of electronic alerts there was a fall in the percentage of patients 
dying by day 30. There was also a smaller fall in the non-AKI group. 
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Figure 3-9 Thirty-day mortality following AKI 
Table 3-22 summarises the relative risk, 95% confidence interval, p value and number needed 
to treat based on maximal AKI stage for 30-day mortality following the introduction of AKI 
alerts on the EMAU. The comparison is with the number of deaths within the same AKI stage 
when no alerts were issued. 
Table 3-22 Relative risk of acute kidney injury following alert implementation 
Highest 
AKI stage 
Relative risk 95% confidence interval p Number needed to treat 
No AKI 0.86 0.76 – 1.00 0.048 131 
1 0.75 0.60 – 0.92 0.007 20.1 
2 0.75 0.56 – 1.00 0.047 13.4 
3 0.73 0.57 – 0.95 0.019 10.6 
There was a statistically significant reduction in the 30-day mortality associated with an episode 
of acute kidney injury following the introduction of electronic alerts. However, there was also a 
decrease in the number of non-AKI related deaths.  
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The percentage figures from table 3-21 demonstrate a reduction in thirty-day mortality 
between the pre-alert and post alert phase periods.  If the mortality rate had remained 
unchanged in the post-alert phase the expected number of deaths would have been 448, 206, 
111 and 109 in each AKI stage (no AKI, stage 1, 2 and 3) respectively.  This simplistic comparison 
appears to show that the post alert phase there were 110 fewer deaths than expected in the 
AKI groups and 65 fewer in the non-AKI group. 
In their paper, Wilson et al. (2015) used a 7-day period to look at mortality data using the 
KDIGO algorithm. For comparative purposes, the data in the current study has been extracted 
based on this algorithm for both 7 and 30-day mortality (table 3-23).  
Table 3-23 Seven-day mortality pre and post alerts using the KDIGO algorithm 
Phase  Total 7 days 30 days 
Pre alert No AKI 4,454 181 (4.1%) 360 (8.1%) 
 AKI 830 113 (13.6%) 168 (20.2) 
Alert No AKI 4,834 193 (4.0%) 382 (7.9%) 
 AKI 1,752 150 (8.6%) 227 (13.0%) 
The relative risk for mortality in the 7-day period following AKI (or sampling in the case of non-
AKI patients) was 0.98 (0.81 – 1.20; p = 0.87) for non AKI patients and 0.65 (0.52 – 0.83; p = 
0.0004). For thirty-day mortality the respective relative risks were 0.98 (0.85 - 1.13; p = 0.80) 
and 0.69 (0.57 – 0.83; p = 0.0001). This study seems to contradict the findings of Wilson et al in 
demonstrating a reduction in mortality even at seven days. 
Overall this data suggests a reduction in the relative risk of thirty-day mortality following the 
introduction of AKI alerts. However, gratifying though it would be to assign this improvement in 
care to the alerts, it may also be the impact of the educational element and journal articles 
rather than the alerts themselves. As a comparison, the Acute Admission Units at Basingstoke 
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was used as the basis of a control group as no alerts were ever issued on patients from this 
location (table 3-24). This demonstrated that the Basingstoke Unit had a lower mortality in the 
pre-alert phase compared with the Winchester unit. In addition, there was a fall in the mortality 
in the post-alert phase even though the Basingstoke Unit did not receive AKI alerts. However, 
the average age of patients age the Basingstoke Unit was significantly lower than at the 
Winchester unit and this may explain some of these findings as increasing age is a risk factor for 
AKI.  
Table 3-24 Thirty-day mortality comparison across medical units 
AKI 
Stage 
Winchester EMAU Basingstoke AAU 
Pre alert Post alert Pre alert Post alert 
Patients Died (%) Patients Died (%) Patients Died (%) Patients Died (%) 
No AKI 5,877 362 
(6.3) 
7,235 383 
(5.3) 
5,274 240 
(4.6) 
6,271 261 
(4.2) 
1 660 129 
(19.5) 
1,057 154 
(14.7) 
325 45 
(13.8) 
453 63 
(13.9) 
2 195 58 
(29.7) 
371 82 
(22.1) 
108 27 
(25.0) 
177 23 
(13.0) 
3 221 78 
(35.3) 
309 80 
(25.9) 
92 19 
(20.6) 
169 27 
(16.0) 
When comparing the post-alert phase across the two sites, RHCH patients had a relative risk of 
acute kidney injury of 1.29 (1.06 – 1.57; p = 0.013). In the pre-alert phase, the relative risk was 
1.42 (1.15 – 1.76; p = 0.001). 
In order to try to assess the impact (or otherwise) of the alerts and educational elements, the 
patients in both locations were grouped into age bands (> 85, 75 – 84, 65 – 74 and 55 - 64) and 
the mortality compared across the sites (table 3-25). 
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Table 3-25 Thirty-day mortality across sites by age band 
Age 
band 
 Winchester EMAU Basingstoke AAU 
Pre-alert Post-alert Pre-alert Post-alert 
Patients Died Patients Died Patients Died Patients Died 
>= 85 
No AKI 1465 167 (11.4) 
1601 228 
(14.2) 
745 115 
(15.4) 
929 99  
(10.7) 
AKI 286 100 (35.0) 
545 142 
(26.1) 
125 42 
(33.6) 
173 40  
(23.1) 
75 – 
84 
No AKI 1177 135 (11.5) 
1691 152  
(9.0) 
986 69  
(7.0) 
1300 100 
(7.7) 
AKI 284 79 (27.8) 
494 92 
(18.6) 
131 19 
(14.5) 
196 43 
(21.9) 
65 – 
74 
No AKI 873 60 (6.9) 
1293 92 
(7.1) 
925 43 
(4.6) 
1132 50 
(4.4) 
AKI 149 27 (18.1) 
304 50 
(16.4) 
95 17 
(17.9) 
169 16 
(9.5) 
55 - 
64 
No AKI 580 18  (3.1) 
840 31 
(3.7) 
695 22 
(3.2) 
829 15 
(1.8) 
AKI 74 13 (17.6) 
148 16 
(10.8) 
68 9 
(13.2) 
111 6 
(5.4) 
The figures in the grey rows are those where there was no AKI; those with AKI are shown in the 
clear rows. The thirty-day mortality percentage data are charted in figure 3-10. 
 
Figure 3-10 Thirty-day mortality comparison between AKI and non-AKI groups across sites 
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To compare thirty-day mortality between the sites and age banding and after the introduction 
of AKI alerts, the relative risk of AKI was calculated using the non-alert site (Basingstoke) as a 
control group; the relative risk was calculated using the post alert phase for each age banding 
and location (table 3-26). 
Table 3-26 Relative risk of thirty-day mortality following acute kidney injury between sites 
Age band (years) Relative risk (95% CI) p 
>= 85 1.13 (0.83 – 1.53) 0.45 
75 – 84 0.85 (0.62 – 1.17) 0.32 
65 – 74 1.76 (1.03 – 3.00) 0.035 
55 - 64 2.00 (0.81 – 4.95) 0.13 
 
This seems to suggest that there is little statistically significant difference in thirty-day mortality 
following acute kidney injury between the two locations in the alert phase with the exception 
of the 65 to 74 years old age band. This may suggest that the alerts were not directly 
responsible for the observed fall in mortality. 
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3.16 Seasonal variation of acute kidney injury on the RHCH Medical Admissions Unit 
 
As pneumonia is the leading cause of AKI in patients admitted to HHFT, it may be expected 
there would be a seasonal variation in the winter months as such cases become more 
prevalent. However, seasonal decomposition analysis using SPSS did not reveal a significant 
seasonal element (figure 3-11 and figure 3-12). Whilst the autocorrelation function reveals a 
significant lag at periods 2 and 3 they decline to non-significant values after this and, 
importantly, there is no spike at a lag of 12 which would indicate a lack of any significant 
seasonal factor. This is confirmed by the lack of any significant partial autocorrelation factor in 
figure 3-12. 
 
Figure 3-11 Seasonal decomposition analysis of AKI cases at RHCH MAU 
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Figure 3-12 Partial autocorrelation analysis of AKI cases at RHCH MAU 
It was then hypothesised that the seasonal variations that may exist in the causes of AKI 
admission, namely dehydration and infections may be cancelling each other out over the course 
of the year. The work on seasonal variation was then repeated stratifying the cases by the 
concentration of C-reactive protein (CRP), a routine assay used as an indicator of inflammation 
and infection. Breaking the data down and analysing those cases where the CRP was greater 
than 200 mg/L and with acute kidney injury did not reveal the presence of any seasonal factor 
(figure 3-13). 
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Figure 3-13 Autocorrelation of AKI cases with CRP > 200 mg/L 
 
3.17 Seasonal variation and Acute Kidney Injury thirty-day mortality 
 
To assess the seasonal variability in 30-day mortality, data was extracted from the database for 
all patients aged 18 years and over who had a sample taken within 30 days of death where the 
presence of acute kidney injury was demonstrated using the NHS England algorithm. The 
patients were grouped according to the month and year when the highest AKI stage was 
recorded. The data was then analysed within SPSS version 22 using the seasonal decomposition 
module as previously described. The raw data is tabulated in table 3-27 and displayed in 
graphical format in figure 3-14.  
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Table 3-27 Thirty-day mortality associated with acute kidney injury by month and year 
Date Deaths Date Deaths Date Deaths Date Deaths 
Jan-11 76 Jan-12 70 Jan-13 84 Jan-14 75 
Feb-11 65 Feb-12 86 Feb-13 79 Feb-14 71 
Mar-11 71 Mar-12 85 Mar-13 86 Mar-14 70 
Apr-11 75 Apr-12 66 Apr-13 84 Apr-14 73 
May-11 62 May-12 60 May-13 61 May-14 70 
Jun-11 57 Jun-12 51 Jun-13 59 Jun-14 75 
Jul-11 54 Jul-12 59 Jul-13 57 Jul-14 63 
Aug-11 52 Aug-12 57 Aug-13 64 Aug-14 63 
Sep-11 54 Sep-12 47 Sep-13 70 Sep-14 51 
Oct-11 62 Oct-12 67 Oct-13 70 Oct-14 72 
Nov-11 57 Nov-12 64 Nov-13 75 Nov-14 76 
Dec-11 54 Dec-12 88 Dec-13 79 Dec-14 97 
Visually there appear to be a lower number of deaths within 30 days of acute kidney injury in 
the summer months compared with the winter months.  
 
Figure 3-14 Number of deaths within thirty days of AKI (EMAU) 
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there is a time element comparison of means may be invalid due to the temporal dependency 
(termed autocorrelation). Within SPSS it is possible to analyse the data for seasonal trends.  
The visual impression from figure 3-14 is that there are fewer deaths at thirty days in the 
summer months is further strengthened by the autocorrelation function of the seasonal 
analysis demonstrating a significant increase at a lag period of 10 to 13 with a significant 
decrease at lag periods 5, 6 and 7 (figure 3-15). Each lag period corresponds to one month with 
lag period 1 being the January of each year. The strength of the correlation is given by the r2 
value. This is calculated as the square of the autocorrelation function at lag period 12. In the 
current data set the autocorrelation value at lag period 12 is 0.361 (standard error 0.121) which 
gives an r2 value of 0.130. From this we can conclude that just 13% of the variability may be 
explained by a seasonal component and 87% of the variability remains unexplained within this 
model. Therefore, whilst there is some degree of seasonality in thirty-day mortality following 
AKI, this is not the main explanation for the apparent trend seen over the year. 
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Figure 3-15 Autocorrelation function for 30-day mortality with acute kidney injury 
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3.18 Community acquired acute kidney injury 
 
 
Community acquired acute kidney injury was defined as those cases where the initial detection 
was based on a requesting source that was classified as one of either general practice, 
emergency department, outpatient department or medical admission unit.  
Between January and December 2013 a total of 4,919 (66.0%) patients were identified as 
meeting the inclusion criteria for acute kidney injury presenting as a community based event 
from a total of 7,492 patients with AKI. A total of 2,281 (46.4%) patients were female and 2,629 
(53.4%) were male. There were 1,910 (38.8%) patients who were known to have CKD. 
Stage 1 AKI accounted for 3,248 (66.0%) of patients with stage 2 being 1,021 (20.8%) and stage 
3 being 650 (13.2%). When stratified based on those with chronic kidney disease, 1,142 (34.4%) 
were AKI stage 1 with 400 (38.4%) being AKI stage 2 and 368 (55.3%) being AKI stage 3 (figure 
3-16). When comparing the CKD with the non-CKD group by AKI stage using the Pearson Chi-
square test the p value was < 0.0001 indicating statistically significant association between the 
chronic kidney disease status and the highest AKI stage.  
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Figure 3-16 Community acquired AKI by CKD status and AKI stage 
The average age (and 95% confidence interval) for the patients was 59.6 years (58.5 - 60.8) for 
Casualty presentation, 60.1 years (59.1 – 61.2) for general practice, 72.6 years (71.5 -73.6) for 
admissions unit and 60.1 years (58.4 – 61.8) for outpatient. Patients with stage 1 AKI tended to 
be younger (61.5 years; 95% confidence interval 60.8 – 62.3) than those with stage 2 (63.8 
years; 95% CI 62.4 – 65.1) and stage 3 (66.6 years; 95% CI 65.0 – 68.3); the p value for a one-
way ANOVA analysis was less than 0.001. Additionally, patients known to have CKD were older 
at every stage of presentation compared with the non-CKD group; stage 1 mean age 53.1 vs 
77.6 (non-CKD vs CKD), stage 2 mean age 56.0 vs 76.3 and for stage 3 was 55.7 vs 75.5. 
The most common mode of presentation was via the Casualty Department (34.1%) and then 
general practice (32.5%), the admission unit (21.9%) and the outpatient department (11.5%). 
Those patients presenting via the Casualty Department and the Admission Unit tended to have 
more severe AKI than those from the general practice or outpatients (table 3-28). 
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Table 3-28 Presentation by source and stage for community AKI 
 AKI stage 1 AKI Stage 2 AKI Stage 3 
Casualty 1,114 (20.5%) 443 (8.2%) 274 (5.0%) 
Admissions Unit 778 (14.3%) 286 (5.3%) 230 (4.2%) 
General Practice 1,253 (23.1%) 277 (5.1%) 161 (3.0%) 
Outpatients 424 (7.8%) 106 (2.0%) 80 (1.5%) 
The figures in Table 3-28 do not match the numbers stated in the text as patients may have 
been seen in more than one source. As a consequence, the percentage figures are based on the 
totals number within the table. 
Of the 4,919 patients presenting with community-acquired AKI, 387 patients died within 30 
days of AKI presentation giving a community AKI mortality of 7.9%. When categorized by AKI 
stage the thirty-day mortality was 5.6% for stage 1, 10.0% for stage 2 and 12.7% for stage 3. 
There was no statistically significant difference in the ages of those who died within 30 days 
(81.2 vs 79.9 vs 79.1 for stages 1, 2 and 3 respectively; one-way ANOVA p = 0.328). Despite CKD 
patients representing 38.0% of all the patients in this group they accounted for 63.2% of the 
deaths within thirty days (relative risk 2.80; 95% confidence interval 2.40 – 3.27; p < 0.0001). 
In an attempt to understand the pathway for patients where acute kidney injury is detected 
and currently handled in general practice (defined as requested by a general practitioner and 
the sample being taken at a general practice), data were extracted that linked the current 
primary care episode with the subsequent sample (table 3-29). 
 Page 129 
 
Table 3-29 Primary care acute kidney injury and subsequent review 
 AKI Stage 
1 2 3 
Number 1,232 306 272 
Age (years) 70.2 
(69.3 – 71.0) 
69.7 
(67.9 – 71.6) 
68.9 
(67.1 – 70.7) 
Creatinine (µmol/L) 160 
(156 - 164) 
207 
(199 – 216) 
485 
(456 - 515) 
eGFR (mls/min) 47 
(44 - 49) 
33 
(29 - 36) 
14 
(12 – 17) 
Next creatinine (µmol/L) 144 
(141 – 148) 
183 
(173 – 193) 
441 
(416 – 466) 
Next sample taken at: 
 GP 
 ED/MAU 
 In-patient 
 Out-patient 
 
1,595 (69.2%) 
434 (18.8%) 
72 (3.1%) 
154 (6.7%) 
 
296 (67.7%) 
98 (22.4%) 
23 (5.3%) 
17 (3.9%) 
 
188 (47.7%) 
146 (37.1%) 
21 (5.3%) 
13 (3.3%) 
The figures for age, creatinine and eGFR are displayed as the mean and 95% confidence 
interval. This demonstrated that, despite the presence of acute kidney injury, the majority of 
follow up was performed by the general practice. As the acute kidney injury became more 
severe, as evidenced by the stage, the percentage of patients with a subsequent sample being 
taken within general practice fell from 69.2% to 47.7% with a corresponding increase in 
patients being seen next in either the Emergency Department or Medical Admissions Unit. 
Similarly, the follow-up period (time from when AKI would have been detected to the follow up 
sample) also fell from a mean of 73 days for stage 1 AKI to 37 days for stage 3. 
The average time between the general practice AKI and being seen in a Medical Assessment 
Unit was 13.8 days (95% confidence interval 7.7 – 20.0 days) with a median of 1.0 days whilst 
for Casualty assessment it was 65.1 days (95% confidence interval 51.8 – 78.4 days) with a 
median of 14 days. Data detailing the time interval between the ‘AKI sample’ and the 
subsequent sample for emergency review are shown in table 3-30. 
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Table 3-30 Interval for subsequent review of AKI by stage 
AKI Stage Casualty Department Medical Assessment Unit 
Number Mean (95% CI) Median Number Mean (95% CI) Median 
Stage 1 239 75.1 
(59.0 – 91.2) 
20.0 195 24.2 (12.7 – 
35.7) 
1.0 
Stage 2 32 19.9 
(-3.6 – 43.4) 
2.5 66 4.7 (1.0 – 8.4) 1.0 
Stage 3 35 38.5 
(12.0 – 65.0) 
1.0 111 1.1 (0.9 – 1.4) 1.0 
However, when the data are stratified by the creatinine value at the point when AKI is detected 
there appears to be a relationship between this value and the subsequent follow-up sample 
interval (table 3-31 and figure 3-17).  
Table 3-31 Interval for subsequent review by creatinine value 
Creatinine 
(µmol/L) 
Casualty Medical Assessment Unit 
Number Mean (95% CI) Median Number Mean (95% CI) Median 
< 100 66 104.5 
(77.1 – 132.0) 
74.0 14 122.5  
(27.3 – 217.7) 
50.5 
100 - < 200 147 69.3 
 (46.4 – 92.1) 
14.0 128 19.6  
(7.0 – 32.1) 
1.0 
200 - < 300 49 29.4  
(13.6 – 45.3) 
10.0 97 3.3  
(2.3 – 19.6) 
12.5 
300 - < 500 24 33.3  
(1.7 – 64.8) 
2.5 90 6.4  
(-1.8 – 14.6) 
1.0 
>= 500 20 30.4  
(-0.4 – 61.2) 
1.0 43 0.9  
(0.6 – 1.1) 
1.0 
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Figure 3-17 Interval to next sample based on initial creatinine value 
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3.19 Comparison of the NHS England algorithm for AKI with other algorithms 
 
One of the aims of the project was to compare the performance of the different algorithms in 
detecting AKI in the same group of patients. To do this data were extracted from the database 
for both the NHS England evaluation and the comparator algorithm. As the NHS England 
algorithm used a longer baseline of up to 365 days, there were cases where no comparator 
algorithm was present so these cases have not been included.  
3.20 KDIGO algorithm 
 
The KDIGO (RIFLE) algorithm uses a 7-day baseline but, unlike the NHS England algorithm, also 
uses changes in the eGFR as well as creatinine to define and stage acute kidney injury. Data 
were extracted where there was an evaluation for both the NHS England algorithm and the 
KDIGO algorithm (table 3-32). 
 
Table 3-32 Comparison of NHS England algorithm with the KDIGO algorithm 
KDIGO No AKI Stage 1 Stage 2 Stage 3 TOTAL 
Number (%) Number (%) Number (%) Number (%) 
No AKI 354,265 81.8 7,431 1.7 2,074 0.5 2,271 0.5 366,041 
1 33,788 7.8 14,042 3.2 1,102 0.3 774 0.2 49,706 
2 1,107 0.3 5,143 1.2 4,428 1.0 1,260 0.3 1,1938 
3 407 0.1 549 0.1 758 0.2 3,505 0.8 5,219 
TOTAL 389,567 27,165 8,362 7,810 432,904 
 
Of the samples that could be classified by both the KDIGO and NHS England algorithm 81.4% 
were classed as not having AKI and 7.4% were classed as having AKI. Of the samples where 
there was a discordance in classification, 8.5% were classed as AKI by the KDIGO algorithm and 
not AKI by the NHS England algorithm and 2.7% were classed as having AKI by the NHS England 
algorithm but no AKI by KDIGO. 
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3.21 Waikar & Bonventre algorithm 
 
Waikar and Bonventre proposed their algorithm following an examination of the kinetics of 
creatinine, notably for patients with chronic kidney disease. However, their algorithm utilised a 
baseline occurring in the last 48 hours (table 3-33). 
Table 3-33 Comparison between the NHS England and the Waikar and Bonventre algorithms 
Waikar NHS England 
No AKI Stage 1 Stage 2 Stage 3 TOTAL 
Number (%) Number (%) Number (%) Number (%) 
No AKI 246,331 87.6 15,629 5.6 4,007 1.4 3,482 1.2 269,449 
AKI 33 <0.1 5,842 2.1 2,714 1.0 3,322 1.2 11,911 
TOTAL 246,364 21,471 6,721 6,804 281,360 
There was agreement in 91.4% of samples that AKI was not present and 4.5% of samples that 
AKI was present. In only 4 samples was AKI detected by the Waikar & Bonventre algorithm but 
not by the NHS England algorithm whereas 8.63% of samples had AKI by the NHS England 
algorithm but not by the Waikar algorithm. 
3.22 Acute Kidney Injury Network algorithm 
 
The NHS England algorithm is based, to large part, on the Acute Kidney Injury Network 
algorithm. However, the former uses two possible baselines; one being the lowest value within 
7 days of the current sample and then the median value from days 8 to 365. The AKIN algorithm 
does not explicitly state a baseline so the study used a baseline at 2, 7, 30 and 90 days for 
comparative purposes (table 3-34). 
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Table 3-34 Comparison between the NHS England and AKIN algorithm (varying baseline time) 
Baseline AKI 
Stage 
No AKI Stage 1 Stage 2 Stage 3 
N % N % N % N % 
2 days No AKI 246,308 87.5 10,561 3.8 3,293 1.2 3,090 1.1 
1 21 <0.1 10,546 3.7 1,896 0.7 1,040 0.4 
2 2 <0.1 0 0 1,526 0.5 260 0.1 
3 33 <0.1 364 0.1 6 <0.1 2,414 0.9 
7 days No AKI 389,521 90.0 7,772 1.8 2,190 0.5 2,446 0.6 
1 18 <0.1 19,030 4.4 1,470 0.3 893 0.2 
2 0 0 0 0 4,695 1.1 575 0.1 
3 57 <0.1 364 <0.1 6 <0.1 3,906 0.9 
30 days No AKI 589,222 90.1 5,569 0.9 1,377 0.2 1,717 0.3 
1 13,737 2.1 21,999 3.4 1,102 0.2 773 0.1 
2 1,930 0.3 2,603 0.4 6,106 0.9 816 0.1 
3 646 0.1 598 0.1 702 0.1 5,256 0.8 
90 days No AKI 806,454 90.4 3,609 0.4 787 0.1 1,031 0.1 
1 26,671 3.0 24,778 2.8 650 0.1 714 0.1 
2 4,364 0.5 4,751 0.5 7,245 0.8 974 0.1 
3 1,270 0.1 903 0.1 1,380 0.2 6,426 0.7 
 
 
For the 2 day baseline there was concordance in 87.5% of samples that AKI was not present and 
in 6.4% of samples that AKI was present. Only 56 samples were classed as AKI by the AKIN 
algorithm but negative by the NHS England algorithm. The NHS England algorithm classed 6.1% 
of samples as having AKI which the AKIN algorithm classed as negative for the condition. 
For the 7 day baseline there was agreement that 90.0% of samples that AKI was not present 
and in 7.0% of samples that AKI was present. Only 75 samples were classed as AKI by the AKIN 
algorithm but negative by the NHS England algorithm. The NHS England algorithm classed 2.5% 
of samples as having AKI which the AKIN algorithm classed as negative for the condition. 
For the 30 day baseline there was agreement in 90.1% of samples that AKI was not present and 
in 6.1% of samples that AKI was present. In 2.5% of samples AKI was detected by the AKIN 
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algorithm but not by the NHS England algorithm and in 1.4% of samples AKI was detected by 
the NHS England algorithm but not the AKIN algorithm. 
Finally, for the 90 day baseline there was concordance in 90.4% of samples that AKI was not 
present and in 5.4% of samples that AKI was present. In 3.6% of samples AKI was detected by 
the AKIN algorithm but not by the NHS England algorithm and in 0.6% of samples AKI was 
detected by the NHS England algorithm but not the AKIN algorithm. 
As the baseline period became longer the agreement between the NHS England and AKIN 
algorithms that there was no AKI increased (from 87.4% at 2 days to 90.4% at 90 days). At the 
same time the agreement that AKI was present fell from 6.1% to 5.4%. 
3.23 Summary comparison with the NHS England algorithm 
 
As there is no definitive ‘gold standard’ for the classification of AKI it is not possible to calculate 
the summary data as false positive, false negative or positive and negative predictive values.  
Table 3-35 Summary AKI algorithm comparison 
Algorithm NHS England 
No AKI AKI 
KDIGO No AKI 81.8% 2.7% 
AKI 8.2% 7.3% 
Waikar No AKI 87.6% 8.2% 
AKI <0.1 4.3% 
AKIN (2 day baseline) No AKI 87.5% 6.1% 
AKI <0.1% 6.4% 
AKIN (7 day baseline) No AKI 90.0% 2.5% 
AKI <0.1% 7.0% 
AKIN (30 day baseline) No AKI 90.1% 1.4% 
AKI 2.5% 6.1% 
AKIN (90 day baseline) No AKI 90.4% 0.6% 
AKI 3.6% 5.4% 
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3.24 Urine albumin:creatinine ratio and subsequent acute kidney injury 
 
 
The measurement of urinary albumin and total protein is a key aspect of the management of 
patients with chronic kidney disease. The practice in the laboratory at Hampshire Hospital NHS 
Foundation Trust is to measure urine albumin as the first line assay and to reflex a urine protein 
if the urine albumin concentration is above 450 mg/L and automatically dilute the urine sample 
to provide an albumin result up to 4500 mg/L. As these assays are performed on the same 
analyser as the serum creatinine, these results were entered into the database and provided 
the ability to, opportunistically, assess urine albumin output with subsequent acute kidney 
injury. To do this data was collected on all samples between 2011 and 2014 on patients aged 18 
years and over at the time of sampling where there was a urine albumin and creatinine request. 
This was then combined with subsequent AKI data to produce a single dataset with one line per 
patient containing: 
 Urine albumin and creatinine 
 Date of urine sample 
 Subsequent acute kidney injury stage, creatinine and eGFR 
The acute kidney injury stage was the highest value that was recorded in the database in the 14 
days after the urine sample had been analysed. The albumin:creatinine ratio (ACR) was 
calculated to correct for dilutional effects within the urine sample. The summary results are 
shown in table 3-36 and figure 3-18. 
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Table 3-36 Urine albumin and creatinine values with subsequent AKI stage 
 AKI Stage 
No AKI 1 2 3 
Number 3,093 55 15 10 
Age (years) 70.3 
(69.0 – 71.7) 
77.3  
(73.0 – 81.6) 
69.3  
(58.7 – 79.9) 
69.0 
(50.6 – 87.4) 
Urine albumin 
(mg/L) 
104 
(89 - 118) 
323 
(107 - 539) 
192 
(36 – 348) 
634 
(-66 – 1334) 
Urine creatinine 
(µmol/L) 
9,475 
(9253 – 9696) 
7,596 
(6366 – 8825) 
8,692 
(6389 – 10994) 
6,466 
(2423 – 10469) 
ACR 27.0  
(4.3– 49.7) 
40.2 
(11.3 – 69.0) 
26.3 
(5.4 – 47.1) 
2381 
(-2853 – 7617) 
The values for urine creatinine were not significantly skewed (skewness 1.79) whereas both 
urine albumin (15.93) and albumin:creatinine ratio (97.1) were significantly skewed.  
Statistical analysis by ANOVA revealed a significant difference between the acute kidney injury 
groups with respect to urine albumin:creatinine ratio (p < 0.001) and urine albumin 
concentration (p <0.001). There was also a trend of falling creatinine concentrations as the 
acute kidney injury stage increased but this was not statistically significant (p = 0.088). 
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Figure 3-18 Urine albumin:creatinine ratio by subsequent AKI stage 
To assess the usefulness of urine albumin measurement as a potential marker of occult acute 
kidney injury, receiver operator curve (ROC) analysis was performed. The area under the curve 
is shown in table 3-37 and, for stage 3 AKI, charted in figure 3-19. 
Table 3-37 ROC area under the curve for urine albumin and ACR by AKI stage 
 No AKI Stage 1 Stage 2 Stage 3 
Urine albumin 0.272 
(0.221 – 0.322) 
0.712 
(0.653 – 0.771) 
0.707 
(0.573 – 0.841) 
0.829 
(0.730 – 0.927) 
ACR 0.262 
(0.212 – 0.313) 
0.722 
(0.665 – 0.779) 
0.696 
(0.550 – 0.842) 
0.860 
(0.787 – 0.934) 
When all patients with acute kidney injury are grouped together the area under the curve for 
urine albumin was 0.716 (0.657 – 0.774) and for urine albumin:creatinine ratio was 0.725 
(0.670 – 0.781). 
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Figure 3-19 ROC area under the curve for urine albumin:creatinine ratio 
The data suggest that patients with raised urinary albumin excretion appear to be more likely to 
be either experiencing acute kidney injury or to experience an episode of acute kidney injury 
within the subsequent 14 days. However, the number of patients especially those at the higher 
stages of acute kidney injury, are very low and hence it may not be possible to draw accurate 
conclusions from the data.  
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Chapter 4 Discussion 
 
 
This chapter will discuss the findings of the study in the context of existing knowledge, how the 
study contributes to that body of existing knowledge and to what extent the aims and 
objectives stated earlier have been met. 
This study implemented an automated electronic alert for acute kidney injury initially based on 
the Acute Kidney Injury Network criteria using a 90-day baseline. This was switched to the NHS 
England algorithm when it was first published in June 2013. This algorithm extended the 
baseline to 365 days by using the lowest value up to day 7 and the median value at days 8 to 
365 pre-AKI to help determine the baseline value. The alerts operated as close to real time as 
possible such that they appeared, to the clinical end user, to be generated at exactly the same 
time as the original creatinine value. This was an important element to the project as there was 
a need to present the AKI evaluation information at the same time as the clinicians viewed the 
results rather than at a later time to maximize the chance it would be seen and acted upon but 
also to prevent disillusionment in the system by having clinicians check at a later time for the 
AKI status. This was achieved by using existing mechanisms within the Laboratory Information 
Management System (LIMS) and bespoke software coding. The ultimate aim was to improve 
the care of patients by ensuring that cases of acute kidney injury were appropriately flagged for 
the clinical staff in a clear, consistent and unambiguous manner. In turn, this should lead to 
patients being reviewed in a timely and appropriate manner but also raise awareness of acute 
kidney injury to clinical staff by having a comment to that effect on those laboratory reports 
where acute kidney injury had been detected and reported. 
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It must be acknowledged at the outset to this chapter that a comment on a report does not, in 
and of itself, improve patient care. There needs to be an understanding by the recipient of the 
message, of its importance and of the appropriate actions to be undertaken. To this end there 
needs to be an educational aspect that sits alongside and complements the electronic alert. The 
educational element sits outside this study but, it can be argued, is more important than the 
electronic alert as it is the part that actually delivers the benefit to the patient. Accordingly, it is 
a credit to all the clinical staff involved that the study appeared to show small but statistically 
significant benefits in terms of patient outcomes. The main findings with respect to the acute 
kidney injury alerts are: 
• A reduction in thirty-day mortality following the introduction of AKI alerts with stage 1 
falling from 19.5% to 14.6%, stage 2 falling from 30.1% to 22.1% and stage 3 falling from 
35.3% to 25.9%.  
• An improvement in renal function at six months following an episode of acute kidney 
injury although this was not statistically significant for those with stage 2 and 3 AKI. 
A number of publications have previously attempted to demonstrate that acute kidney injury 
could be automatically detected within the laboratory information management system or the 
results reporting system (Flynn & Dawnay, 2015; Garner et al., 2012; Thomas et al., 2011). 
However, many of these have been based on percentage increases or delta checks rather than 
algorithms published by various learned bodies. In these publications, the authors have been 
constrained by limitations within the software. The issue with using delta checks is that the 
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previous value may include results of an established acute kidney injury episode and hence 
does not reflect the best possible recent renal function of the patient. 
The way in which this study differs from other published work was the ability to utilise a 
number of algorithms to detect AKI (although only one was in use at any one time) and, as such, 
was able to perform far more complex calculations and comparisons. The coding for the NHS 
England algorithm took less than one hour once the logic flow had been drafted. In common 
with most other software, the majority of time implementing the algorithm was spent on 
checks and error trapping and correction. However, this demonstrates the relative ease in 
which some complex calculations can now be performed and integrated into the laboratory 
report. This, perhaps, points the way that future laboratory reports can be far more 
interpretative in nature rather than just present figures and ranges. Whilst not included in this 
thesis, the integration of neural network software was successfully attempted but did cause 
some considerable slowing of the AKI detection software. However, with the correct hardware 
and software architecture highly complex evaluations are possible in real time as is the ability 
to integrate self-learning algorithms.  
4.1 Issues with the Creatinine Assay Method 
 
Many studies have highlighted the poor performance of the Jaffé method for measuring 
creatinine especially at low concentrations or when interfering substances are present. The 
National Quality Assurance Scheme distributes samples to laboratories for analysis at regular 
intervals (2 weeks for general chemistry) and one of the exercises was to assess the ability of 
laboratories to detect stage 1 acute kidney injury by having two samples where the creatinine 
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concentration was 26 µmol/L apart (100 and 126 µmol/L) and two further samples that were 
50% apart (104 and 156 µmol/L). In the former group only 63% of laboratories using the Jaffé 
method were able to detect stage 1 AKI whilst in the latter group the number was 86%. The 
performance of the enzymatic method was superior to the Jaffé method with the respective 
percentages being 82% and 98%. This highlights the need for laboratories to move towards 
analytical methods that are capable of the performance required for detecting significant 
changes in creatinine concentration especially at very low concentrations. 
The issues with the creatinine method may be further compounded with the use of absolute 
values and/or small changes in creatinine compared with the baseline concentration. A recent 
study using mathematical modelling has highlighted that there is a potential that an average of 
8% of AKI classifications may be false positive results (Lin et al., 2015). This is dependent on the 
creatinine concentration and, at higher creatinine concentrations (over 133 µmol/L) the false 
positive rate may be over 30%. 
4.2 Using the computer system for other analytes and conditions 
 
This study focused on acute kidney injury, but the same logic of using laboratory results to 
evaluate clinical conditions could apply across a number of scenarios e.g. differentiation of 
thalassaemia from iron deficiency (Schoorl et al., 2012). Such an approach allows the clinician 
to concentrate on the diagnostic message rather than spend time performing calculations, 
some quite complex, by hand. The other advantage of computerized algorithms is the 
consistency of the output given the same input. But herein lies a disadvantage in that most hard 
coded algorithms do not learn from experience and cannot adapt to new situations. Thus, 
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whilst a reasonably new biomedical scientist can be trained to spot an aberrant result e.g. drip 
arm sample, this can be quite hard to code into an algorithm and, as a consequence, the 
reporting of false positive results can and did occur in this study. 
4.3 Criticisms of the NHS algorithm 
 
In common with the other algorithms, the lack of a ‘gold standard’ definition of the magnitude 
of change in creatinine concentration and the time period over which this change is to be 
effected hampers acute kidney injury research. Unlike some studies on other analytes and 
disease processes, there is no gold standard definition for acute kidney injury which explains 
the multitude of algorithms. For this reason, it is not possible to evaluate the efficacy of one 
algorithm against another. Most data on acute kidney injury have been based either on clinical 
coding at discharge or retrospective evaluation of laboratory results. This study had the 
advantage of using the nationally mandated algorithm over a period of 18 months. By 
comparing this algorithm with the other algorithms for the same sample and patient it was 
possible to show that more patients were evaluated by the NHS England algorithm compared 
with the other algorithms. This is not surprising as the longer the baseline period used, the 
higher the chances that the patient has had a previous sample thus allowing an evaluation to 
take place.  
During the study period 7.4% of the patients had an episode of acute kidney injury as defined 
by the NHS England algorithm. This compares with 6.2% by the KDIGO algorithm, 3.6% by the 
Acute Kidney Injury Network algorithm (seven-day baseline) and 1.8% by the Waikar and 
Bonventre algorithm. Therefore, more patients will be classified as having AKI by the current 
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national algorithm than by any other algorithm in this study. The practical implications of this 
will be an increase in the apparent number of cases of acute kidney injury being detected and 
coded which, in turn could lead to a upward revision in the financial impact of acute kidney 
injury to the NHS. Whilst one can imagine that this could be seized by some sensationalist 
organizations to highlight deteriorations in medical care or the well-being of the country’s 
population, the truth is that unless the same algorithm is used throughout the comparison 
periods, the simple move to a longer baseline will inevitably lead to the classification of more 
cases of AKI. 
However, the role of a staging system is to provide clinical staff with an assessment of how 
severe the condition is and provide an indication of likely outcome. In this respect the national 
AKI algorithm would appear to be a useful functioning staging system which correlates the 
severity of the condition with the thirty-day mortality. 
4.4 Effect of alerts on thirty-day mortality 
 
The data suggest that there is a decrease in thirty-day mortality following the introduction of 
the acute kidney injury alerts compared with the pre-alert period.  
There was a significant fall in the percentage of deaths seen at 30 days with an overall relative 
risk of 0.75 compared with the pre-alert phase (p<0.0001). The largest falls in the percentage 
mortality were seen at the highest AKI stage where the thirty-day mortality fell from 35.3% to 
25.9% but there were significant changes in the relative risk of mortality in all groups (including 
the non-AKI patients). 
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It could be argued that the fall in thirty-day mortality in all three AKI groups merely reflects 
changes that may have occurred during the merging of the two Trusts with a higher number of 
Emergency Care Consultants being available. This argument is reinforced by the data comparing 
the two sites that demonstrates a small but significant difference in terms of thirty day 
mortality relative risk which was 1.42 (1.15 – 1.76) in the pre-alert phase falling slightly to 1.29 
(1.06 – 1.57) in the post-alert phase. As a consequence, it could be argued that the educational 
elements associated with the introduction of the alerts or sharing of senior clinical staff across 
sites had a much larger impact on care than the alerts alone.  
In their study, (Colpaert et al., 2012) showed that the alerts were successful in changing 
behavior by the requesting clinicians only as long as the alerts remained in place. Removing the 
alerts led to a reversion to pre-alert behavior. This emphasises the importance of constantly 
reminding clinical staff, via the use of directed comments, of the need to assess patients in the 
clinical setting. Many pathology results are seen and acted upon by relatively junior clinical staff 
and this group are also in a constant state of flux with staff rotating around departments at 
regular intervals to gain experience. Therefore, the alerts act as a reminder to undertake 
appropriate clinical assessment whilst also acting as an educational prompt for those staff who 
have had little clinical contact with the condition. 
In their paper,Wilson et al. (2015) state that the alerts issued to 1,201 AKI patients had 
essentially the same mortality outcome at 7 days compared with those patients where the alert 
was not issued. The difference between the current study and that by Wilson is that the latter 
study excluded patients where the creatinine was above 354 µmol/L or there was pre-existing 
CKD. In addition, the Wilson study utilised the KDIGO criteria as the primary algorithm for AKI 
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detection and they sent only one alert per patient in order to minimise alert fatigue. In the 
current study, appropriate clinical comments were issued for each sample where acute kidney 
injury was detected by the algorithm which maximized the chances of the alert being 
recognized and acted upon. Whilst the current study was not designed to utilise the KDIGO 
criteria and hence alerts would not have been triggered in the same manner, when the 
mortality data are analysed based on this algorithm at seven days (rather than thirty) it can be 
seen that there remains a significant reduction in the relative risk of mortality 0.65 (95% 
confidence interval 0.52 – 0.83). The key differences between this study and that of Wilson et al 
is the use of alerts on every result where acute kidney injury was detected rather than a one-off 
alert, reporting to staff who had a keen interest in acute kidney injury and the use of AKI care 
bundles and educational material. 
In unpublished data from Bournemouth and Poole Hospital (Partridge, 2015), the introduction 
of a nurse-led AKI service in conjunction with electronic alerts has led to a reduction in 
mortality following acute kidney injury from 14% to 5%. It must be stated that this service only 
sees those patients with stage 2 and 3 AKI and covers the whole hospital and not just the 
Medical Admission Unit. This may explain the lower mortality rate seen in this service 
compared with Hampshire Hospitals NHS Foundation Trust. However, this appears to support 
the findings of this study that the introduction of an AKI package, which included electronic 
alerts along with AKI education, can lead to a reduction in the mortality rate. 
One aspect that may make attributing the findings of a fall in thirty-day mortality is the fact that 
clinical care is an ever changing system. There have been major initiatives relating to sepsis in 
the UK and it is known that this is a major cause of acute kidney injury. Sepsis may be 
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responsible for 25% of acute kidney injury with a mortality of up to 35% (Nejat et al., 2010). As 
there was no linkage between the acute kidney injury database and diagnostic and procedure 
codes it is possible that active interventions related to the treatment of sepsis were responsible 
for some of the mortality reduction seen in this study.  
This study has shown that the NHS England phase of the study was associated with a fall in the 
thirty-day mortality which was statistically significant for stage 1 and 3 AKI. The fall in the 
overall mortality percentage was 4.9%, 8.0% and 9.4% for stages 1, 2 and 3 respectively. 
Therefore, if we consider the stated aims of improving patient outcomes and/or quality of life, 
these appear to have been met by the introduction of electronic alerts.  
In their study G. M. Chertow et al. (2005) showed that a rise in serum creatinine of 50% or more 
was associated with an unadjusted odds ratio of mortality of 5.9 (95% CI 4.6 – 7.5) and a rise of 
100% or more with an unadjusted odds ratio of 8.9 (95% CI 6.9 – 11.4). Unfortunately, this 
paper does not specify a timescale for the baseline but the percentage figures equate to the 
AKIN stage 1 and 2 respectively. This study found that the relative risk (rather than odds ratio) 
for 30-day mortality using the 90 day baseline to be 5.9 (95% CI 5.5 – 6.3) and 9.6 (95% CI 8.9 – 
10.4) for stage 1 and stage 2 respectively. Whilst it is not possible to directly convert from odds 
ratio to relative risk, where the outcome occurs in less than 10% of the unexposed population, 
the odds ratio provides a reasonable approximation of the relative risk (Viera, 2008). 
There is no direct evidence of any improvement to operational efficiency. However, it would be 
highly surprising if alerts presented to clinicians at the same time as the results were available 
(and without the need for previous result look-up and manual calculation of AKI stages) did not 
improve the triage of patients when the results were inspected. However, to caution against 
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this assumption, authors have highlighted that many laboratory results are never viewed (Bates 
& Leape, 2005; Callen, Paoloni, Georgiou, Prgomet, & Westbrook, 2010) and this study did not 
examine whether results were reviewed in a timely manner or attempt to stratify this against 
the subsequent outcomes. The Best Practice guidelines suggest that all new stage 3 AKI should 
be telephoned immediately and new stage 2 within 24 hours. The laboratories at Hampshire 
Hospitals NHS Foundation Trust have implemented these guidelines in full and try to go beyond 
the minimum level of service by telephoning all stage 2 AKI within 1 hour. 
In terms of reducing the length of the patient journey, again there is no direct evidence 
available from this study that would support such an assertion. Many authors have 
demonstrated the impact that acute kidney injury has on both excess bed days and intensive 
care stay (G. M. Chertow et al., 2005; Coca et al., 2009). Therefore, it would seem intuitive that 
early detection and prompt treatment would have beneficial effects for the patient. Indeed, 
Partridge (2015) has demonstrated a fall in both mortality and re-admission rate following the 
introduction of acute kidney injury alerts and a nurse-led review service. Therefore, whilst not 
being able to prove, via this study, any improvement in re-admission rates or patient journey 
times, it would seem to follow from other data that this is likely to have occurred. Finally, if we 
accept the data that the introduction of acute kidney injury alerts led to a reduction in mortality 
and the premise that this would be associated with improvements in re-admission rates and 
patient journeys, this is likely to have had a beneficial impact on operational costs.  
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4.5 Community acquired acute kidney injury 
 
 
This main focus of this study was focused on a relatively small group of patients within the 
Emergency Admission Unit at RHCH and demonstrated a beneficial impact of alerts on thirty-
day mortality. Many other studies have either focused on selected groups of patients e.g. 
following cardiac surgery or hospital acquired acute kidney injury. However, the data presented 
in this study reveal that community based acute kidney injury is the most common form making 
up 66% of AKI presentations in 2013.  
The statistics for community acquired acute kidney injury, which constitutes the majority of AKI 
cases, provides a useful baseline from which it will be possible to assess any behavioral changes 
associated with the introduction of alerts to this group of patients starting in March 2016. At 
present the local guidelines dictate that only creatinine values over 500 µmol/L are telephoned 
to the requesting source as a matter of urgency and even then only if they are significantly 
increased compared with any previous samples. The data in this study suggest that relatively 
few samples met the threshold for urgent contact with the average creatinine for stage 1 and 2 
AKI being less than half the current threshold.  
As the AKI stage increased the delay between the incident sample and the subsequent sample 
decreased but still averaged 37 days for stage 3 AKI.  More patients were subsequently seen in 
the emergency department and assessment unit as the AKI stage increased (18.8% for stage 1 
and 37.1% for stage 3). The overall data is encouraging in that it demonstrates that, within each 
AKI stage, the follow-up creatinine average was lower. However, this data excludes those 
patients who may have died prior to another sample being taken or in whom there was no 
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follow-up. In addition, it does not include patients who may have been referred to another 
hospital for assessment and treatment. 
Despite the presence of acute kidney injury, referral of patients to the Medical Assessment Unit 
showed a relationship with the creatinine value; those with higher creatinine values being 
referred earlier. This may change when AKI alerts are issued to general practice and will form 
the basis of further study in this area. 
The data suggest that, at present, the majority of general practice based AKI remains managed 
within that setting. There may be good reasons why this is the case e.g. some patients may be 
receiving palliative care only and therefore it may not be appropriate for secondary care 
admission to be contemplated. Again the isolation of the laboratory computer system makes 
the determination of these factors difficult to incorporate into any analysis of such large 
numbers. 
In the current study, no community based locations were issued with AKI alerts therefore these 
figures represent the current state of play prior to the roll out of the NHS England algorithm to 
primary care. Further studies will be required to assess the impact of the alerts on primary care 
and how these affect referrals rates to secondary care. 
4.6 Seasonal variation in acute kidney injury and thirty-day mortality 
 
Seasonal variation in acute kidney injury have been previously described. However, these 
studies have been located in areas where the variation in AKI incidence has been attributed to 
clinical conditions associated with the monsoon season e.g. malaria, gastroenteritis, dysentery 
and leptospirosis (Noronha et al., 1997; Yang, 2007). These diseases are not associated with the 
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current study population and it is, therefore, not surprising that no statistically significant 
seasonal variation in AKI was found. In the study population, a small but significant association 
between acute kidney and thirty-day mortality was found in the winter months. However, the 
seasonal component could only account for 13% of the effect seen. This may be explained by 
the presence of other conditions that increase in the winter months that can lead to AKI e.g. 
myocardial infarction and stroke (Sheth, Nair, Muller, & Yusuf, 1999). The lack of any seasonal 
variation in this study would suggest that seasonal targeting of education, as seen with flu, 
would not be beneficial.  
4.7 Urine albumin excretion and subsequent acute kidney injury 
 
The study into urine albumin within this project was a fortuitous by-product of having an 
integrated database of results rather than being a pre-conceived design. It found a significant 
difference in the urine albumin concentration up to 14 days prior to the recognition of AKI via 
serum creatinine measurement. This latter method of adjustment is a typical method used 
within clinical laboratories to correct for changes in urine concentration at the time of 
sampling. The number of patients in whom AKI was detected in the following 14 days after 
urine testing was very small but the results may reflect existing albeit unrecognized AKI. 
Whilst the ROC analysis appears to show that there is some value in measuring urine albumin, 
the values obtained in the 0.7 – 0.8 range would indicate that the test only has a ‘fair’ chance of 
classifying the clinical condition.  
Whilst many other urine markers for AKI have been proposed, notably neutrophil gelatinase-
associated lipocalin (NGAL), these are generally quite novel and acceptance into routine use will 
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take some time. This is not because of the reluctance of laboratories to embrace new analytes 
but there may be the requirement for new analysers and there would certainly be much work 
around the accreditation of new assays according to the ISO standards for clinical laboratories. 
However, most laboratories already have the capability of accurately and rapidly measuring 
urine albumin and the work on accreditation and quality control is already in place. Therefore, 
if the early work demonstrating the role of urine albumin measurements can be reliably 
replicated, this could be rapidly translated into routine clinical use. 
Albumin is the most abundant of the plasma protein (~65kDa) with a circulating concentration 
in healthy individuals around 44 g/L. It performs a wide variety of functions including 
maintenance of oncotic pressure, binding and transport of a wide variety of substances 
including calcium/magnesium, fatty acids, drugs etc. Despite its wide variety of functions, some 
individuals survive without any serum albumin (analbuminaemia) and this is only discovered 
during investigations of unrelated clinical conditions. In terms of renal handling of albumin, the 
amount filtered by the glomerulus is estimated at 0.7 – 7g/24 hrs. Specific albumin binding 
receptors have been demonstrated in the renal tubular cells resulting in reabsorption of the 
protein, its degradation in the tubular cells and re-use of the amino acids.  
In acute kidney injury, the loss of tubular function could lead to failure of albumin reabsorption 
(and other proteins) and they will then appear in the urine in increased concentrations. There is 
a hypothesis that the presence of excess quantities of albumin in the renal tubular lumen 
initiates an inflammatory response that can lead to fibrosis (Birn & Christensen, 2006). This 
inflammatory response can also lead to inhibition of albumin endocytosis which, in turn, 
increases the urinary albumin concentration. 
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Animal studies have suggested that AKI, notably that leading to intrinsic disease, can result in 
induction of the normally silent renal albumin and α-fetoprotein genes (Ware, Johnson, & 
Zager, 2011 3774). In this same study, the authors then performed urine analysis on patients in 
the ITU and found increased urine albumin:creatinine in AKI patients compared with non-AKI 
patients and a control group. Metzger et al. (2010) demonstrated the upregulation of urinary 
albumin fragments (amongst other proteins) in patients with acute kidney injury on an 
intensive care unit. Additionally, in their study, the use of a specific proteomic pattern preceded 
the rise in serum creatinine by up to 5 days. 
In intrinsic AKI the contribution of albumin to the total protein concentration was up to 65% 
(17% in controls) suggesting the assay may act as a biomarker for intrinsic AKI but not pre or 
post-renal AKI. Work by (Dickson, Wagner, Sandoval, & Molitoris, 2014) shows the role played 
by normal proximal tubule cells in the reabsorption of filtered albumin. It is therefore easy to 
see a role for urinary albumin measurements in intrinsic AKI where these proximal cells fail to 
function and albumin is lost in the urine. 
There are conflicting reports on the correlation of urinary albumin and protein measurements. 
In their paper, Methven, MacGregor, Traynor, O'Reilly, and Deighan (2010) suggested that the 
urinary albumin:creatinine ratio cannot be used to predict the urinary protein:creatinine ratio 
and suggested the former could not be used to predict the latter. However,Fisher, Hsu, 
Vittinghoff, Lin, and Bansal (2013) demonstrated that there was little difference between the 
measurement of urinary albumin and protein with regard to the association with outcomes. 
The demonstration here of an increased urinary albumin associated with acute kidney injury is 
not new. However, the context in which it was discovered, namely the management of chronic 
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kidney disease and diabetes monitoring has not been previously described. However, the 
numbers are very small and further work will need to be performed to confirm these findings 
and also attempt to distinguish between those without acute kidney injury but high urinary 
albumin concentrations and those who subsequently were found to have acute kidney injury. 
At present, these results could not be used by laboratory and clinical professionals as the basis 
for patient triage or further assessment. To this end a far wider date range needs to be included 
as part of the search parameters together with data on current serum creatinine, urea and 
albumin and well as historical results. 
4.8 Comparison of the NHS England and other algorithms 
 
The data show that the NHS England algorithm allows more patients to be evaluated for acute 
kidney injury than other published algorithms due to the much longer period used for the 
baseline determination. This longer baseline allowed the evaluation of 74.0% of patients 
compared with 21.3% by the KDIGO (RIFLE) algorithm and 15.7% using the Waikar and 
Bonventre algorithm.  
The presence of known chronic kidney disease impacted on the performance of the algorithms 
with respect to acute kidney injury evaluation. Those known to have the condition had a higher 
percentage of evaluations than non-CKD patients (94.1% vs 69.9%). The guidance for 
monitoring patients with CKD is stated in the guidelines from the National Institute for Health 
and Clinical Excellence (2014) and is dependent on the eGFR and the urine albumin:creatinine 
ratio. In general those patient where the eGFR is below 45 mls/min will be monitored at least 
annually (this may be higher if the urine albumin:creatinine ratio is above 30 mg/mmol). 
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Therefore, it is not surprising, that this group of patients are more likely to be evaluated using 
the NHS England algorithm than those not know to have the condition. 
The apparent incidence of acute kidney injury seen in this study varied depending on the 
algorithm used. Overall, using the NHS England algorithm, 7.4% of patients were categorised as 
having an episode of acute kidney injury. This compares with 6.3% using the KDIGO (RIFLE) 
algorithm, 1.8% using the Waikar and Bonventre algorithm and 2.6%, 3.6%, 5.3% and 7.0% with 
the Acute Kidney Injury Network with a 2, 7, 30 and 90 baseline respectively. Thus the NHS 
England algorithm classifies more patients as having acute kidney injury than the other 
algorithms in this study. Where the algorithms also stage the acute kidney injury, the lowest 
stage was always the most common with the highest being the least common. Whilst the 
incidence varied greatly with algorithm, the proportion of those with stage 1 AKI was relatively 
similar lying between 64% and 74%. 
It is not possible to compare algorithms in the sense of which one is the best as the lack of a 
gold standard definition of acute kidney injury limits the applicability of metrics such as 
sensitivity, specificity etc. There was disagreement in terms of acute kidney injury classification 
in 10.9% of patients where was an evaluation by both NHS England and KDIGO (RIFLE) 
algorithms. For the Waikar and Bonventre algorithm this was 8.2% almost exclusively being due 
to patients being classified as having AKI by the NHS England algorithm and not having AKI by 
the Waikar and Bonventre algorithm.  
These data demonstrate that direct comparison of the different algorithms is very difficult and 
highlights the need to move to more sensitive and specific markers than serum creatinine 
measurement. All algorithms are only as good as the data associated with the patient and all 
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the algorithms will produce incorrect evaluations if pre-analytical errors e.g. incorrect patient 
identifiers are promulgated to the database. However, the impact of these errors only lasts as 
long as the baseline for evaluation. The use of the median within the NHS England algorithm 
mitigates this to some degree but is then very dependent on the number of values used to 
determine that median; smaller numbers of values will be impacted more by a single incorrect 
result. Additionally, as demonstrated with patient B, some normal physiological conditions e.g. 
pregnancy, can be affected by algorithms with longer baselines whereas this is not seen with 
those that use shorter timeframes. 
In a systematic review of acute kidney injury mortality using the KDIGO (RIFLE) classification, 
Ricci, Cruz, and Ronco (2008) found a relative risk of mortality at stages risk, injury and failure 
to be 2.40 (95% confidence interval 1.94 – 2.97), 4.15 (3.14 – 5.48) and 6.37 (5.14 – 7.90) 
respectively. In this study the same criteria produced values of 2.8 (2.6 – 3.0), 5.0 (4.6 – 5.4) and 
5.6 (5.1 – 6.2). There are no published data on the mortality rates associated with the NHS 
England algorithm but the similarity of the KDIGO relative risks would provide re-assurance that 
this study is in line with other studies. This study would seem to suggest that the thirty day 
mortality using the NHS England algorithm is higher than that seen with the other algorithms. 
As a single centre study using a very limited patient population this would need to be confirmed 
by much larger, multi-centre studies. If this proves to be correct then the mortality associated 
with acute kidney injury is much higher than the current literature suggests and supports the 
need for actions aimed at reducing this healthcare burden. In addition, if the incidence of acute 
kidney injury is as high as the data suggest, then the burden on the wider healthcare economy 
may also be far higher than current estimates. 
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4.9 Meeting the stated objectives  
 
In the first chapter the objectives of the research project were stated as 
 Perform a review of acute kidney injury (AKI) with emphasis on the use of the 
automated systems to detect deteriorating renal function. 
 Develop a robust, automated and scalable system to analyse serum creatinine results 
and alert clinicians/biomedical scientists to potential acute kidney injury according to 
current accepted diagnostic criteria.  
These objectives were achieved and a robust system for detecting and alerting in real-time was 
developed. The software demonstrated versatility in that the algorithm was changed by 
national mandate and it was possible to implement this with less than 60 minutes of coding and 
1 day of testing. This also demonstrates the potential of the software to detect other conditions 
based on laboratory data and alert clinicians. The utilization of a programming language like C# 
or Visual Basic makes it possible to perform some quite sophisticated processing but does 
require a knowledge of the programming languages and the actual algorithm in order to 
implement it and perform changes. 
 Perform a retrospective analysis to compare the incidence of AKI in all patients using 
current techniques against the proposed system. 
 Perform an analysis on the impact of electronic alerting on detection, treatment and 
subsequent outcomes of patients found to have AKI.  
The results have demonstrated that the 30-day mortality from AKI has decreased since the 
introduction of AKI alerts. However, this study did not conclusively show that this benefit could 
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be attributed to the alerts themselves and it may be that the educational efforts of the 
clinicians and the higher profile AKI has received in both medical and popular literature may be 
of more benefit than alerts alone. 
 Perform a benefit analysis on the introduction of the proposed system across the entire 
Trust (including GP catchment areas). 
 Once the study has concluded and, if successful, scale up the proposed solution across 
the entire Trust (which consists of two geographical sites).  
Due to the mandate from NHS England that the algorithm was to be located within the 
Laboratory Information Management System and not utilise bespoke software, this objective 
was not met. However, there is no reason why this could not have been achieved as the 
benchmark figures indicated that the proposed solution would cope very well with workloads 
far in excess of those anticipated within even the largest UK Trust. 
4.10 Towards an integrated approach to AKI management 
 
One of the main issues with the piecemeal development of the electronic alert system is a lack 
of overall ownership and direction that integrates the various systems to produce the best care 
possible in an integrated and coherent single pathway. The current system was conceived and 
grown by individuals using their expertise for the benefit of the individual patient. Attempts to 
combine the alerting, education and clinical care in a systematic manner have been hampered 
by lack of funds and a perception that meeting the requirements of the Patient Safety Notice 
and subsequent Commissioning for Quality and Innovation initiative (CQUIN) were sufficient to 
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improve patient care. However, other hospital Trusts have shown that an approach that 
integrates the various hospital services can improve subsequent outcomes whilst delivering 
financial savings. 
At present, any first time AKI stage 2 and 3 is notified to the requesting clinician by telephone; 
this is part of the Best Practice guidance issued by NHS England. However, there is no 
mechanism to ensure that the message is understood and acted upon by that clinical team. A 
system that integrates this into the electronic patient record, prompting the clinician to 
perform pre-defined actions e.g. urinalysis, follow up investigations etc. and audit the actions 
and results would ensure that consistent and timely care is delivered to all patients. There is a 
counter argument that this results in deskilling of clinicians and bypasses the clinical judgment; 
after all not all stage 3 AKI patients will require full investigation e.g. terminally ill. However, at 
a time when staff are under tremendous pressure in terms of time and throughput, such a 
system would ensure that appropriate care is highlighted and, in the event that no action is 
undertaken, the system can provide further prompting and alerting.  
It also seems counter intuitive that stage 1 AKI does not need to be notified and the electronic 
message could go unnoticed for several days, even weeks. Of course, if the patient deteriorates 
rapidly they will reach either stage 2 or 3 and the telephone message would be given but it 
seems we risk missing the opportunity to prevent some patients proceeding down this road. 
The flagging of episodes of AKI against the patient record can also serve as an indicator on 
future admissions of the risk of another episode of AKI and ensure staff take appropriate 
actions even for ‘routine admissions’. Such actions may include pharmacy advice on 
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appropriate medication or more intensive monitoring of renal function during the care episode 
etc. 
In terms of medication review, the study Trust does not routinely notify pharmacy staff of new 
cases of AKI that occur in the previous 24 hours. This is a system that would be relatively easy 
to implement and would help to ensure that the medication prescribed is not contra-indicated. 
However, support, at present, for such is system is limited. 
Many Trusts have implemented AKI outreach teams but, to date, few have provided any 
publicly available feedback on the success of this approach. The author is aware of one scheme 
at a local Trust where the use of a single, dedicated AKI nurse reviewing all stage 2 and 3 AKI 
patients has resulted in a fall in the 30-day mortality, a reduction in the length of bed stay and a 
decrease in the rate of readmissions within 28 days.  These measures seem to indicate that this 
approach leads to an improvement in patient outcomes whilst achieving a financial gain to the 
Trust by reducing bed-stays and fines for re-admissions. However, the workload is such that 
those patients with AKI stage 1 are not reviewed and the fact that the post is single handed 
means that care is lessened when that staff member is not present. 
This study has demonstrated that acute kidney injury is a common yet under-recognised 
condition but that improvements to both short term and long term outcomes can be achieved 
by rapid recognition and appropriate care. An integrated approach would include the following: 
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 Integration of clinical information management systems to provide advice of 
appropriate care and audits of the actions undertaken. 
 Review by trained staff of all AKI in-patients to ensure they receive proper and timely 
care.  
 Outpatient clinics manned by trained staff so patients can be discharged at the earliest 
opportunity but monitored regularly and admitted if there is deterioration in their 
condition. Such clinics could be used to bridge the gap between discharge from hospital 
and care being assumed by the general practitioner. These clinics could also be a focus 
for the general practitioner to refer those patients with an AKI alert but whose condition 
does not warrant immediate admission.  
 Liaison between the local Trust and more specialist units. 
Such a system would need to operate 7 days a week in order to provide benefit to all patients 
and counter arguments that the NHS is inconsistent in the way in which patients are treated. 
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Chapter 5 Reflections on the Doctoral Journey 
 
This chapter will outline to progression from Royal Air Force laboratory technician through to 
doctoral candidate. It will discuss, candidly, the difficulties, motivations (or lack of) that led me 
to this point in life where I present myself and my work for examination. 
5.1 Before the doctorate 
 
 
A journey of a thousand miles begins with a single step.   
Laozi (c 604 BC - c 531 BC) 
 
Maybe if I had realised the length of the journey and how arduous and lonely it could be I 
would have studied harder at school. Instead the journey, undertaken with no clear map or idea 
where the ultimate end was, has been a lifetime of part-time and distance study. 
It was more through accident than design that I embarked on the career path I have found 
myself on. As a young and naive sixteen year old I failed to attain the required ‘O’ level grades 
and joined the Royal Air Force as a trainee laboratory technician. During a year of full time 
study I came to the realization that study was a necessary tenet and that I actually liked what I 
was doing. Upon passing my HNC whilst serving at the Royal Air Force Hospital Ely I started the 
traditional route of enrolling on the Fellowship of the Institute of Biomedical Sciences but found 
the lecturing somewhat underwhelming. Therefore I embarked on a 3 year part-time BSc in 
Applied Biology (and some 160 miles of car travel per week) eventually gaining a 2:ii. This was 
followed by a two year-part time MSc course in General Biochemistry in which the lecturers 
were thoroughly engaging and emphasized the importance of an understanding rather than 
rote learning. At this stage I had reached the rank of Sergeant and successfully applied for a 
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commission. On returning from Germany in 1991 I undertook an MSc in Clinical Biochemistry 
which I completed in 1993. The aim from here was to take the MRCPath but this application 
was rejected by the RAF.  
At this time I attended two courts-martial which had a profound impact on me leading to an 
interest in law. As a consequence of witnessing legally correct but, what I viewed as unjust 
decisions, I undertook a law degree with the Open University to try to understand why my 
perceptions of justice were at odds with those of the judiciary. Whilst my understanding of 
those initial decisions has been illuminated the outcomes for the individuals still leaves me with 
a sense of unease that it was legally correct but not just. An even better lesson from those 
hours spent studying case law and legal opinions was the capacity to view things from both 
prosecutor and defence in order to try to formulate a coherent argument of one’s case.  
In 1996 I was made redundant from the RAF as part of the Defence Costs review. At this stage I 
needed to support the children and made the decision to take a well-paid job in the 
Information Technology industry rather than start in the NHS but I returned to healthcare in 
2001.  
5.2 Why a doctorate? 
 
Following the law degree, a conscious decision was made to see if I was capable of reaching the 
pinnacle of academic success and earn a doctoral award. There has been many a moment 
where I have questioned this decision (and so have my nearest and dearest). The high times 
where something has worked as expected have been more than equaled by the number of low 
moments where unexpected (and unnecessary) hurdles have been presented. In turn this leads 
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to motivational issues where there are bursts of work and thesis typing followed by long 
periods of questioning and reflection on the reasons for doing this. The altruistic reason is to 
make a difference, no matter how small, to the lives of those patients that I never see as a 
Biomedical Scientist. There is also an egotistical thread of proving my teachers wrong when 
they said I would never amount to anything. Finally, there is probably an element of proving it 
to myself. 
5.3 What did I achieve on the doctoral journey? 
 
Writing the actual software and getting reports out on the patients was probably the easiest 
section of Part 2 of the doctoral course. It was much harder to come to terms with the fact that 
I, slowly, became something of an authority on detection acute kidney injury. Initially I had a 
very pretty application that ran without issues and a very large database of results. However, 
the advent of the NHS England mandate to detect AKI from within the Laboratory Management 
Information System raised the status of the project from a local initiative to something that was 
now at the forefront of the NHS preventative medicine agenda. A chance email from a local 
member of Wessex Cardiovascular Strategic Clinical Network to the Pathology IT Manager 
resulted in an introduction to the Wessex AKI initiative. After a while I became the chair of the 
Wessex AKI e-alert sub group. This group was responsible for the ‘smooth’ implementation of 
the NHS mandate on detection and reporting. In common with many NHS IT projects it has 
been a far from smooth journey and we have had to overcome IT companies failing to deliver 
software on time, NHS financial constraints leaving us fighting to pay software vendors and 
issues with data governance, privacy and research.  
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This latter issue was one I took up with the national body on behalf of the Wessex group and, as 
a consequence, I was invited to join the National Measurement work stream. I was also a 
speaker at the Wessex Acute Kidney Injury Launch Event in April 2015. 
Despite the fact that the original software could no longer be used as the mandate dictated 
that the algorithm must reside within the LIMS, we have installed, tested and implemented the 
commercial solution in a relatively short timescale. The original go-live date for secondary care 
was March 2015 but this date was not met due to the delivery of the software being delayed 
until early June 2015. However, the knowledge gained over the years with the project allowed a 
plan to be drawn up and implemented with minimal effort allowing the Trust to meet their 
Commissioning for Quality and Innovation (CQUIN) target. 
5.4 What next? 
 
The question now arises as to whether I have reached the final destination or there are more 
steps to be taken. This is something I have given no real or constructive thought to as I have 
prepared this thesis. I am aware that there are aspects of domestic life that my wife would like 
me to take responsibility for; the garden for instance. With every course of study I have 
undertaken as an adult I have always taken at least one year out to allow time to reflect on 
what I felt would be the right step next. Usually towards the end of a course I am thinking of 
the next steps but this has been the longest and most arduous academic undertaking and, as I 
enter the latter stages of my career I question whether there is much more I need to do to 
prove to myself or others. That said there is a large database of results that would be worthy as 
projects for other staff members who wish to move away from the usual forms of projects such 
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as method evaluations and comparisons to something more clinically orientated. Removing the 
pressure of the formal study may also fire the motivation to use the database to publish papers 
on other aspects of AKI e.g. AKI prediction, urine albumin and protein prior to AKI. 
The value of AKI detection and alerts has been questioned by some therefore I would expect to 
see an increase in the number of papers in this area related to improved recording of the 
condition, the impact on mortality and morbidity; all areas where there is very little published 
evidence of effect. Further work will also come in the form of AKI prediction algorithms on 
admission and even in the community setting.  
Several Trusts have introduced the AKI nurse specialist whose role is to review all new cases 
notified by the laboratory, provide education to clinical staff and hold clinics to get patients 
back into the community as soon as reasonably practicable. Currently, my employing Trust has 
no immediate plans to introduce such a role but I would see myself as an ambassador for this 
and promoting the use of Biomedical Scientists in this area. 
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Appendix A - Query used to extract data for community based acute kidney injury 
 
DECLARE @Start DATETIME 
DECLARE @End DATETIME 
 
SET @Start = '1-Jan-2013 00:00:00' 
SET @End = '31-Dec-2014 23:59:59' 
 
 
SELECT  
 P.Sex as Gender, 
 DATEDIFF(year, P.DOB, S.[Sampled]) AS Age,  
 P.DoD as Death, 
 P.CKD as PatientCKD, 
 S.CKD AS SampleCKD,  
 S.Patient_ID AS ID,   
 --S.LabNo AS LabNo,  
 R.Result AS AKIStage,  
 Creat.Result as Creat,  
 E.Result AS EGFR,  
 Src.Class AS Class, S.Sampled as Sampled, 
 dbo.PreviousAKI(P.Unique_ID, DATEADD(day, -365, S.Sampled), DATEADD(day, -30, 
S.Sampled)) AS PrevAKIStage, 
 n.*,  
 A.*, 
 x.* 
from Patients AS P 
INNER JOIN Samples as S on P.Unique_ID = S.Patient_ID  
INNER JOIN Results AS R ON S.LabNo = R.LabNo 
INNER JOIN Results as Creat on S.LabNo = Creat.LabNo 
INNER JOIN Results as E On R.LabNo = E.LabNo 
INNER JOIN Sources AS Src on S.Source = Src.Code 
 
CROSS APPLY  
( 
 SELECT TOP 1  
  R1.Result as PostStage,  
  Creat1.Result as PostCreat, 
  E1.Result AS PostEGFR, 
  DATEDIFF(day, S.Sampled, S1.[Sampled]) as Interval,  
  Src1.Class AS PostClass 
 from Patients AS P1 
 INNER JOIN Samples as S1 on P1.Unique_ID = S1.Patient_ID  
 INNER JOIN Results AS R1 ON S1.LabNo = R1.LabNo 
 INNER JOIN Results as Creat1 on S1.LabNo = Creat1.LabNo 
 INNER JOIN Results as E1 on S1.LabNo = E1.LabNo 
 INNER JOIN Sources AS Src1 on S1.Source = Src1.Code 
 where P1.Unique_ID = P.Unique_ID 
 AND S1.[Sampled] > DATEADD(day, 30, S.[Sampled]) 
 AND DATEDIFF(day, S.Sampled, S1.Sampled) <= 90 
 AND R1.Code = 'AKI' 
 and Creat1.Code = 'CRE2' 
 AND E1.Code = 'EGFR' 
 order by Creat1.Result ASC) n 
 
 CROSS APPLY  
( 
 SELECT TOP 1  
  RA.Result as PostStage180,  
  CreatA.Result as PostCreat180, 
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  EA.Result AS PostEGFR180, 
  DATEDIFF(day, S.Sampled, SA.[Sampled]) as Interval180,  
  SrcA.Class AS PostClass180 
 from Patients AS Pa 
 INNER JOIN Samples as Sa on Pa.Unique_ID = Sa.Patient_ID  
 INNER JOIN Results AS RA ON SA.LabNo = RA.LabNo 
 INNER JOIN Results as CreatA on SA.LabNo = CreatA.LabNo 
 INNER JOIN Results as EA on SA.LabNo = EA.LabNo 
 INNER JOIN Sources AS SrcA on SA.Source = SrcA.Code 
 where PA.Unique_ID = P.Unique_ID 
 AND SA.[Sampled] > DATEADD(day, 90, S.[Sampled]) 
 AND DATEDIFF(day, S.Sampled, SA.Sampled) <= 180 
 AND RA.Code = 'AKI' 
 and CreatA.Code = 'CRE2' 
 AND EA.Code = 'EGFR' 
 order by CreatA.Result ASC) a 
 
CROSS APPLY  
( 
 SELECT TOP 1  
  R2.Result as PreStage,  
  Creat2.Result as PreCreat, 
  DATEDIFF(day, S.Sampled, S2.[Sampled]) as PreInterval,  
  Src2.Class AS PreClass 
 from Patients AS P2 
 INNER JOIN Samples as S2 on P2.Unique_ID = S2.Patient_ID  
 INNER JOIN Results AS R2 ON S2.LabNo = R2.LabNo 
 INNER JOIN Results as Creat2 on S2.LabNo = Creat2.LabNo 
 INNER JOIN Results as E2 ON S2.LabNo = E2.LabNo 
 INNER JOIN Sources AS Src2 on S2.Source = Src2.Code 
 where P2.Unique_ID = P.Unique_ID 
 --AND S2.[Sampled] < S.[Sampled] 
 AND DATEDIFF(day, S2.Sampled, S.Sampled) > 30 
 AND R2.Code = 'AKI' 
 and Creat2.Code = 'CRE2' 
 AND E2.Code = 'EGFR' 
 order by Creat2.Result ASC 
) x 
where Src.Class IN ('GP', 'CAS', 'RHCH OP', 'BNH OP') 
and S.Sampled BETWEEN @Start and @end 
AND R.Code = 'AKI' 
and R.Result > 0 
and Creat.Code = 'CRE2' 
AND E.Code = 'EGFR' 
ORDER BY S.Patient_ID, S.Sampled ASC 
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Appendix B - Visual Basic code examples 
 
Imports System.IO 
Imports System.Data 
Imports System.Data.SqlClient 
Imports System.Linq 
    
#Region "Difference Class" 
'/ Calculates the difference between two values. Not really needed as a class but done to  
'/ maintain standardisation for the AKI evaluation 
'/ Usage : 
'/      Dim oDiff as new AKIDifference 
'/      oDiff.CurrentValue = 100 
'/      oDiff.Comparator = 75 
'/      Diff = oDiff.Difference() 
'/  OR 
'/      Dim oDiff = New AKIDifference(100, 74) 
'/      Diff = oDiff.Differnce() 
 
Public Class AKIDifference 
  
    Public Property CurrentValue As Single 
    Public Property Comparator As Single 
    '// 
****************************************************************************************** 
    '// CLASS EVENTS 
    '// 
    ''// fired whenever an error is detected in the ASTM class 
    PublicEvent IsError(ByVal Routine AsString, ByVal Message As String, ByVal Data AsString) 
    PublicEvent IsDifference(ByVal Algorithm AsString, ByVal Stage AsInteger) 
  
    Public Sub New() 
  
    End Sub 
  
    Public Sub New(ByVal Current As Single, By Val Previous As Single) 
        Me.CurrentValue = Current 
        Me.Comparator = Previous 
    End Sub 
  
  
    Public Function Difference() As Single? 
        Dim diff As Single 
        Try 
            If Comparator = -1 Then Return Nothing 
  
            diff = CurrentValue - Comparator 
            'RaiseEvent IsDifference("Difference", diff) 
            Return diff 
        Catch ex As Exception 
            RaiseEvent IsError("AKIDifference.Difference()", ex.Message, "") 
            Return Nothing 
        End Try 
  
    End Function 
  
End Class 
#End Region 
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#Region "Rate of Change Class" 
'/ Calculates the difference between two values. Not really needed as a class but done to 
maintain 
'/ standardisation for the AKI evaluation 
'/ Usage : 
'/      Dim oDelta as new AKIRateOfChange 
'/      oDelta.CurrentValue = 100 
'/      oDelta.Comparator = 75 
'/      oDelta.CurrentDate = CDate("1-Jan-2013 12:01:00") 
'/      oDelta.ComparatorDate = CDate("1-Dec-2012 14:21:00") 
'/      Diff = oDelta.RateOfChange() 
'/  OR 
'/      Dim oDelta = New AKIDifference(100, 74, CDate("1-Jan-2013 12:01:00"), CDate("1-Dec-
2012 14:21:00")) 
'/      Diff = oDelta.RateOfChange() 
Public Class AKIRateOfChange 
  
    Public Property CurrentValue As Single 
    Public Property Comparator As Single 
    Public Property CurrentDate As Date 
    Public Property ComparatorDate As Date 
  
    '// 
****************************************************************************************** 
    '// CLASS EVENTS 
    '// 
    ''// fired whenever an error is detected in the ASTM class 
    PublicEvent IsError(ByVal Routine AsString, ByVal Message As String, ByVal Data AsString) 
    PublicEvent IsRate(ByVal Routine AsString, ByVal Value AsSingle) 
  
    Public Sub New() 
    End Sub 
    PublicSub New(By Val CurrentVal As Single, By Val CurrentDate As Date, By 
Val PreviousValue As Single, By Val PreviousDate As Date) 
        Me.CurrentValue = CurrentVal 
        Me.CurrentDate = CurrentDate 
        Me.Comparator = PreviousValue 
        Me.ComparatorDate = PreviousDate 
    EndSub 
  
    Public Function RateOfChange() As Single? 
        Dim rate As Single 
        Dim hours As Integer = DateDiff(DateInterval.Hour, ComparatorDate, CurrentDate) 
        Try 
            If Comparator = -1 Then Return Nothing 
  
            Dim oDiff As New Difference() 
            oDiff.CurrentValue = CurrentValue 
            oDiff.Comparator = Comparator 
  
            rate = oDiff.Difference / hours 
  
            Return rate 
  
        Catch ex As Exception 
            RaiseEvent IsError("RateOfChange()", ex.Message, "") 
            Return Nothing 
        EndTry 
  
    End Function 
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End Class 
#EndRegion 
  
  
#Region"Waikar Class" 
'/ Calculates the AKI stage based on the Waikar criteria. 
'/ Usage : 
'/      Dim oWaikar as new AKIWaikar 
'/      oWaikar.CurrentCreatinine = 100 
'/      oWaikar.LowCreatinine_1 = 75 
'/      oWaikar.LowCreatinine_2 = 56 
'/      
'/      Stage = oWaikar.Stage() 
'/  OR 
'/      Dim oWaikar = New AKIWaikar(100, 75, 56) 
'/      Stage = oWaikar.Stage() 
Public Class AKIWaikar 
  
    Public Property CurrentCreatinine As Integer 
    Public Property LowCreatinine_1 A sInteger? 
    Public Property LowCreatinine_2 As Integer? 
  
    '// 
****************************************************************************************** 
    '// CLASS EVENTS 
    '// 
    ''// fired whenever an error is detected in the ASTM class 
    Public Event IsError(By Val Routine As String, ByVal Message As String, By Val Data As 
String) 
    Public Event IsStage(ByVal Algorithm As Integer, ByVal Stage As Integer) 
  
    '/ Calculate AKI based on the Waikar algorithm 
  
    Public Sub New() 
  
    End Sub 
    Public Sub New(ByVal CurrentCreatinine As Integer, ByVal lowCreatinine_1 As 
Integer?, ByVal lowCreatinine_2 As Integer?) 
        Me.CurrentCreatinine = CurrentCreatinine 
        Me.LowCreatinine_1 = lowCreatinine_1 
        Me.LowCreatinine_2 = lowCreatinine_2 
    End Sub 
    Public Function Stage() As Integer? 
  
        Dim oDiff1 As Integer? = Nothing 
        Dim oDiff2 As Integer? = Nothing 
        Dim oStage As Integer? = Nothing 
  
        Try 
            If LowCreatinine_1 = -1 Then LowCreatinine_1 = Nothing 
            If LowCreatinine_2 = -1 Then LowCreatinine_2 = Nothing 
  
            If LowCreatinine_1 IsNothingAnd LowCreatinine_2 IsNothing ThenReturnNothing 
  
            Dim oDiff As New AKIDifference() 
            oDiff.CurrentValue = CurrentCreatinine 
            If LowCreatinine_1 IsNot Nothing Then 
                oDiff.Comparator = LowCreatinine_1 
                oDiff1 = oDiff.Difference() 
            EndIf 
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            If LowCreatinine_2 IsNot Nothing Then 
                oDiff.Comparator = LowCreatinine_2 
                oDiff2 = oDiff.Difference() 
            EndIf 
  
            If oDiff1 <= 26 Or oDiff2 <= 44 Then oStage = 0 
            If oDiff1 > 26 Or oDiff2 > 44 Then oStage = 1 
            If oDiff1 > 44 Or oDiff2 > 88 Then oStage = 2 
            If oDiff1 > 88 Or oDiff2 > 132 Then oStage = 3 
            'RaiseEvent IsStage("Waikar", Stage) 
            Return oStage 
  
        Catch ex As Exception 
            RaiseEvent IsError("Waikar.Waikar()", ex.Message, "") 
            Return Nothing 
        End Try 
    End Function 
End Class 
  
  
#EndRegion 
  
  
#Region "RIFLE algorithm class" 
'/ Calculates the AKI stage based on the RIFLE criteria. 
'/ Usage : 
'/      Dim oRIFLE as new AKIRIFLE 
'/      oRIFLE.CurrentCreatinine = 154 
'/      oRIFLE.CurrentGFR = 54 
'/      oRIFLE.LowCreatinine_7 = 75 
'/      oRIFLE.HighGFR = 89 
'/      
'/      Stage = oRIFLE.Stage() 
'/  OR 
'/      Dim oRIFLE = New AKIRIFLE(154, 54, 75, 89) 
'/      Stage = oRIFLE.Stage() 
Public Class AKIRIFLE 
  
    Public Property CurrentCreatinine As Integer 
    Public Property CurrentGFR As Integer 
    Public Property HighGFR_7 As Integer? 
    Public Property LowCreatinine_7 As Integer? 
  
  
  
    '// 
****************************************************************************************** 
    '// CLASS EVENTS 
    '// 
    ''// fired whenever an error is detected in the ASTM class 
    Public Event IsError(ByVal Routine As String, ByVal Message As String, ByVal Data As 
String) 
  
  
    Public Sub New() 
  
    End Sub 
    Public Sub New(ByVal CurrentCreatinine As 
Integer, ByVal CurrentGFR AsInteger, ByVal LowCreatinine_7 As Integer?, ByVal HighGFR_7As 
Integer?) 
        Me.CurrentCreatinine = CurrentCreatinine 
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        Me.CurrentGFR = CurrentGFR 
        Me.LowCreatinine_7 = LowCreatinine_7 
        Me.HighGFR_7 = HighGFR_7 
    End Sub 
  
    Public Function Stage() As Integer? 
  
        Dim Difference As Integer? = Nothing 
        Dim CreatRatio As Single? = Nothing 
        Dim GFRRatio As Single? = Nothing 
        Dim _Stage As Integer? = Nothing 
  
        Try 
            If LowCreatinine_7 < 1 Then LowCreatinine_7 = Nothing 
            If HighGFR_7 < 1 Then HighGFR_7 = Nothing 
  
            If IsNothing(LowCreatinine_7) And IsNothing(HighGFR_7) Then Return Nothing 
  
            If Not IsNothing(LowCreatinine_7) Then 
                CreatRatio = CurrentCreatinine / LowCreatinine_7 
                Difference = CurrentCreatinine - LowCreatinine_7 
            EndIf 
  
            If Not IsNothing(HighGFR_7) Then GFRRatio = 1 - (CurrentGFR / HighGFR_7) 
            _Stage = 0 
            If CreatRatio >= 1.5 Or GFRRatio >= 0.25 Then _Stage = 1 
            If CreatRatio >= 2.0 Or GFRRatio >= 0.5 Then _Stage = 2 
            If CurrentCreatinine > 354 And Difference > 44 Then _Stage = 3 
            If CreatRatio >= 3.0 Or GFRRatio >= 0.75 Then _Stage = 3 
  
            Return _Stage 
  
        Catch ex As Exception 
            RaiseEvent IsError("RIFLE.Stage()", ex.Message, "") 
            Return Nothing 
        End Try 
    End Function 
End Class 
  
#EndRegion 
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#Region "AKIN algorithm class" 
'/ Calculates the AKI stage based on the AKIN criteria. 
'/ Usage : 
'/      Dim oAKIN as new AKIAKIN 
'/      oAKIN.CurrentCreatinine = 154 
'/      oAKIN.PreviousCreatinine = 75 
'/      
'/      Stage = oAKIN.Stage() 
'/  OR 
'/      Dim oAKIN = New AKIAKIN(154, 75) 
'/      Stage = oAKIN.Stage() 
Public Class AKIAKIN 
  
    Public Property CurrentCreatinine As Integer 
    Public Property PreviousCreatinine As Integer 
    Public Property LowCreat2 As Integer? 
  
    '// 
****************************************************************************************** 
    '// CLASS EVENTS 
    '// 
    ''// fired whenever an error is detected in the ASTM class 
    Public Event IsError(ByVal Routine As String, ByVal Message As String, ByVal Data As 
String) 
  
    Public Sub New() 
  
    End Sub 
    Public Sub New(ByVal CurrentCreatinine As Integer, _ 
                   ByVal PreviousCreatinine As Integer, 
                   ByVal LowCreat2 As Integer?) 
        Me.CurrentCreatinine = CurrentCreatinine 
        Me.PreviousCreatinine = PreviousCreatinine 
        Me.LowCreat2 = LowCreat2 
    End Sub 
  
    Public Function Stage() As Integer? 
  
        Dim oRatio As Single? = Nothing 
        Dim oDifference As Integer? = Nothing 
        Dim oStage As Integer? = Nothing 
  
        Try 
            If LowCreat2 < 1 Then LowCreat2 = Nothing 
            If PreviousCreatinine < 1 Then PreviousCreatinine = Nothing 
            If IsNothing(LowCreat2) And IsNothing(PreviousCreatinine) Then Return Nothing 
  
            If Not IsNothing(PreviousCreatinine) Then oRatio = CurrentCreatinine / 
PreviousCreatinine 
            If (Not IsNothing(LowCreat2)) Or (LowCreat2 > 0) Then oDifference = 
CurrentCreatinine - LowCreat2 
  
            If oRatio <= 1.5 Then oStage = 0 
            If Not IsNothing(oDifference) Then 
                If oDifference > 26 Then oStage = 1 
            EndIf 
            If oRatio >= 1.5 Then oStage = 1 
            If oRatio >= 2 Then oStage = 2 
            If (oRatio >= 3) Or (CurrentCreatinine >= 354 And oDifference > 44) Then oStage = 
3 
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            Return oStage 
        Catch ex As Exception 
            RaiseEvent IsError("AKIAKIN.Stage()", ex.Message, "") 
            Retur nNothing 
        End Try 
    End Function 
End Class 
#EndRegion 
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#Region "AKI Isolate raised creatinine" 
'/ Determines if the current creatinine is above the cut off 
'/ Usage : 
'/      Dim oRaised as new AKIIsolatedCreatinine 
'/      oRaised.Creatinine = 154 
'/      oRaised.CreatinineCutOff = 125 
'/      
'/      IsRaised = oRaised.IsCreatineRaised 
'/  OR 
'/      Dim oRaised = New AKIIsolatedCreatinine(154, 125) 
'/      IsRaised = oRaised.IsCreatineRaised 
  
Public Class AKIIsolatedCreatinine 
    Public Property Creatinine As Integer 
    Public Property CreatinineCutOff As Integer 
  
    '// 
****************************************************************************************** 
    '// CLASS EVENTS 
    '// 
    ''// fired whenever an error is detected in the ASTM class 
    Public Event IsError(ByVal Routine As String, ByVal Message As String, ByVal Data As 
String) 
  
    Public Sub New() 
  
    End Sub 
  
    Public Sub New(ByVal Creatinine As Integer, ByVal CutOff As Integer) 
        Me.Creatinine = Creatinine 
        Me.CreatinineCutOff = CutOff 
    End Sub 
  
    Public Function IsCreatinineRaised() As Boolean 
  
        Try 
            If Creatinine > CreatinineCutOff Then 
                Return True 
            Else 
                Return False 
            End If 
        Catch ex As Exception 
            RaiseEvent IsError("AKIIsolatedCreatinine.IsRaised()", ex.Message, "") 
        End Try 
    End Function 
End Class 
  
#EndRegion 
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#Region "NHS England AKI staging" 
  
Public Class AKINHSEngland 
  
    Public Property Creatinine As Integer 
    Public Property LowCreatinine_7 As Integer? 
    Public Property Median As Single? 
    Public Property Age As Integer 
    Public Property LowCreatinine_2 As Integer? 
    Public Property Sex As String 
    Public Property Paediatric As Boolean 
  
    '// 
****************************************************************************************** 
    '// CLASS EVENTS 
    '// 
    ''// fired whenever an error is detected in the ASTM class 
    Public Event IsError(ByVal Routine AsString, ByVal Message As String, ByVal Data AsString) 
  
  
    Private Property RV1 As Single? = Nothing 
    Private Property RV2 As Single? = Nothing 
    Private Property HighestRatio As Single? = Nothing 
    Private Property _Stage As Integer? = Nothing 
  
    Public Sub New() 
  
    End Sub 
    Public Sub New(ByVal Creatinine As Integer, _ 
                   ByVal LowCreat_7 As Integer?, _ 
                   ByVal Median As Single?, _ 
                   ByVal Age As Integer, _ 
                   ByVal LowCreat_2 As Integer?, _ 
                   ByVal Sex As String) 
  
  
        If LowCreat_2 = -1 Then LowCreat_2 = Nothing 
        If LowCreat_7 = -1 Then LowCreat_7 = Nothing 
        If Median = -1 Then Median = Nothing 
  
        Me.Creatinine = Creatinine 
        Me.LowCreatinine_7 = LowCreat_7 
        Me.Median = Median 
        Me.Age = Age 
        Me.LowCreatinine_2 = LowCreat_2 
        Me.Sex = Sex 
  
    EndSub 
  
    Private Sub CalculateRatios() 
        Try 
            If Not IsNothing(LowCreatinine_7) Then RV1 = Creatinine / LowCreatinine_7 
            If Not IsNothing(Median) Then RV2 = Creatinine / Median 
  
            If IsNothing(RV1) And IsNothing(RV2) Then HighestRatio = Nothing 
            If IsNothing(RV1) Then HighestRatio = RV2 
            If IsNothing(RV2) Then HighestRatio = RV1 
  
            If RV1 > RV2 Then HighestRatio = RV1 
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            If RV1 < RV2 Then HighestRatio = RV2 
            If RV1 = RV2 Then HighestRatio = RV1 
  
        Catch ex As Exception 
            RaiseEvent IsError("NHSEngland.CalculateRatios()", ex.Message, "") 
        End Try 
  
    End Sub 
  
    Private Function PaediatricULN() As Integer 
  
        Select Case Age 
            CaseIs < 2 : Return 34 
            CaseIs < 8 : Return 48 
            CaseIs < 12 : Return 63 
            CaseIs < 14 : Return 72 
            CaseIs < 15 : Return 104 
            Case Else : If Sex = "M" Then Return 115 Else Return 97 
        End Select 
    End Function 
 
    Public Function Stage() As Integer? 
  
        Try 
            CalculateRatios() 
            If HighestRatio >= 1.5 And Age >= 18 Then 
                If Creatinine > 354 Or HighestRatio >= 3.0 Then 
                    _Stage = 3 
                    Return _Stage 
                End If 
                If HighestRatio >= 2.0 And HighestRatio < 3.0 Then 
                    _Stage = 2                    
                    Return _Stage 
                End If 
                If HighestRatio >= 1.5 And HighestRatio < 2.0 Then 
                    _Stage = 1 
                   Return _Stage 
                End If 
            End If 
  
            If HighestRatio < 1.5 And Age >= 18 Then 
                If (LowCreatinine_2 > 0) And (Creatinine - LowCreatinine_2 > 26) Then 
                    _Stage = 1 
                    Return _Stage 
                End If 
                _Stage = 0 
                Return _Stage 
            End If 
  
            '/ Paediatric 
            If Paediatric Then 
                If Age < 18 And (Creatinine / PaediatricULN() > 3) Then 
                    _Stage = 3 
                    Return _Stage 
                End If 
                If HighestRatio >= 3.0 Then 
                    _Stage = 3 
                    Return _Stage 
                End If 
                If HighestRatio >= 2.0 And HighestRatio < 3 Then 
                    _Stage = 2                    
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                    Return _Stage 
                End If 
                If HighestRatio >= 1.5 And HighestRatio < 2.0 Then 
                    _Stage = 1 
                    Return _Stage 
                End If 
                If HighestRatio < 1.5 Then 
                    _Stage = 0 
                    Return _Stage 
                End If 
            End If 
            Return _Stage 
        Catch ex As Exception 
            RaiseEvent IsError("NHSEngland.Stage()", ex.Message, "") 
        End Try 
    End Function 
End Class 
#EndRegion 
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Public Class AKIEvaluate 
  
#Region "properties" 
    '/ 
********************************************************************************************* 
    '/ PROPERTIES 
********************************************************************************** 
    Public Property ConnectionString As String 
    Public Property LogFile As String 
    Public Property CreatinineCutOff As Integer 
    Public Property Creatinine As Integer = 0 
    Public Property GFR As Integer = 0 
    Public Property DoPaediatric As Boolean = False 
  
    Public Property CanDoDifference As Boolean = False 
    Public Property CanDoRateOfChange As Boolean = False 
    Public Property CanDoRIFLE As Boolean = False 
    Public Property CanDoAKIN As Boolean = False 
    Public Property CanDoWaikar As Boolean = False 
    Public Property CanDoNHSEngland As Boolean = False 
    Public Property CanCheckForCKD As Boolean = False 
  
  
    Public Property oPatient As AKIPatient 
    Public Property oSample As AKI_Specimen 
    Public Property oResults As AKIResults 
  
    Private Property LatestDate As Date 
    Private Property EarliestDate As Date 
    Private Property PatientID As Integer 
    Private Property NumberOfCreatinineValues As Integer 
    Private Property PreviousCreatinine As Integer? = Nothing 
    Private Property PreviousCreatDate As Date? = Nothing 
    Private Property LowCreatinine_1 As Integer? 
    Private Property LowCreatinine_2 As Integer? 
    Private Property LowCreatinine_7 As Integer? 
    Private Property LowCreatinine_30 As Integer? 
    Private Property LowCreatinine_90 As Integer? 
    Private Property MedianCreatinine As Integer? 
    Private Property HighGFR_7 As Integer? 
    Private Property MaxGFR As Integer 
    Private Property Age As Integer 
    Private Property Sex As String 
  
    Dim resultList As New Dictionary(Of String, Single) 
    '/ 
********************************************************************************************* 
  
    Public Property writeLog A sBoolean 
#EndRegion 
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    Dim oPreviousResults As New PreviousResults() 
  
  
    '/ EVENTS 
********************************************************************************** 
    '/ fired whenever an error is detected in the ASTM class 
    Public Event IsError(ByVal Routine As String, ByVal Message As String, ByVal Data As 
String) 
    '/ fired to provide details of the current processing 
    Public Event IsData(ByVal Data As String) 
    '/ fired whenever an AKI evaluation is performed and staged 
    Public Event IsEvaluated(ByVal Algorithm As String, ByVal Stage As Integer) 
  
    Public Sub New() 
  
    End Sub 
  
    Public Sub New(ByVal o_Results As AKIResults, _ 
                    ByVal o_Sample As AKI_Specimen, _ 
                    ByVal o_Patient As AKIPatient, _ 
                    ByVal ConnStr As String) 
        Me.oPatient = o_Patient 
        Me.oSample = o_Sample 
        Me.oResults = o_Results 
        Me.ConnectionString = ConnStr 
  
        resultList.Clear() 
    End Sub 
  
    Private Sub Initialise() 
        resultList = oResults.Load(oSample.Specimen.LabNo, resultList, True) 
        LatestDate = DateAdd(DateInterval.Minute, -5, oSample.Specimen.Sampled.Value) 
        EarliestDate = DateAdd(DateInterval.Day, -365, oSample.Specimen.Sampled.Value) 
        PatientID = oPatient.Patient.ID 
  
        GetDataForEvaluation() 
  
        If GFR = 0 Then DoGFR() 
        If GFR > 0 Then resultList = oResults.Add("EGFR", GFR, resultList) 
    End Sub 
  
    Private Sub Finalise() 
        oResults.InsertResultsIntoDB(resultList, oSample.Specimen.LabNo) 
    End Sub 
  
  
    '/ Gets all the data required prior to AKI evaluation 
    Private Sub GetDataForEvaluation() 
        LowCreatinine_1 = Nothing 
        LowCreatinine_2 = Nothing 
        LowCreatinine_7 = Nothing 
        LowCreatinine_30 = Nothing 
        LowCreatinine_90 = Nothing 
        MedianCreatinine = Nothing 
        HighGFR_7 = Nothing 
        MaxGFR = Nothing 
        NumberOfCreatinineValues = 0 
  
        oPreviousResults.ConnectionString = ConnectionString 
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        oPreviousResults.GetPreviousResults(PatientID, LatestDate) 
        NumberOfCreatinineValues = oPreviousResults.CountRows("CRE2", EarliestDate, 
LatestDate) 
        If NumberOfCreatinineValues > 0 Then 
            PreviousCreatinine = oPreviousResults.PreviousValue("CRE2", EarliestDate, 
LatestDate) 
            PreviousCreatDate = oPreviousResults.PreviousDateTime("CRE2", EarliestDate, 
LatestDate) 
            LowCreatinine_1 = oPreviousResults.LowestValue("CRE2", _ 
                                                           DateAdd(DateInterval.Hour, -24, 
oSample.Specimen.Sampled.Value), _ 
                                                           LatestDate) 
            LowCreatinine_2 = oPreviousResults.LowestValue("CRE2", _ 
                                                           DateAdd(DateInterval.Hour, -48, 
oSample.Specimen.Sampled.Value), _ 
                                                           LatestDate) 
            LowCreatinine_7 = oPreviousResults.LowestValue("CRE2", _ 
                                                           DateAdd(DateInterval.Day, -7, 
oSample.Specimen.Sampled.Value), _ 
                                                           LatestDate) 
            LowCreatinine_30 = oPreviousResults.LowestValue("CRE2", _ 
                                                           DateAdd(DateInterval.Day, -30, 
oSample.Specimen.Sampled.Value), _ 
                                                           LatestDate) 
            LowCreatinine_90 = oPreviousResults.LowestValue("CRE2", _ 
                                                           DateAdd(DateInterval.Day, -90, 
oSample.Specimen.Sampled.Value), _ 
                                                           LatestDate) 
            MedianCreatinine = oPreviousResults.Median("CRE2", _ 
                                                       DateAdd(DateInterval.Day, -365, 
oSample.Specimen.Sampled.Value), _ 
                                                       DateAdd(DateInterval.Day, -7, 
oSample.Specimen.Sampled.Value)) 
            HighGFR_7 = oPreviousResults.HighestValue("EGFR", 
                                                     DateAdd(DateInterval.Day, -7, 
oSample.Specimen.Sampled.Value), _ 
                                                     LatestDate) 
            MaxGFR = oPreviousResults.HighestValue("EGFR", EarliestDate, _ 
                                                   DateAdd(DateInterval.Day, -30, 
oSample.Specimen.Sampled.Value)) 
        EndIf 
        Age = DateDiff(DateInterval.Year, oPatient.Patient.DoB.Value, 
oSample.Specimen.Sampled.Value) 
        Sex = oPatient.Patient.Sex 
  
    End Sub 
  
    Public Sub DoEvaluations() 
        Initialise() 
        If NumberOfCreatinineValues = 0 Then Exit Sub 
  
        If CanDoDifference Then DoDifference() 
        If CanDoRateOfChange Then DoRateOfChange() 
        If CanDoRIFLE Then DoRIFLE() 
        If CanDoAKIN Then 
            DoAKIN(LowCreatinine_2, "AKIN2") 
            DoAKIN(LowCreatinine_7, "AKIN7") 
            DoAKIN(LowCreatinine_30, "AKIN30") 
            DoAKIN(LowCreatinine_90, "AKIN90") 
        End If 
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        If CanDoWaikar Then DoWaikar() 
  
        If CanDoNHSEngland Then DoNHSEngland()        
  
        If CanCheckForCKD Then CheckForCKD() 
  
        Finalise() 
    End Sub 
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#Region"Dispatch methods" 
    Private Sub DoDifference() 
        If PreviousCreatinine = -1 Then Exit Sub 
        Dim value As Single 
  
        Dim oDifference As New AKIDifference(Creatinine, PreviousCreatinine) 
        Try 
            AddHandler oDifference.IsError, AddressOf AKIDifferenceErrorHandler 
            AddHandler oDifference.IsDifference, AddressOf AKIDifferenceHandler 
            value = oDifference.Difference() 
            resultList = oResults.Add("DIFF_CRE2", value, resultList) 
  
        Catch ex As Exception 
            RaiseEvent IsError("DoDifference()", ex.Message, "") 
        EndTry 
  
    End Sub 
  
    Private Sub AKIDifferenceErrorHandler(ByVal r A sString, ByVal m As 
String, ByVal d As String) 
        RaiseEvent IsError(r, m, d) 
    End Sub 
 
    Private Sub AKIDifferenceHandler(ByVal a As String, ByVal v As Integer) 
        RaiseEvent IsEvaluated(a, v) 
    End Sub 
  
    Private Sub DoRIFLE() 
        If LowCreatinine_7 = -1 Then Exit Sub 
  
        Dim value As Integer 
  
        Dim oRifle As New AKIRIFLE(Creatinine, GFR, LowCreatinine_7, HighGFR_7) 
        Try 
            AddHandler oRifle.IsError, AddressOf AKIRIFLEErrorHandler 
            value = oRifle.Stage() 
            resultList = oResults.Add("RIFLE", value, resultList) 
  
        Catch ex As Exception 
            RaiseEvent IsError("DoRIFLE()", ex.Message, "") 
        End Try 
    End Sub 
  
    Private Sub AKIRIFLEErrorHandler(ByVal r As String, ByVal m As String, ByVal d As String) 
        RaiseEvent IsError(r, m, d) 
    End Sub 
  
    Private Sub DoAKIN(ByVal ValueToUse As Integer, ByVal Code As String) 
        If ValueToUse = -1 Then Exit Sub 
  
        Dim oAKIN As New AKIAKIN(Creatinine, ValueToUse, LowCreatinine_2) 
        Dim stage As Integer? 
  
        Try 
            AddHandler oAKIN.IsError, AddressOf AKIAKINErrorHandler 
            stage = oAKIN.Stage() 
            If Not IsNothing(stage) Then resultList = oResults.Add(Code, stage, resultList) 
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        Catch ex As Exception 
            RaiseEvent IsError("DoAKIN()", ex.Message, "") 
        EndTry 
  
    End Sub 
  
    Private Sub AKIAKINErrorHandler(ByVal r As String, ByVal m AsString, ByVal d As String) 
        RaiseEvent IsError(r, m, d) 
    EndSub 
#Region"Rate of change" 
    PrivateSub DoRateOfChange() 
        If PreviousCreatinine = -1 ThenExit Sub 
        Dim value As Single? 
  
        Dim oDelta As NewAKIRateOfChange(Creatinine, LatestDate, PreviousCreatinine, 
PreviousCreatDate) 
  
        Try 
            AddHandler oDelta.IsError, AddressOf AKIRateOfChangeErrorHandler 
            AddHandler oDelta.IsRate, AddressOf AKIRateHandler 
            value = oDelta.RateOfChange() 
            IfNot IsNothing(value) Then resultList = oResults.Add("DELTA_CRE2", value, 
resultList) 
  
        Catch ex As Exception 
            ErrorHandler("RateOfChange()", ex.Message, "") 
        EndTry 
    EndSub 
  
    PrivateSub AKIRateOfChangeErrorHandler(ByVal r AsString, ByVal m AsString, ByVal d As Stri
ng) 
        RaiseEvent IsError(r, m, d) 
    EndSub 
  
    PrivateSub AKIRateHandler(ByVal a AsString, ByVal v AsSingle) 
        RaiseEvent IsEvaluated(a, v) 
    EndSub 
#EndRegion 
  
    PrivateSub DoWaikar() 
        If (LowCreatinine_2 = -1) And (LowCreatinine_1 = -1) Then Exit Sub 
  
        Dim oWaikar As NewAKIWaikar(Creatinine, LowCreatinine_1, LowCreatinine_2) 
        Dim stage As Integer? 
        Try 
            AddHandler oWaikar.IsError, AddressOf AKIWaikarErrorHandler 
            AddHandler oWaikar.IsStage, AddressOf AKIWaikarStage 
            stage = oWaikar.Stage() 
            If stage = -1 Then 
                MsgBox("What") 
            EndIf 
            IfNot IsNothing(stage) Then resultList = oResults.Add("WAIKAR", stage, resultList) 
  
        Catch ex As Exception 
            RaiseEvent IsError("DoWaikar()", ex.Message, "") 
        EndTry 
    EndSub 
  
    PrivateSub AKIWaikarErrorHandler(ByVal r AsString, ByVal m AsString, ByVal d As String) 
        RaiseEvent IsError(r, m, d) 
    EndSub 
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    PrivateSub AKIWaikarStage(ByVal a AsString, ByVal v AsInteger) 
        RaiseEvent IsEvaluated(a, v) 
    EndSub 
  
  
    PrivateSub DoNHSEngland() 
  
        If LowCreatinine_7 = -1 And MedianCreatinine = -1 Then Exit Sub 
  
        Dim oNHSEngland AsNewAKINHSEngland(Creatinine, LowCreatinine_7, MedianCreatinine, Age, 
LowCreatinine_2, Sex) 
        Dim _stage As Integer? = Nothing 
  
        Try 
            AddHandler oNHSEngland.IsError, AddressOf AKINHSEnglandErrorHandler 
            oNHSEngland.Paediatric = DoPaediatric 
            _stage = oNHSEngland.Stage() 
            IfNot IsNothing(_stage) Then resultList = oResults.Add("AKI", _stage, resultList) 
  
        Catch ex As Exception 
            RaiseEvent IsError("AKINHSEngland()", ex.Message, "") 
        EndTry 
    EndSub 
  
    PrivateSub AKINHSEnglandErrorHandler(ByVal r AsString, ByVal m AsString, ByVal d As String
) 
        RaiseEvent IsError(r, m, d) 
    EndSub 
#EndRegion 
  
  
#Region"Check for CKD" 
    '/ Check the patient for CKD by looking back 1 year 
    PrivateSub CheckForCKD() 
  
        Try 
            If MaxGFR = -1 ThenExit Sub 
  
            If MaxGFR >= 60 Then 
                oSample.SetCKDFlag(oSample.Specimen.LabNo, False) 
            Else 
                oSample.SetCKDFlag(oSample.Specimen.LabNo, True) 
            EndIf 
  
  
        Catch ex As Exception 
            ErrorHandler("CheckForCKD()", ex.Message, "Lab No : " & oSample.Specimen.LabNo) 
        EndTry 
  
    EndSub 
#EndRegion 
  
#Region"eGFR calculation" 
  
    PrivateSub DoGFR() 
        Dim _GFR As Single = -1 
        Dim GFR As Integer = -1 
  
        Try 
            IfNot IsDate(oPatient.Patient.DoB) ThenExit Sub 
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            Dim Age As Integer = DateDiff(DateInterval.Year, CDate(oPatient.Patient.DoB), 
oSample.Specimen.Sampled.Value) 
            If Age < 16 Then Exit Sub 
  
            Dim GFR1 As Single = 0.0122028 * Creatinine - 0.2011274 
            Dim GFR2 As Single = 1 / Math.Pow(Age, 0.203) 
            Dim GFR3 As Single = 1 / Math.Pow(GFR1, 1.154) 
  
            _GFR = 175 * GFR3 * GFR2 
  
            If oPatient.Patient.Sex = "F"Then _GFR = _GFR * 0.742 
            GFR = Convert.ToInt32(_GFR) 
  
            If IsNumeric(GFR) Then resultList = oResults.Add("EGFR", GFR, resultList) 
        Catch ex As Exception 
            ErrorHandler("DoGFR", ex.Message, "Lab No: " & oSample.Specimen.LabNo) 
        EndTry 
    EndSub 
  
#EndRegion 
  
  
#Region"Error Handling" 
    '// handles error reporting 
    PrivateSub ErrorHandler(ByVal Routine AsString, ByVal Message As String, ByVal Data AsStri
ng) 
        Dim o_Error As NewError_Handler 
  
        Try 
            With o_Error 
                .ConnectionString = ConnectionString 
                .Clear() 
                .Routine = "AKIEvaluate." & Routine 
                .Message = Message 
                .Data = Data 
                .Add() 
            EndWith 
        Catch ex As Exception 
  
        Finally 
            RaiseEvent IsError(Routine, Message, Data) 
            o_Error = Nothing 
        EndTry 
  
    EndSub 
  
#EndRegion 
  
#Region"Add AKI comment" 
    '/ writes the comment to the comment table    
    PrivateFunction AddComment(ByVal Comment AsString) AsBoolean 
        Dim SQL As String = "INSERT INTO Comments(LabNo, Code, Comment, Output) VALUES(@lab, 
'AKIC', @comm, 0)" 
  
        If CommentExists(oSample.Specimen.LabNo, "AKIC") ThenExit Function 
  
        Try 
            Using conn As NewSqlConnection(ConnectionString) 
                Using cmd As NewSqlCommand(SQL, conn) 
                    conn.Open() 
                    cmd.Parameters.Clear() 
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                    cmd.Parameters.Add(NewSqlParameter("@lab", oSample.Specimen.LabNo)) 
                    cmd.Parameters.Add(NewSqlParameter("@comm", Comment)) 
                    cmd.ExecuteNonQuery() 
                EndUsing 
            EndUsing 
  
            ReturnTrue 
  
        Catch ex As Exception 
            ErrorHandler("AddComment", ex.Message, "Comment : " & Comment & "(" & 
oSample.Specimen.LabNo & ")") 
            ReturnFalse 
        EndTry 
  
    EndFunction 
  
    '/ Checks whether the comment has already been added to the database 
    PrivateFunction CommentExists(ByVal LabNo AsString, ByVal Code AsString) AsBoolean 
        '// return true if the labNo/code exists and false if not present 
        Dim _ds As Integer 
        Dim _SQL As String = "SELECT COUNT (LabNo) FROM Comments WHERE LabNo = @lab AND Code = 
@code" 
  
        Try 
            Using conn As NewSqlConnection(ConnectionString) 
                Using cmd As NewSqlCommand(_SQL, conn) 
                    cmd.CommandText = _SQL 
                    cmd.Parameters.Clear() 
                    cmd.Parameters.Add("@lab", SqlDbType.VarChar).Value = LabNo.Trim 
                    cmd.Parameters.Add("@code", SqlDbType.VarChar).Value = Code.Trim 
                    cmd.CommandType = CommandType.Text 
                    conn.Open() 
                    _ds = cmd.ExecuteScalar() 
                    If _ds > 0 Then 
                        ReturnTrue 
                    Else 
                        ReturnFalse 
                    EndIf 
                EndUsing 
            EndUsing 
  
        Catch ex As Exception 
            ErrorHandler("CommentExists()", ex.Message, "LabNo : " & LabNo) 
            ReturnFalse 
        EndTry 
  
    EndFunction 
#EndRegion 
  
#Region"Log file" 
    '/ Write data to the log file 
    PrivateSub Log(ByVal Text AsString, ByVal LabNo AsString) 
  
        If writeLog = FalseThenExit Sub 
  
        Dim file As System.IO.StreamWriter 
        file = My.Computer.FileSystem.OpenTextFileWriter(LogFile & LabNo & ".txt", True) 
        file.WriteLine(Text) 
        file.Close() 
  
    EndSub 
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#EndRegion 
EndClass 
  
 Page 191 
 
References 
 
 
References 
 
Acute Kidney Injury - Prevent this Silent Killer. (June 2011). Health Service Journal. 
Ali, T., Khan, I., Simpson, W., Prescott, G., Townend, J., Smith, W., & Macleod, A. (2007). Incidence and 
outcomes in acute kidney injury: a comprehensive population-based study. J Am Soc Nephrol, 18(4), 
1292-1298. 
Amdur, R. L., Chawla, L. S., Amodeo, S., Kimmel, P. L., & Palant, C. E. (2009). Outcomes following 
diagnosis of acute renal failure in U.S. veterans: focus on acute tubular necrosis. Kidney Int, 76(10), 
1089-1097. 
Bagnasco, S., Good, D., Balaban, R., & Burg, M. (1985). Lactate production in isolated segments of the rat 
nephron. Am J Physiol, 248(4 Pt 2), F522-526. 
Bates, D. W., & Leape, L. L. (2005). Doing better with critical test results. Jt Comm J Qual Patient Saf, 
31(2), 66-67, 61. 
Batstone, G., & Abdi, Z. (April 2012). What Are The Laboratory's Responsiblities re Acute Kidney Injury. 
ACB News, 13-15. 
Bellomo, R., Ronco, C., Kellum, J. A., Mehta, R. L., Palevsky, P., & Acute Dialysis Quality Initiative, w. 
(2004). Acute renal failure - definition, outcome measures, animal models, fluid therapy and information 
technology needs: the Second International Consensus Conference of the Acute Dialysis Quality 
Initiative (ADQI) Group. Crit Care, 8(4), R204-212. 
Birn, H., & Christensen, E. I. (2006). Renal albumin absorption in physiology and pathology. Kidney Int, 
69(3), 440-449. 
Braun, A. B., & Christopher, K. B. (2013). Vitamin D in acute kidney injury. Inflamm Allergy Drug Targets, 
12(4), 262-272. 
Bucaloiu, I. D., Kirchner, H. L., Norfolk, E. R., Hartle, J. E., & Perkins, R. M. (2012). Increased risk of death 
and de novo chronic kidney disease following reversible acute kidney injury. Kidney Int, 81(5), 477-485. 
Callen, J., Paoloni, R., Georgiou, A., Prgomet, M., & Westbrook, J. (2010). The rate of missed test results 
in an emergency department: an evaluation using an electronic test order and results viewing system. 
Methods Inf Med, 49(1), 37-43. 
Challiner, R., Ritchie, J. P., Fullwood, C., Loughnan, P., & Hutchison, A. J. (2014). Incidence and 
consequence of acute kidney injury in unselected emergency admissions to a large acute UK hospital 
trust. BMC Nephrol, 15, 84. 
Chawla, L. S. (2011). Acute kidney injury leading to chronic kidney disease and long-term outcomes of 
acute kidney injury: the best opportunity to mitigate acute kidney injury? Contrib Nephrol, 174, 182-190. 
Chawla, L. S., Amdur, R. L., Amodeo, S., Kimmel, P. L., & Palant, C. E. (2011). The severity of acute kidney 
injury predicts progression to chronic kidney disease. Kidney Int, 79(12), 1361-1369. 
Chertow, G., Burdick, E., Honour, M., Bonventre, J., & Bates, D. (2005). Acute Kidney Injury, Mortality, 
Length of Stay, and Costs in Hospitalized Patients. JASN, 16(11), 3365-3370. 
Chertow, G. M., Burdick, E., Honour, M., Bonventre, J. V., & Bates, D. W. (2005). Acute Kidney Injury, 
Mortality, Length of Stay, and Costs in Hospitalized Patients. Journal of the American Society of 
Nephrology, 16(11), 3365-3370. 
Coca, S. G., Singanamala, S., & Parikh, C. R. (2012). Chronic kidney disease after acute kidney injury: a 
systematic review and meta-analysis. Kidney Int, 81(5), 442-448. 
Coca, S. G., Yalavarthy, R., Concato, J., & Parikh, C. R. (2008). Biomarkers for the diagnosis and risk 
stratification of acute kidney injury: a systematic review. Kidney Int, 73(9), 1008-1016. 
 Page 192 
 
Coca, S. G., Yusuf, B., Shlipak, M. G., Garg, A. X., & Parikh, C. R. (2009). Long-term risk of mortality and 
other adverse outcomes after acute kidney injury: a systematic review and meta-analysis. Am J Kidney 
Dis, 53(6), 961-973. 
Colpaert, K., Hoste, E. A., Steurbaut, K., Benoit, D., Van Hoecke, S., De Turck, F., & Decruyenaere, J. 
(2012). Impact of real-time electronic alerting of acute kidney injury on therapeutic intervention and 
progression of RIFLE class. Crit Care Med, 40(4), 1164-1170. 
Davies, D. F., & Shock, N. W. (1950). Age changes in glomerular filtration rate, effective renal plasma 
flow, and tubular excretory capacity in adult males. J Clin Invest, 29(5), 496-507. 
de Braganca, A. C., Volpini, R. A., Canale, D., Goncalves, J. G., Shimizu, M. H., Sanches, T. R., . . . Andrade, 
L. (2015). Vitamin D deficiency aggravates ischemic acute kidney injury in rats. Physiol Rep, 3(3). 
Devarajan, P. (2010). Neutrophil gelatinase-associated lipocalin: a promising biomarker for human acute 
kidney injury. Biomark Med, 4(2), 265-280. 
Dickson, L. E., Wagner, M. C., Sandoval, R. M., & Molitoris, B. A. (2014). The proximal tubule and 
albuminuria: really! J Am Soc Nephrol, 25(3), 443-453. 
Endre, Z. H., Walker, R. J., Pickering, J. W., Shaw, G. M., Frampton, C. M., Henderson, S. J., . . . George, P. 
M. (2010). Early intervention with erythropoietin does not affect the outcome of acute kidney injury (the 
EARLYARF trial). Kidney Int, 77(11), 1020-1030. 
Feehally, J., Gilmore, I., Barasi, S., Bosomworth, M., Christie, B., Davies, A., . . . Stevens, P. E. (2013). 
RCPE UK consensus conference statement: Management of acute kidney injury: the role of fluids, e-
alerts and biomarkers. J R Coll Physicians Edinb, 43(1), 37-38. 
Fisher, H., Hsu, C. Y., Vittinghoff, E., Lin, F., & Bansal, N. (2013). Comparison of associations of urine 
protein-creatinine ratio versus albumin-creatinine ratio with complications of CKD: a cross-sectional 
analysis. Am J Kidney Dis, 62(6), 1102-1108. 
Flynn, N., & Dawnay, A. (2015). A simple electronic alert for acute kidney injury. Ann Clin Biochem, 52(Pt 
2), 206-212. 
Fraser, C. G. (2012). Reference change values. Clin Chem Lab Med, 50(5), 807-812. 
Garner, A. E., Lewington, A. J., & Barth, J. H. (2012). Detection of patients with acute kidney injury by the 
clinical laboratory using rises in serum creatinine: comparison of proposed definitions and a laboratory 
delta check. Ann Clin Biochem, 49(Pt 1), 59-62. 
Goldhaber, J. I., Kim, K. H., Natterson, P. D., Lawrence, T., Yang, P., & Weiss, J. N. (1996). Effects of TNF-
alpha on [Ca2+]i and contractility in isolated adult rabbit ventricular myocytes. Am J Physiol, 271(4 Pt 2), 
H1449-1455. 
Gowans, E. M., & Fraser, C. G. (1988). Biological variation of serum and urine creatinine and creatinine 
clearance: ramifications for interpretation of results and patient care. Ann Clin Biochem, 25 ( Pt 3), 259-
263. 
Hall, J. E., Guyton, A. C., Jackson, T. E., Coleman, T. G., Lohmeier, T. E., & Trippodo, N. C. (1977). Control 
of glomerular filtration rate by renin-angiotensin system. Am J Physiol, 233(5), F366-372. 
Harty, J. (2014). Prevention and management of acute kidney injury. Ulster Med J, 83(3), 149-157. 
Herget-Rosenthal, S., Marggraf, G., Husing, J., Goring, F., Pietruck, F., Janssen, O., . . . Kribben, A. (2004). 
Early detection of acute renal failure by serum cystatin C. Kidney Int, 66(3), 1115-1122. 
Hill, R., & Selby, N. (2014). Acute Kidney Injury, Warning algorithm best practice guidance (1 Dec 2014 
ed.): Think Kidneys National Program. 
Hoste, E. A., Clermont, G., Kersten, A., Venkataraman, R., Angus, D. C., De Bacquer, D., & Kellum, J. A. 
(2006). RIFLE criteria for acute kidney injury are associated with hospital mortality in critically ill 
patients: a cohort analysis. Crit Care, 10(3), R73. 
Hoste, E. A., Kashani, K., Gibney, N., Wilson, F. P., Ronco, C., Goldstein, S. L., . . . Group, A. C. (2016). 
Impact of electronic-alerting of acute kidney injury: workgroup statements from the 15(th) ADQI 
Consensus Conference. Can J Kidney Health Dis, 3, 10. 
 Page 193 
 
Hou, S. H., Bushinsky, D. A., Wish, J. B., Cohen, J. J., & Harrington, J. T. (1983). Hospital-acquired renal 
insufficiency: a prospective study. Am J Med, 74(2), 243-248. 
Hsu, C. Y., Chertow, G. M., McCulloch, C. E., Fan, D., Ordonez, J. D., & Go, A. S. (2009). Nonrecovery of 
kidney function and death after acute on chronic renal failure. Clin J Am Soc Nephrol, 4(5), 891-898. 
Hsu, C. Y., McCulloch, C. E., Fan, D., Ordonez, J. D., Chertow, G. M., & Go, A. S. (2007). Community-based 
incidence of acute renal failure. Kidney Int, 72(2), 208-212. 
Ishani, A., Nelson, D., Clothier, B., Schult, T., Nugent, S., Greer, N., . . . Ensrud, K. E. (2011). The 
magnitude of acute serum creatinine increase after cardiac surgery and the risk of chronic kidney 
disease, progression of kidney disease, and death. Arch Intern Med, 171(3), 226-233. 
Jang, H. R., & Rabb, H. (2009). The innate immune response in ischemic acute kidney injury. Clin 
Immunol, 130(1), 41-50. 
Kaufman, J., Dhakal, M., Patel, B., & Hamburger, R. (1991). Community-acquired acute renal failure. Am 
J Kidney Dis, 17(2), 191-198. 
Kerr, M., Bedford, M., Matthews, B., & O'Donoghue, D. (2014). The economic impact of acute kidney 
injury in England. Nephrol Dial Transplant, 29(7), 1362-1368. 
Kesselheim, A. S., Cresswell, K., Phansalkar, S., Bates, D. W., & Sheikh, A. (2011). Clinical decision support 
systems could be modified to reduce 'alert fatigue' while still minimizing the risk of litigation. Health Aff 
(Millwood), 30(12), 2310-2317. 
Kirkwood, B., & Sterne, J. (2006). Essential Medical Statistics. In Blackwell Science (Ed.), (pp. 455). 
Kolhe, N. V., Staples, D., Reilly, T., Merrison, D., McIntyre, C. W., Fluck, R. J., . . . Taal, M. W. (2015). 
Impact of Compliance with a Care Bundle on Acute Kidney Injury Outcomes: A Prospective Observational 
Study. PLoS One, 10(7), e0132279. 
Lassnigg, A., Schmidlin, D., Mouhieddine, M., Bachmann, L. M., Druml, W., Bauer, P., & Hiesmayr, M. 
(2004). Minimal changes of serum creatinine predict prognosis in patients after cardiothoracic surgery: a 
prospective cohort study. J Am Soc Nephrol, 15(6), 1597-1605. 
Lee, E. K., Mejia, A. F., Senior, T., & Jose, J. (2010). Improving Patient Safety through Medical Alert 
Management: An Automated Decision Tool to Reduce Alert Fatigue. AMIA Annu Symp Proc, 2010, 417-
421. 
Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., & Roth, D. (1999). A more accurate method 
to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of 
Diet in Renal Disease Study Group. Ann Intern Med, 130(6), 461-470. 
Lewington, A., & Kanagasundaram, S. (2011). Renal Association Clinical Practice Guidelines on acute 
kidney injury. Nephron Clin Pract, 118 Suppl 1, c349-390. 
Lin, J., Fernandez, H., Shashaty, M. G., Negoianu, D., Testani, J. M., Berns, J. S., . . . Wilson, F. P. (2015). 
False-Positive Rate of AKI Using Consensus Creatinine-Based Criteria. Clin J Am Soc Nephrol, 10(10), 
1723-1731. 
Lo, L., Liu, K. D., & Hsu, C. Y. (2009). Long-term outcomes after acute kidney injury: where we stand and 
how we can move forward. Am J Kidney Dis, 53(6), 928-931. 
Lobo, D. N., Dube, M. G., Neal, K. R., Allison, S. P., & Rowlands, B. J. (2002). Peri-operative fluid and 
electrolyte management: a survey of consultant surgeons in the UK. Ann R Coll Surg Engl, 84(3), 156-
160. 
Lobo, D. N., Dube, M. G., Neal, K. R., Simpson, J., Rowlands, B. J., & Allison, S. P. (2001). Problems with 
solutions: drowning in the brine of an inadequate knowledge base. Clin Nutr, 20(2), 125-130. 
Medicines and Healthcare Products Regulatory Agency. (Aug 2014). Medical device stand-alone software 
including apps. 
Methven, S., MacGregor, M. S., Traynor, J. P., O'Reilly, D. S., & Deighan, C. J. (2010). Assessing 
proteinuria in chronic kidney disease: protein-creatinine ratio versus albumin-creatinine ratio. Nephrol 
Dial Transplant, 25(9), 2991-2996. 
 Page 194 
 
Metzger, J., Kirsch, T., Schiffer, E., Ulger, P., Mentes, E., Brand, K., . . . Herget-Rosenthal, S. (2010). 
Urinary excretion of twenty peptides forms an early and accurate diagnostic pattern of acute kidney 
injury. Kidney Int, 78(12), 1252-1262. 
Molitoris, B. A., Levin, A., Warnock, D. G., Joannidis, M., Mehta, R. L., Kellum, J. A., . . . Acute Kidney 
Injury Network working, g. (2007). Improving outcomes of acute kidney injury: report of an initiative. 
Nat Clin Pract Nephrol, 3(8), 439-442. 
National Confidential Enquiry into Patient Outcomes and Death. (2009). Adding Insult to Injury: A Review 
of the Care of Patients who Died in Hospital with a Primary Diagnosis of Acute Kidney Injury (acute Renal 
Failure): a Report by the National Confidential Enquiry Into Patient Outcome and Death: NCEPOD. 
National Institute for Health and Care Excellence. (2013). Acute kidney injury : Prevention, detection, 
and management of acute kidney injury up to the point of renal replacement therpy  Retrieved 3 May 
2015, 2015 
National Institute for Health and Care Excellence. (2014). Chronic kidney disease in adults : assessment 
and management. 
Nejat, M., Pickering, J. W., Walker, R. J., Westhuyzen, J., Shaw, G. M., Frampton, C. M., & Endre, Z. H. 
(2010). Urinary cystatin C is diagnostic of acute kidney injury and sepsis, and predicts mortality in the 
intensive care unit. Crit Care, 14(3), R85. 
NHS England. (June 2014). Patient Safety Alert; Standardising the early identification of Acute Kidney 
Injury. 
Nissenson, A. R. (1998). Acute renal failure: definition and pathogenesis. Kidney Int Suppl, 66, S7-10. 
Noronha, I. L., Schor, N., Coelho, S. N., Jorgetti, V., Romao Junior, J. E., Zatz, R., & Burdmann, E. A. 
(1997). Nephrology, dialysis and transplantation in Brazil. Nephrol Dial Transplant, 12(11), 2234-2243. 
Ostermann, M., Chang, R., & Riyadh, I. C. U. P. U. G. (2008). Renal failure in the intensive care unit: acute 
kidney injury compared to end-stage renal failure. Crit Care, 12(5), 432. 
Partridge, H. (2015). [Acute kidney injury - nurse led service]. 
Powell-Tuck, J., Crichton, S., Raimundo, M., Camporota, L., Wyncoll, D., & Ostermann, M. (2016). 
Anaemia is not a risk factor for progression of acute kidney injury: a retrospective analysis. Crit Care, 20, 
52. 
Prevent this silent killer. (2011). Health Service Journal, Supplement, 1. 
Rabb, H., Wang, Z., Nemoto, T., Hotchkiss, J., Yokota, N., & Soleimani, M. (2003). Acute renal failure 
leads to dysregulation of lung salt and water channels. Kidney Int, 63(2), 600-606. 
Renal Association. (2009). The UK eCKD guide  Retrieved 1 Oct 2015, 2015, from 
http://www.renal.org/information-resources/the-uk-eckd-guide#sthash.H2aiuzT7.dpbs 
Ricci, Z., Cruz, D., & Ronco, C. (2008). The RIFLE criteria and mortality in acute kidney injury: A systematic 
review. Kidney Int, 73(5), 538-546. 
Schoorl, M., Schoorl, M., Linssen, J., Villanueva, M. M., NoGuera, J. A., Martinez, P. H., & Bartels, P. C. 
(2012). Efficacy of advanced discriminating algorithms for screening on iron-deficiency anemia and beta-
thalassemia trait: a multicenter evaluation. Am J Clin Pathol, 138(2), 300-304. 
Selby, N. M., Kolhe, N. V., McIntyre, C. W., Monaghan, J., Lawson, N., Elliott, D., . . . Fluck, R. J. (2012). 
Defining the cause of death in hospitalised patients with acute kidney injury. PLoS One, 7(11), e48580. 
Sheth, T., Nair, C., Muller, J., & Yusuf, S. (1999). Increased winter mortality from acute myocardial 
infarction and stroke: the effect of age. J Am Coll Cardiol, 33(7), 1916-1919. 
Song, Y. R., Lee, T., You, S. J., Chin, H. J., Chae, D. W., Lim, C., . . . Na, K. Y. (2009). Prevention of acute 
kidney injury by erythropoietin in patients undergoing coronary artery bypass grafting: a pilot study. Am 
J Nephrol, 30(3), 253-260. 
Stevens, P. E., Tamimi, N. A., Al-Hasani, M. K., Mikhail, A. I., Kearney, E., Lapworth, R., . . . Carmichael, P. 
(2001). Non-specialist management of acute renal failure. QJM, 94(10), 533-540. 
 Page 195 
 
Thomas, M., Sitch, A., & Dowswell, G. (2011). The initial development and assessment of an automatic 
alert warning of acute kidney injury. Nephrol Dial Transplant, 26(7), 2161-2168. 
Uchino, S., Bellomo, R., Goldsmith, D., Bates, S., & Ronco, C. (2006). An assessment of the RIFLE criteria 
for acute renal failure in hospitalized patients. Crit Care Med, 34(7), 1913-1917. 
Uchino, S., Kellum, J. A., Bellomo, R., Doig, G. S., Morimatsu, H., Morgera, S., . . . Ending Supportive 
Therapy for the Kidney, I. (2005). Acute renal failure in critically ill patients: a multinational, multicenter 
study. JAMA, 294(7), 813-818. 
Viera, A. J. (2008). Odds ratios and risk ratios: what's the difference and why does it matter? South Med 
J, 101(7), 730-734. 
Waikar, S. S., Betensky, R. A., & Bonventre, J. V. (2009). Creatinine as the gold standard for kidney injury 
biomarker studies? Nephrol Dial Transplant, 24(11), 3263-3265. 
Waikar, S. S., & Bonventre, J. V. (2009). Creatinine kinetics and the definition of acute kidney injury. J Am 
Soc Nephrol, 20(3), 672-679. 
Wald, R., Quinn, R. R., Adhikari, N. K., Burns, K. E., Friedrich, J. O., Garg, A. X., . . . University of Toronto 
Acute Kidney Injury Research, G. (2012). Risk of chronic dialysis and death following acute kidney injury. 
Am J Med, 125(6), 585-593. 
Wald, R., Quinn, R. R., Luo, J., Li, P., Scales, D. C., Mamdani, M. M., . . . University of Toronto Acute 
Kidney Injury Research, G. (2009). Chronic dialysis and death among survivors of acute kidney injury 
requiring dialysis. JAMA, 302(11), 1179-1185. 
Ware, L. B., Johnson, A. C., & Zager, R. A. (2011). Renal cortical albumin gene induction and urinary 
albumin excretion in response to acute kidney injury. Am J Physiol Renal Physiol, 300(3), F628-638. 
Westhuyzen, J. (2006). Cystatin C: a promising marker and predictor of impaired renal function. Ann Clin 
Lab Sci, 36(4), 387-394. 
White, & Hassoun. (2012). Inflammatory Mechanisms of Organ Crosstalk during Ischemic Acute Kidney 
Injury. Int J Nephrol, 2012, 505197. 
White, G. H., & Farrance, I. (2004). Uncertainty of measurement in quantitative medical testing: a 
laboratory implementation guide. Clin Biochem Rev, 25(4), S1-24. 
Wilson, F. P., Shashaty, M., Testani, J., Aqeel, I., Borovskiy, Y., Ellenberg, S. S., . . . Fuchs, B. (2015). 
Automated, electronic alerts for acute kidney injury: a single-blind, parallel-group, randomised 
controlled trial. Lancet, 385(9981), 1966-1974. 
Wohlauer, M. V., Sauaia, A., Moore, E. E., Burlew, C. C., Banerjee, A., & Johnson, J. (2012). Acute kidney 
injury and posttrauma multiple organ failure: The canary in the coal mine. Journal of Trauma and Acute 
Care Surgery, 72(2), 373-380. 
Wonnacott, A., Meran, S., Amphlett, B., Talabani, B., & Phillips, A. (2014). Epidemiology and outcomes in 
community-acquired versus hospital-acquired AKI. Clin J Am Soc Nephrol, 9(6), 1007-1014. 
Yacoub, R., Patel, N., Lohr, J. W., Rajagopalan, S., Nader, N., & Arora, P. (2013). Acute kidney injury and 
death associated with renin angiotensin system blockade in cardiothoracic surgery: a meta-analysis of 
observational studies. Am J Kidney Dis, 62(6), 1077-1086. 
Yang, C. W. (2007). Leptospirosis in Taiwan--an underestimated infectious disease. Chang Gung Med J, 
30(2), 109-115. 
 
 
  
 Page 196 
 
 
FORM UPR16 
Research Ethics Review Checklist 
 
Please include this completed form as an appendix to your thesis (see the Postgraduate Research 
Student Handbook for more information 
 
 
 
Postgraduate Research Student (PGRS) Information 
 
 
Student ID: 
 
410870 
 
PGRS Name: 
 
 
Graham Andrew White 
 
Department: 
 
 
School of Pharmacy 
and Biomedical 
Science 
 
First Supervisor: 
 
Dr J Young 
 
Start Date:  
(or progression date for Prof Doc students) 
 
 
2010 
 
Study Mode and Route: 
 
Part-time 
 
Full-time   
 
 
 
 
 
MPhil  
 
PhD 
 
 
 
 
 
 
 
MD 
 
Professional Doctorate 
 
 
 
 
 
 
 
Title of Thesis: 
 
 
Implementation of an automated system for the detection of acute kidney injury in a 
district general hospital and its impact on patient outcomes 
 
 
 
Thesis Word Count:  
(excluding ancillary data) 
 
 
44,550 
 
 
 
If you are unsure about any of the following, please contact the local representative on your Faculty Ethics Committee 
for advice.  Please note that it is your responsibility to follow the University’s Ethics Policy and any relevant University, 
academic or professional guidelines in the conduct of your study 
Although the Ethics Committee may have given your study a favourable opinion, the final responsibility for the ethical 
conduct of this work lies with the researcher(s). 
5.1  
 
 
UKRIO Finished Research Checklist: 
(If you would like to know more about the checklist, please see your Faculty or Departmental Ethics Committee rep or see the online 
version of the full checklist at: http://www.ukrio.org/what-we-do/code-of-practice-for-research/) 
 
 
a) Have all of your research and findings been reported accurately, honestly and 
within a reasonable time frame? 
 
 
YES 
NO    
 
 
 
 
 
b) Have all contributions to knowledge been acknowledged? 
 
 
YES 
NO    
 
 
 
 
 
c) Have you complied with all agreements relating to intellectual property, publication 
and authorship? 
 
YES 
NO    
 
 
 
 
 
d) Has your research data been retained in a secure and accessible form and will it 
remain so for the required duration?  
 
YES 
NO    
 
 
 
 
 Page 197 
 
 
e) Does your research comply with all legal, ethical, and contractual requirements? 
 
 
YES 
NO    
 
 
 
 
      
 
Candidate Statement: 
 
 
I have considered the ethical dimensions of the above named research project, and have successfully 
obtained the necessary ethical approval(s) 
 
 
Ethical review number(s) from Faculty Ethics Committee (or from 
NRES/SCREC): 
 
 
N/A 
 
If you have not submitted your work for ethical review, and/or you have answered ‘No’ to one or more of 
questions a) to e), please explain below why this is so: 
 
 
This study did not require formal ethical approval as the samples were being analysed for the assessment of  
function (personal communication: Research Group, Royal Hampshire County Hospital). The manner in  
clinical laboratories operate includes an assumed authority for the analysis by virtue of the request being ma   
or under the direct supervision, of an appropriate healthcare professional. By virtue of the request for s  
analyses the laboratory will assume that the patient has been consented for the tests being requested. 
 
 
 
Signed (PGRS): 
 
 
Graham White 
 
 
Date: 10 January 2017 
 
 
 
 
